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Calorie restriction (CR) has well established neuroprotective properties across 
species and is known to prevent cognitive deficits in several mouse models and in 
aged humans. Our group and others have shown that CR beneficial effects are 
dependent on the circulating hormone acyl-ghrelin (AG), that promotes 
hippocampal memory function and protects against neurodegeneration in rodents. 
Indeed, ghrelin knockout (KO) mice show defects in memory task performance and 
plasma ghrelin levels are significantly reduced in aged humans. Because of its 
connection to memory and ageing, AG has been studied in mouse models of 
Alzheimer’s disease (AD) and Parkinson’s disease (PD), the two most common 
causes of dementia in the aged population. However, very few of these studies have 
been performed in human models. 
This project aimed to determine the expression of key regulatory proteins of the 
ghrelin pathway in the young and aged healthy human brain, as well as brain of AD 
and PD patients, combining immunohistochemistry, RNA in situ hybridization, and 
molecular biology. My findings show that the key enzymes of the ghrelinergic axis 
– GHS-R1a, GOAT and APT1 – are highly expressed in the aged healthy human
hippocampus, but their expression level is impaired in PD with dementia . Further 
studies are needed to determine a potential correlation between the activity of 
ghrelin in the brain and the level of cognitive impairment and dementia. On the 
contrary, very little difference is observed between early and late stage of AD, 
suggesting that the ghrelinergic system may not be impaired in these patients.  
The second aim was to characterize the effects of AG on a human neuronal cell line 
treated with rotenone or amyloid-β oligomers (AβOs) to simulate oxidative stress 
from PD and AD, respectively. Using confocal microscopy and molecular biology 
techniques, I assessed neuronal cell death and mitochondrial function and reported 
significant mitochondrial toxicity in these models, that worsen by chronic pre-
treatment with the inactive form of AG, unacylated ghrelin (UAG). 
Ultimately, this project supports the ghrelinergic axis as a potential target for 
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1.1 Calorie Restriction 
 
 CR effects on health and lifespan 
The term ‘Calorie Restriction’ (CR) refers to a dietary intervention that consists of 
reducing the daily food intake by 20-40% without causing malnutrition. CR is the 
most robust non-pharmacological intervention known for extending lifespan and 
quality of life for several species, from yeast (Lin et al. 2000) to primates (Mattison 
et al. 2017), including fruit flies (Pletcher et al. 2002), worms (Houthoofd et al. 
2002), rodents (McCay et al. 1935; Omodei and Fontana 2011) and dogs (Kealy et 
al. 2002). The first evidence of the beneficial effects of a dietary intervention dates 
back 85 years (McCay et al. 1935). Since then, numerous studies performed in 
rodents reported that life-long CR extends lifespan by up to 50% (Weindruch and 
Walford 1982b; Byung Pal Yu et al. 1985; Pugh et al. 1999; Lee et al. 2002a; Dhahbi 
et al. 2004), reduces the severity of auto-immune diseases (Jolly et al. 2001) and 
prevents the onset of several disorders, including diabetes (Ohneda et al. 1995; 
Baumeier et al. 2015), and cancer (Rous 1911; Weindruch and Walford 1982a; 
Pugh et al. 1999; Dhahbi et al. 2004; Shelton et al. 2010; Lashinger et al. 2016). 
Since the 1980s, three 30 year-long CR studies have taken place on rhesus monkeys 
(Bodkin et al. 2003; Colman et al. 2009; Colman et al. 2014), a species that shares 
93% of the human genome and shows similar ageing patterns (Gibbs et al. 2007). 
The three studies adopted a 30% reduction dietary regimen, however they 
produced conflicting results on the animals’ survival rate. Indeed, there were 
numerous differences in the experimental design, for instance one study used 
prevalently female monkeys and included diabetic and healthy animals (Bodkin et 
al. 2003), the other two used only healthy animals, both male and female, but the 
feeding patterns and macronutrient intake were very different.  
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Despite the discrepancies, all three studies showed significant reduction of age-
related conditions, such as osteoporosis and arthritis, cancer, cardiovascular 
diseases and diabetes (Mattison et al. 2017). Consistently, CR monkeys also had a 
reduction in markers of inflammation (Willette et al. 2010), oxidative stress (Zainal 
et al. 2000) and brain astrogliosis (Sridharan et al. 2013), all hallmarks of ageing 
and cognitive decline. Another major feature of ageing is brain atrophy. 
Unfortunately, this trait is rarely visible in small animals, making it difficult to 
reproduce in most models of ageing. Notably, CR rhesus monkeys showed 
significantly higher grey matter volume in subcortical brain areas involved in 
motor and executive functions, compared to ad-libitum fed animals (Colman et al. 
2009), although the exact consequences of these findings are unknown – since no 
behavioural testing was reported for these animals. 
Interestingly, CR in non-human primates was more effective if started during 
adulthood (Mattison et al. 2017). This is contrary to studies carried out in mice 
which mostly suggest that better results are obtained when the dietary regime is 
initiated early in life (Goodrick et al. 1990; Forster et al. 2003). Considering the 
great potential of CR as a therapeutic agent, especially for age-related disorders, 
further studies will be needed to determine the cellular mechanisms that are 
involved in different species and to clarify the optimal timings for therapeutic 
strategy. 
 
In humans, the study of long-term CR is quite challenging due to scarce adherence 
to the dietary regime and difficulties in following-up with the subjects through 
many decades. However, there have been occasions in history when such dietary 
conditions have been required. Two cases were documented in Scandinavian 
countries, where the government forced their populations to undertake a CR 
regime with balanced nutrients: for 2 years in Denmark during world war I 
(Hindhede 1920), and 4 years in Norway during world war II (Strom and Jensen 
1951). As a consequence, a significant drop in the death rate was observed in the 
two populations, 30 and 34% respectively. In particular, the authors noticed that 
the nutrient-balanced diet imposed by the government was lower in fat compared 
to the usual diet of the general population, suggesting a correlation with the 
significant reduction of cardio-vascular diseases, like atherosclerosis, observed in 
the 10-year period since the beginning of the war (Hindhede 1920). 
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In 1994 the “Calorie Restriction Society” was founded in North Carolina, USA, 
whose members self-impose a 30% CRON diet (Calorie Restriction with Optimal 
Nutrition) in order to extend their lifespan and health. On average, this diet has 
been maintained for 15 years so far, and it is the only documented long-term CR 
practice ever performed in humans. Preliminary data on participant general health 
showed improved heart rate, reduction of cardio-metabolic risk factors and 
reduction of molecular damage markers, like antioxidants and enzymes associated 
to autophagy and protein misfolding, to an extent that resemble those of 
individuals 10-20 years younger (Fontana et al. 2004; Stein et al. 2012; Mercken et 
al. 2013). 
Sadly, one of the founders of the society, Roy Walford, died at the age of 79 due to 
ALS, a neurological disease with metabolic impairment. Indeed, it has been 
hypothesised that negative energy balance may negatively affect motor neurones, 
although there are only indirect evidences of this in humans (Mattson et al. 2007) 
and conflicting evidence in mice (Patel et al. 2010; Bhattacharya et al. 2012). 
Despite the few negative reports, the increasing number of references indicating 
the beneficial effects of CR on health and lifespan induced the US National Institute 
of Aging in 2002, to coordinate a series of CR randomised clinical trials on non-
obese healthy individuals, named CALERIES (Comprehensive Assessment of the 
Long-term Effects of Reducing Intake of Energy). A total of six studies were 
performed, divided in two phases of different length – between 6 months and 3 
years – and CR between 16% and 30%, aiming to identify the best CR approach and 
its feasibility and safety in humans (Heilbronn et al. 2006; Racette et al. 2006; Das 
et al. 2007; Rickman et al. 2011; Rochon et al. 2011; Martin et al. 2016). All studies 
showed many positive outcomes: a decline in inflammatory markers; reduced 
insulin resistance; a decrease in total cholesterol and low density lipoprotein (LDL) 
versus an increase in high density lipoproteins (HDL); increase of growth hormone 
(GH); increase of pro-autophagic proteins and molecular chaperons like the 5' 
AMP-activated protein kinase (AMPK) and the sirtuins, that regulate DNA repair, 
stress resistance and stem cell function (Fontana et al. 2015; Das et al. 2017; Most 





One of the positive hallmarks of CR in all species is the improvement of 
mitochondrial efficiency, defined as the ratio between oxygen consumption and 
reactive oxygen species (ROS) production (Martin-Montalvo and De Cabo 2013). 
Skeletal muscle biopsies were collected from the subjects in the CALERIE studies, 
revealing that CR subjects have 35% more mitochondrial mass than controls. 
Moreover, several specific mitochondrial transcription factors are increased, 
resulting in an overall improved mitochondrial function and ultimately reduced 
ROS and ROS-derived damage (Civitarese et al. 2007). Overall, the modulation of 
these factors contributes to general health, increases lifespan and most 
importantly, prevent the onset of age-related disorders. 
 
 CR effects on brain and cognition 
One of the main medical concerns about dieting is the occurrence of negative 
behaviours associated with eating disorders, like binge eating and guilt (Fuhrman 
et al. 1951). However, several studies in rodents showed that CR improves mood 
and reduces anxiety and depression-like behaviour (Inoue et al. 2004; Parikh et al. 
2016). Studies performed in humans undergoing CR also reported improved 
morale, reduced food inhibition, reduced tension and improved perception of 
general health (Redman and Ravussin 2011; Hussin et al. 2013; Martin et al. 2016). 
In rodents, CR exerts numerous positive effects on the brain: it increases recovery 
after brain injury (Sandu et al. 2018), improves synaptic plasticity (Fontán-Lozano 
et al. 2008), preserves neuronal stem cell function (Apple et al. 2019), and 
increases neurogenesis, memory and learning in the adult brain (Hornsby et al. 
2016; Morgan et al. 2017). CR is also neuroprotective in mouse models of ageing 
(Singh et al. 2018), Alzheimer’s disease (AD) (Van Cauwenberghe et al. 2016) and 
Parkinson’s disease (PD) (Maswood et al. 2004; Bayliss et al. 2016a). 
In humans, results from the first phase of the CALERIE studies, did not show any 
significant effect, neither positive or negative, on memory or attention after 6 
months of CR (Martin et al. 2016), suggesting CR is safe, but not necessarily 
beneficial. Interestingly, a study from the second phase, performed over a longer 
period of time (2 years) reported a significant increase in working memory 




An independent research performed on healthy elderly volunteers outside of the 
CALERIE studies, showed highly improved memory in CR subjects, as early as 3 
months into the CR regimen (Witte et al. 2009), suggesting that differences in 
experimental strategies, testing techniques and possibly other factors like an 
individual’s social background, and more, may heavily influenced the outcome of 
these studies. Although numerous evidences reported the beneficial effect of CR on 
memory and cognition, more studies will be needed to define the exact terms and 
conditions to get the most benefit out of the CR regime. 
 
 General considerations about CR feasibility 
The last 20 years have seen increased interest in the CR paradigm in the context of 
age-related cognitive disorders, since most studies indicate that CR positively 
affects brain function. However, there are still concerns regarding applying these 
 studies to humans. For instance, there are conflicting views about: 1) by what 
extent should they undergo CR; 2) for how long 3) at what age should CR be carried 
out to maximise benefit; and 4) whether subjects’ metabolic state may limit CR 
effects. Indeed, some evidence suggest that CR may not be suitable for all 
individuals. A stand-alone CR study reported adverse effects in elderly humans, 
including changes in bone density and structure (Villareal et al. 2016), 
discouraging its use in the aged, most vulnerable population. Moreover, a study 
performed on 41 of the most common wild type strains of rats used in research, 
showed that the CR response is heavily affected by their genotype: in half of the 
strains, dieting shortened the lifespan or induced no significant change (Liao et al. 
2010). A deeper analysis showed that the beneficial effects positively correlated 
with the strain’s efficiency in using dietary resources and maintaining adiposity 
(Rikke et al. 2010; Liao et al. 2011), suggesting that CR effects may be reliant on the 
individual’s own metabolic state. 
In the literature, the overall effects of CR are still unclear. The organism’s response 
to CR is a very complex, well conserved, mechanism of defence from starvation and 
energy imbalance. To study a phenomenon like this, with so many variables, yet 
maintaining scientific accuracy, is challenging. More studies are needed to clarify 
the actual feasibility in humans. Research should focus on obtaining a deeper 
knowledge on the ‘hormonal signature’ and the molecular mediators of CR, to plan 





 Discovery and functions 
Ghrelin is a 28 amino-acid hormone mainly produced within the oxyntic glands of 
the stomach by X/A-like cells in rats (Date et al. 2000) and P/D1 cells in humans 
(Rindi et al. 2002). An increasing number of studies support the hypothesis that 
ghrelin is the key mediator of the anti-ageing (Fujitsuka et al. 2016) and 
neuroprotective effects of CR (reviewed in Bayliss and Andrews 2016). Indeed, it 
has been shown to significantly increase during CR (Cummings et al. 2002), and 
also to affect the central nervous system in most species (Malik et al. 2008; Reimer 
et al. 2010).  
Ghrelin was first discovered in 1999 as the endogenous ligand of the GH 
secretagogue receptor (GHS-R), able to stimulate the release of GH from the 
pituitary gland in rats (Kojima et al. 1999). Ghrelin is an orexigenic hormone, 
meaning it is able to induce food intake and regulate energy homeostasis (Tschöp 
et al. 2000). Indeed, its level in the bloodstream increases before meal times 
(Cummings et al. 2001) and decreases after feeding (Tschöp et al. 2001). Its release 
is dependent on the dietary supply, hence ghrelinergic cells in the stomach exhibit 
chemosensory capacity and express gustatory proteins and various fatty acid (FA) 
receptors (Müller et al. 2015). Moreover, the vagus nerve modulates secretion 
through a feedback mechanism based on caloric load (Callahan et al. 2004), diet 
composition (Monteleone et al. 2003), insulin (Murdolo et al. 2003) and glucose 
levels (Sakata et al. 2012). Once in the circulation, ghrelin stimulates the sense of 
hunger by acting on neuropeptide Y (NPY) and agouti-related peptide (AGRP) 
neurones in the hypothalamic arcuate nucleus (ARC) in the brain; this effect led to 
the nickname “the hunger hormone” (Nakazato et al. 2001; Cowley et al. 2003). 
Indeed, its primary function is to induce a shift from negative to positive energy 
balance by acting on digestion and metabolism.  
Ghrelin injections in healthy individuals stimulates hunger (Levin et al. 2006), 
gastric motility and secretion (Ang et al. 2009), and regulates insulin and 
circulating glucose levels (Tong et al. 2010). In mice, ghrelin modulates adiposity 
and energy utilization (Theander-Carrillo et al. 2006). Some studies in rodents 
reported that male animals seem to be more sensitive to ghrelin-induced appetite 
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compared to female, unless the female animals have been ovariectomised (Clegg et 
al. 2007; Butera 2010; Asarian and Geary 2013), suggesting that ghrelin may 
interact with circulating estrogens, and this interaction may affect its function. 
Notably, studies conducted in humans reported that plasma ghrelin levels are 
higher in woman than in men (Barkan et al. 2003; Makovey et al. 2007), while other 
studies reported no sex differences (Serra-Prat et al. 2015), although the technical 
variability between the experiments may have influenced the outcome.  
 
Interestingly, in rodents ghrelin has been shown to modulate taste sensation (Cai 
et al. 2013) and reward seeking behaviour (Jerlhag et al. 2006). Indeed, an 
increasing number of studies show that ghrelin does not just affect metabolism, but 
also it exerts a plethora of effects, influencing most organs in the body, including 
the brain (Stievenard et al. 2017) (figure 1.1). 
In rodents, ghrelin-mediated neuroprotective effects were first reported in 2002, 
when Frago and colleagues injected a GHS-R agonist, GH releasing peptide-6 
(GHRP-6), in rats and observed increased neuronal survival and reduction of 
apoptosis via inhibition of caspase 3 and 9 (Frago et al. 2002). Moreover, ghrelin 
has been shown to mediate CR-induced anxiolytic and antidepressant behaviours 
(Lutter et al. 2008), and to stimulate synapse formation in primary cortical 
neurones (Stoyanova et al. 2013). It also exhibits neuroprotective properties in 
various animal and cellular models: mouse models of brain ischemia (Miao et al. 
2007), traumatic injury (Lopez et al. 2012), and neurodegenerative disorders (V. 
dos Santos et al. 2013); cellular models of oxidative damage (Chung et al. 2007) 
and glutamate excitotoxicity (Lee et al. 2012); rat models of glaucoma (Can et al. 
2015) and multiple sclerosis (Liu et al. 2019).  
In the hippocampus, an area of the brain implicated in memory and learning, 
ghrelin affects synaptic density,  induces spine remodelling and increases long-
term potentiation (LTP) (Carlini et al. 2002; Diano et al. 2006; Carlini et al. 2010; 
Perea Vega et al. 2021; Ribeiro et al. 2021). Moreover, it  promotes neural plasticity, 
via adult hippocampal neurogenesis (AHN) (Hornsby et al. 2016; Buntwal et al. 






Ghrelin mediates the beneficial effects of CR on metabolism and health-span, 
affecting all organs and systems of the body, including the brain (created with 
BioRender.com).  
  
Figure 1.1 Ghrelin activity engages the whole organism 
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 Ghrelin effects on human metabolism and brain function 
Following the promising data collected in rodents, numerous researches have been 
performed in humans to determine the effect of ghrelin administration. In 2013, a 
study thoroughly screened the available literature via database searches, in order 
to delineate a comprehensive picture of ghrelin research in humans (Garin et al. 
2013). The authors selected 121 studies where ghrelin was either injected or 
ingested, for a total of more than 2000 patients, with doses ranging from 0.003 to 
1.33µg/kg·min via iv infusions, and from 0.03 to 10.0µg/kg via ingestion.  
One of these studies reported that injecting a single dose of ghrelin on healthy 
subjects, either 1 or 5µg/kg, quickly increase plasma concentration from the 
average baseline of 168.6fmol/mL, to 1058.7 and 6598.9fmol/mL respectively.  
Moreover, the half-life of the injected hormone in the plasma was between 27 and 
31 minutes, while the estimated half-life of the endogenous peptide is 9-13 minutes 
(Akamizu et al. 2004). Another group administered 10µg/kg to healthy volunteers, 
and after 1 minute measured an average of 150ng/mL of circulating ghrelin 
(corresponding to 50550fmol/mL), 61-fold higher than the baseline of the subjects 
before the injections. Despite the higher dosage, this study reported that ghrelin 
half-life was only 10 minutes (Nagaya et al. 2001). The broad difference between 
the studies is attributable to differences in the experimental settings, but it may 
also be a consequence of technical difficulties in isolating the hormone. Indeed, 
ghrelin mostly circulates associated to larger plasma proteins to prevent 
degradation, including albumin and HDL (Beaumont et al. 2003; De Vriese et al. 
2007; Lufrano et al. 2016), making it difficult to precisely separate and quantify the 
active molecule in plasma. Despite the discrepancies, all the studies analysed by 
Garin and colleagues reported only mild adverse effect after ghrelin 
administration, such as gastric rumbles, in about 20% of the participant and no 
severe effects (Garin et al. 2013). Ultimately, the study reported that short-term 
ghrelin administration is safe and well tolerated for clinical use. 
 
Most of the ghrelin studies performed in humans in the past decades, focus on 
appetite and energy intake, confirming ghrelin pivotal role in regulating glucose 
metabolism in healthy (Broglio et al. 2001; Arosio et al. 2003; Akamizu et al. 2004; 
Broglio et al. 2004) and obese subjects (Tassone et al. 2003; Guido et al. 2007). 
However, numerous other beneficial effects have been reported, like improved 
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cardiovascular functions in patients with heart failure (Nagaya et al. 2004), and 
increased respiratory performance and muscle strength in patients with 
respiratory diseases (Nagaya et al. 2005). Interestingly, ghrelin administration has 
also been shown to stimulate the secretion of GH, cortisol and the adreno-cortico-
trophic hormone (ACTH), all involved in the regulation of the circadian rhythm in 
humans (Frieboes et al. 1995; Weikel et al. 2003). Indeed, when injected before 
sleep, ghrelin improves its duration and quality, even after sleep deprivation or in 
subjects affected with insomnia, and the effect is more evident with short-term 
treatments (Morin et al. 2018). 
 
Overall, these data confirm the widespread idea that ghrelin exerts beneficial 
effects on metabolism and general healthspan. However, in contrast to most 
research performed in rodents, data focusing on mood and stress response in 
humans, have been quite inconsistent. Several groups measured endogenous 
ghrelin levels in patients with major depressive disorder, finding it to be either 
reduced (Barim et al. 2009), increased (Gecici et al. 2005; Kurt et al. 2007; Ozsoy et 
al. 2014), or unchanged (Schanze et al. 2008; Kluge et al. 2009; Matsuo et al. 2012). 
Ghrelin level was higher during severe and treatment-resistant depression 
(Ishitobi et al. 2012; Algul and Ozcelik 2018) while anti-depressant medications 
were found to either reduce circulating ghrelin (Barim et al. 2009; Ishitobi et al. 
2012) or increase it (Tunçel et al. 2016). Finally, when used as a therapeutic agent, 
ghrelin administration reduced depressive symptoms in men but not women 
(Kluge et al. 2011; Steiger et al. 2011), while ghrelin injection in 9 healthy subjects 
showed mood improvement in only 3 of them, independently from their gender 
(Schmid et al. 2005). The great variance in these studies is most likely due to the 
multiplicity of the experimental parameters adopted by the different studies, like 
the small sample number and different testing and analysis strategies, but also 
variables such as patients’ gender and metabolic state, severity of the depressive 
condition and type of the therapy. Moreover, chronic stress and depression often 
lead to altered feeding behaviours like binge eating, which will have an impact on 
ghrelin production (Schellekens et al. 2012), making it difficult to study its anti-




Studying memory and cognitive functions in humans is also quite difficult as 
numerous biological, social and environmental factors may influence the outcome. 
One study performed on healthy young males, showed increased memory 
processing of food-related pictures after ghrelin administration, compared to 
unrelated images (Malik et al. 2008). Functional Magnetic Resonance Imaging 
(fMRI) scans performed at the same time, detected activation of areas involved in 
the visual and emotional response to food (amygdala, orbitofrontal cortex, 
thalamus), the dopaminergic areas of the reward system (substantia nigra/ventral 
tegmental area), and also areas involved in attention and memory, like the 
hippocampus (Malik et al. 2008).  
In 2016, Kunath and colleagues reported a similar study on healthy male subjects, 
in which the stimulus was presented in form of food names, rather than images. 
Surprisingly, the authors could not detect any changes on the participant’s 
performance, nor in any of the parameters measured, including fMRI scans (Kunath 
et al. 2016). This discrepancy could be explained by the fact that different types of 
memory, like visual or auditory memory, activate specific brain circuits (Butters et 
al. 1970) with different recall efficiency (Cohen et al. 2009b). Therefore, it is 
possible that ghrelin's effect on memory function only affect certain brain 
pathways (such as the visual circuit), but not the others. Investigating ghrelin's role 
may be fundamental to shed some light on its effect on memory and attention and 
its potential in clinical therapy. 
 
 The “survival” hormone 
In rodents, ghrelin improves performance on different memory tasks, like fear 
conditioning, object recognition and spatial memory retention (Carlini et al. 2002; 
Diano et al. 2006; Kent et al. 2015). To explain these results, Kunath and Dresler 
used the analogy of a wild squirrel awakening from hibernation, whose only way 
to survive from starvation is to remember exactly where it hid the food before 
winter (Kunath and Dresler 2014). In this example, memory retention is intended 
as a survival mechanism to cope with metabolic changes like hunger, of which 
ghrelin represents part of the molecular signature. Higher attention and cognitive 
performances during hunger, would account for increased capability of food-
hunting compared to competitors, and this could also justify how such a complex 
mechanism has been so well conserved among distant species. 
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The same reasoning could be applied to any type of energy deficit, including CR, 
which induces the increase of circulating ghrelin in all tested species (Cummings et 
al. 2002; Reimer et al. 2010). Indeed, both CR (Thanos et al. 2008) and ghrelin 
(Malik et al. 2008) have independently been shown to modulate the activation of 
the dopaminergic reward system that modulates mood, anxiety, and motivation. 
All evidences collected so far, suggest that ghrelin is not just the “hunger” signature, 
but rather acts as a “survival” hormone during low energy conditions, protecting 
both body and mind, alleviating depression, stress, and improving cognitive 
functions, ultimately increasing the chances of survival and the endurance of the 
species. 
 
 Ghrelin gene and protein processing 
The ghrelin gene (GHRL) is a single-copy gene whose sequence is highly conserved 
among species, with 100% identity on the first 10 amino acids at the N-terminal 
region, between all the species tested so far (Tomasetto et al. 2001; Angeloni et al. 
2004; Seim et al. 2007; Kaiya et al. 2008). Indeed, this region is known to be 
essential for ghrelin binding with its receptor (section 1.2.8).  
In humans, GHRL is located on the short arm of chromosome 3 and comprises 4 
exons encoding a 117 amino acid long polypeptides precursor named pre-
proghrelin (Wajnrajch et al. 2000). The precursor undergoes multiple processing 
steps and may generate multiple products which are then secreted (figure 1.2). 
After a first cleavage of the N-terminal signal peptide, the remaining 94 amino acid 
peptide named proghrelin is modified in the endoplasmic reticulum (ER) by the 
possible addition of octanoic acid (Kojima et al. 1999), by the enzyme ghrelin O-
acyl transferase (GOAT), as will be better described in section 1.2.5. Either 
octanoylated or non-octanoylated forms of proghrelin can then be cleaved and the 
main enzymes involved are prohormone convertase 1 and 3 (PC1/3) (Zhu et al. 
2006), although other enzymes, such as PC2 and furin, may also be involved 
(Takahashi et al. 2009). This cleavage process occurs in the Golgi, generating either 
the N-terminal 28 amino acid ghrelin peptide (octanoylated or non-octanoylated) 
(‘mature ghrelin’) (Zhu et al. 2006) or the C-terminal peptide (C-ghrelin), that is 
further processed to generate the hormone obestatin, which is reported to have 
independent functions in comparison to ghrelin (Zhang et al. 2005; Seim et al. 






Pre-proghrelin polypeptide precursor undergoes post-translational modifications 
in the ER and Golgi. Several products can be generated in the process, including 
acyl-ghrelin and unacylated-ghrelin, and ultimately secreted in the circulation 
(5’UTR = untranslated region) (created with BioRender.com). 
   
Figure 1.2 Processing of the human ghrelin peptide 
14 
 
Since not all the proghrelin localised in the ER is acylated before the final cleavage, 
both acylated (AG) and unacylated (UAG) ghrelin are released in the bloodstream, 
through secretory granules (Zhu et al. 2006) in a calcium dependent manner (Mani 
et al. 2014b). Moreover, several shorter ghrelin variants may also be released in 
the circulation. For instance, the des-Gln24-C-ghrelin, is a C-ghrelin peptide lacking 
the exon 2 at the N-terminal and a glutamine residue in position 24 (Seim et al. 
2007). des-Gln24-C-ghrelin has been shown to be expressed in human cancer tissue 
(Jeffery et al. 2005; Yeh et al. 2005) and to bind GHS-R in vitro (Hosoda et al. 2000b) 
although its exact function is still unclear. These evidences, suggest a complicated 
tissue- and/or stage-dependent regulation of GHRL splicing process (Tanaka et al. 
2001). 
 
Lastly, both acyl-ghrelin and unacylated-ghrelin can be phosphorylated while 
transiting the Golgi by protein kinase C (PKC) at the Serine 18 in the C-terminal 
region. This process affects their secondary structure and in particular their ability 
to bind membranes and transport vesicles (Dehlin et al. 2008). It has been 
hypothesised that this modification could influence their release and transport in 
the circulation, their cellular uptake and subcellular localisation, although it is not 
clear whether and how this could affect acyl-ghrelin binding with GHS-R. 
Overall, these studies show that GHRL is a complex gene, with a multitude of 
products, whose fine regulation may be essential in understanding ghrelin’s 
activity in the body. 
 
 GOAT and ghrelin acylation  
Since its discovery, it was clear that ghrelin’s acylation is necessary for its function. 
In 2008, two separate studies identified the membrane-bound O-acyltransferase 4 
(MBOAT4) - commonly referred to as ghrelin O-acyltransferase (GOAT) - as the 
catalysing enzyme in mice (Yang et al. 2008a) and humans (Gutierrez et al. 2008). 
There are 11 known MBOAT sequences in the human genome, from which 16 
different enzymes originate as a result of alternative splicing (Yang et al. 2008a). 
All members of the MBOAT superfamily are integral highly conserved membrane 
enzymes, known to catalyse the addition of FA onto hydroxyl groups of membrane-
embedded targets, mostly lipids or lipopolysaccharides (Hofmann 2000). They also 
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participate in several biological pathways including membrane 
biosynthesis/remodelling and lipid-signaling (Chang et al. 2011).  
Other than GOAT, only two other members of the family are known to transfer FA 
to proteins. First, hedgehog acyltransferase (HHAT), also known as Rasp, that 
palmitoylates a cysteine residue in several substrates like Hedgehog proteins 
(Chamoun et al. 2001) and the Epidermal Growth Factor Receptor ligand, Spitz 
(Miura et al. 2006). Second, Porcupine (Porc), that transfer long-chain fatty acids 
(LCFA, 16 carbons or more) on both a cysteine and a serine in Wingless proteins, 
like Wnt3 (Zhai et al. 2004). In both cases, acylation is essential for the proteins’ 
function and activity. However, neither of those enzymes are able to acylate ghrelin 
(Yang et al. 2008a). 
 
The MBOAT4 gene is located on chromosome 8p12 and its sequence is highly 
conserved from prokaryotes to humans, with 74% gene identity and 98% protein 
similarity between humans, mice, and rats (Stengel et al. 2010). Indeed, extracts of 
the enzyme from mouse, rat and even zebrafish, have been shown to successfully 
catalyse acylation of the human ghrelin peptide (Gutierrez et al. 2008).  
GOAT is a 450 amino acids protein, organised in 11 transmembrane helices, mostly 
localised in the ER compartment – although a recent study reported that it can 
shuffle between the ER and the plasma membrane, via small lipidic vesicles 
(Hopkins et al. 2017). In the ER, GOAT transfers an octanoyl group onto the third 
serine residue (S3) of either the proghrelin peptide just before this is transferred 
to the Golgi, or directly onto the mature unacylated ghrelin (Taylor et al. 2013). The 
exact mechanism of this reaction has been recently reported, revealing that GOAT 
catalyses the reaction inside an internal channel: the acyl donor accesses the 
channel from the cytoplasm, while proghrelin comes from the lumen of the ER. 
After the reaction, octanoylated ghrelin dissociates from the channel and transits 
through GOAT to reach the Golgi (Campaña et al. 2019). Interestingly, it has been 
shown that GOAT is not able to acylate any peptides longer than proghrelin: the in 
vitro addiction of just two extra amino acids at the N-terminus of proghrelin, 
significantly reduces the peptide ability to accept an octanoyl group, suggesting 




Interestingly, two studies have shown that GOAT is the only enzyme involved in 
ghrelin acylation. Using an embryonal cell line, that does not produce ghrelin nor 
express GOAT, Gutierrez and colleagues performed co-transfections with the 
human ghrelin sequence and the cDNA from each one of the MBOAT family 
members: once exposed to octanoic acid, acyl-ghrelin production was detected 
only in the cells that received both ghrelin and MBOAT4 cDNA (Gutierrez et al. 
2008). Shortly after, a second study, performed in vivo, reported complete absence 
of circulating acylated ghrelin in MBOAT4 knockout (KO) mice (Kirchner et al. 
2009), therefore confirming that GOAT is the only enzyme able to acylate ghrelin. 
On the other end, Darling and colleagues in 2015 showed that ghrelin is the only 
substrate of GOAT. In the attempt of identifying other potential substrates, they 
used ghrelin mimetics to characterise the chemical properties that are either 
essential, favoured or tolerated for the activity of the human GOAT enzyme. 
Substitutions at ghrelin N-terminal glycine and serine (G1 and S2) totally abolish 
octanoylation, while peptides that are 10 or 18 amino acids shorter in the C-
terminal sequence exhibit a markedly reduced binding affinity with GOAT. 
Researchers then compared these sequence requirements with bioinformatics 
simulations and protein databases, showing that ghrelin is the only possible GOAT 
substrate within the human proteome (Darling et al. 2015). 
 
This exclusive relationship is unusual in many ways. Numerous proteins are known 
to be modified by the addition of a FA, however, it is uncommon for a protein to be 
esterified on a serine residue, like ghrelin, since most of the known acylation 
processes occur either on a cysteine (S-acylation) or via an amide bond at the N-
terminal residue (N-acylation) (Zeidman et al. 2009). Moreover, ghrelin is the only 
known peptide to receive an octanoic acid (Hougland 2019), although traces of 
ghrelin acylated with FAs of different lengths  have been found in human stomach 
and plasma (Hosoda et al. 2003).  
While the other MBOAT family members mostly transfer LCFA (Chang et al. 2011), 
GOAT in vitro shows an unusual predilection for the short-length chains (SCFA, 6 
carbons or less) and medium-length chains fatty acids (MCFA, between 8 and 16 
carbons). In particular GOAT binds FA with length between C2 and C16, with a 
preference for C8-C12 (Gutierrez et al. 2008). However, it has been shown that 
either the six-carbon (Ohgusu et al. 2009) or the eight-carbon (Yang et al. 2008c; 
17 
 
Taylor et al. 2013) acyl chains, have the best chance to be incorporated into the 
ghrelin structure. Indeed, when GOAT binds to different acyl chains, ghrelin does 
not easily bind the enzyme, suggesting that longer FA may constrict the GOAT 
active site, preventing ghrelin access (Darling et al. 2015). Nevertheless, it has been 
shown that octanoylated ghrelin is the most prevalent circulating form in human 
plasma (Hosoda et al. 2003), although it is not clear why octanoic, and not hexanoic 
acid – for which GOAT shows higher affinity (Ohgusu et al. 2009) – is the primary 
acyl donor for ghrelin acylation. 
 
As for the source of the acyl donor, it is now clear that diet composition affects the 
length of the attached carbon chain. In particular, LCFA are found in plant-based 
oils, such as palm or seeds, and in animal fat, while MCFA are found in dry fruit, 
fish, and dairy (reviewed in Jala and Ganesh Kumar 2018). Before use, LCFA need 
to undergo a fragmentation process called β-oxidation, that produces MCFA, SCFA, 
and energy (Reddy and Hashimoto 2001). Interestingly, pharmacological 
inhibition of the β-oxidation, suppresses acyl-ghrelin production in cells, without 
affecting total protein or mRNA levels (Ikenoya et al. 2018), confirming the 
importance of this process for ghrelin acylation.  
MCFAs are also supplied from the diet, and can be directly utilized for the acylation 
process, without having to be further processed (Nishi et al. 2005; Kirchner et al. 
2009; Lemarié et al. 2018). Notably, digestive cells can be of two type, “open”, 
which can take uptake nutrients directly from the stomach and intestine, or 
“closed”, that do not make contact with the digestive lumen (Solcia et al. 2000). In 
the rat digestive tract, both types are ghrelin-secreting cells, however the “open” 
ones are the most abundant in the duodenum, where most of the diet lipids’ 
absorbance occurs (Sakata et al. 2002). This suggests that MCFA could be taken up 
by ghrelinergic cells during digestion, and directly used for ghrelin synthesis. 
However, this hypothesis does not match with the fact that acyl-ghrelin is notably 
reduced in the plasma after meals. Indeed, more studies are needed to determine 
the timings of ghrelin synthesis and whether the FA may be stored inside the 





Interestingly, the nutrient composition of the diet can also affect ghrelin synthesis 
and secretion (Lee et al. 2002b) and high-fat diets have been shown to significantly 
reduce circulating acyl-ghrelin (Moesgaard et al. 2004; Handjieva-Darlenska and 
Boyadjieva 2009), suggesting that the sensing and/or uptake of FA in the digestive 
track may rather operate a negative feedback on acyl-ghrelin production.  
Taken together, these evidences confirm the importance of a well-balanced dietary 
regimen for the correct functioning of the ghrelinergic system. 
 
Although FA are largely introduced through diet, our body is also able to synthetise 
them in liver (Dorn et al. 2010), adipose tissue (Mayas et al. 2010), and brain 
(Knobloch et al. 2013). The process, known as lipogenesis, occurs when FA are not 
supplied by the diet in sufficient amounts, and is catalysed by the multienzyme 
system of the FA synthase (FASN) that produces LCFA by consecutively adding 
two-carbon acyl donors, in the form of acetyl-coenzyme A (acetyl-CoA), to the 
three-carbons malonyl-CoA substrate (Maier et al. 2006). A study performed in a 
murine ghrelin-producing cell line, showed that pharmacological inhibition of one 
of the enzyme involved in LCFA synthesis, the acyl-CoA synthetase family member 
1 (Acsl1), significantly decreases ghrelin acylation (Bando et al. 2016), suggesting 
de novo FA synthesis is important for this process.  
Interestingly, it has been shown that FASN conditional KO in mice neuronal 
precursor cells, exhibit impaired adult neurogenesis (Knobloch et al. 2013), while 
a specific FASN point mutation, that alters FA biosynthesis and the lipidic 
composition of cellular membranes, has been recently correlated to cognitive 
impairment in mice and humans (Bowers et al. 2020). Since acyl-ghrelin has been 
shown to increase AHN (Kent et al. 2015), and a reduction of its acylation 
significantly correlates with cognitive decline in humans (Hornsby et al. 2020) (as 
will be better described in chapter 3), it could be hypothesised that the detrimental 
effects of FASN KO in rodents, may be mediated by a decrease in ghrelin acylation. 
More studies are needed to confirm this hypothesis, however, it has been long 
known that FA biosynthesis is not favoured in physiological conditions, and solely 
occurs when dietary supply is insufficient (Weiss et al. 1986), hence this process 




Thirdly, the gut microbiota is a highly complex microbial community that populates 
mammals digestive system and is known to produce SCFA, that can be absorbed 
and utilised for numerous scopes (Miller and Wolin 1996). Interestingly, 
microbiome-derived SCFAs have been shown to act as precursor for hepatic 
synthesis of MCFA and LCFA (Kindt et al. 2018), pointing to a potential – direct or 
indirect – role for the gut microbiota SCFA in the generation of acyl- ghrelin. 
Ultimately, it has been hypothesised that all three aforementioned mechanisms – 
diet, de novo synthesis and gut microbiota – may contribute in generating acyl 
donors to be used for ghrelin acylation, suggesting the existence of a 
collaborative/redundant mechanism (Ikenoya et al. 2018). 
 
 APT1 and ghrelin de-acylation 
Once de-acylated, proteins usually lose their biological functions and are quickly 
degraded in the lysosomes. However, in some cases, acylation is reversible, and the 
unacylated forms can circulate and be re-acylated locally, allowing a fine on-site 
modulation of their activity (Zeidman et al. 2009). Notably, the most abundant form 
of circulating ghrelin is unacylated, accounting for 90% of total ghrelin in the blood 
and 67% in the stomach of rats (Hosoda et al. 2000a). Indeed, ghrelin degradation 
by N-terminal proteolysis – that causes total loss of function – does not occur when 
unacylated ghrelin is in the circulation; but rather it requires that the hormone is 
in the stomach, liver, or kidney, as shown by a study that measured total ghrelin 
levels in vitro, after ghrelin was incubated with different tissue lysates (De Vriese 
et al. 2004), suggesting a localization-specific degradation. 
Contrary to ghrelin acylation with GOAT, the deacylation of acyl-ghrelin is 
catalysed by a combination of enzymes, some of which are still unknown. In 2004, 
a study showed that the half-life of acyl-ghrelin in plasma varies notably between 
human (240 minutes) and rat (30 minutes), and the authors hypothesized that 
different enzymes may be involved in deacylating acyl-ghrelin in the two species: 
serine proteases and carboxylesterase in rodents, and other unknown esterases in 
humans (De Vriese et al. 2004). In rodents, acyl-protein thioesterase 1 (APT1) has 
been shown to deacylate ghrelin in vivo (Shanado et al. 2004) and in vitro (Satou et 
al. 2010), and it is currently considered to be the main enzyme involved in the 




APT1 was originally isolated from rat liver in 1996 and called lysophospholipase I 
(LYPLA1), but later renamed due to its high affinity to thioester-containing 
proteins (Sugimoto et al. 1996; Duncan and Gilman 1998). A BLAST (basic local 
alignment search tool, NCBI) search of its sequence reveals homologues in a wide 
variety of species, with 91.74% sequence identity between human and mouse. 
APT1 is a 230 amino acids long protein and a member of the α/β serine hydrolase 
family. It primarily resides in the cytoplasm in a dimeric form, although 
dissociation is required to expose the active site for substrate binding (Devedjiev 
et al. 2000). Its crystalised structure shows a cysteine at the second amino acid 
position, and a highly conserved catalytic trio (Ser114, His203, Asp169); moreover, 
adjacent to the active site, there is a distinctive β5-α2 loop, that is not found in any 
other hydrolase lipases of the family (Devedjiev et al. 2000). This region forms a 
large and flexible hydrophobic channel that accommodates the whole acyl-chain of 
the substrate, allowing its correct positioning for the hydrolysis – albeit without 
contributing to substrate selectivity (Won et al. 2016).  
APT1 has been long been considered the primary depalmitoylase enzyme in cells 
(Won et al. 2017); indeed, it typically catalyses the removal of long acyl chains, like 
palmitic acid, but the high adaptability of its channel would potentially allow the 
enzyme to interact with much shorter or longer carbon chains alike. Consistently, 
APT1 has been shown to have a very broad range of targets, from 
lysophospholipids to a variety of esters and thioester metabolites (Lin and 
Conibear 2015). Interestingly, APT1 does not seem to have a defined substrate 
recognition sequence, and the list of its substrates includes structurally diverse 
proteins: from small soluble intracellular proteins, like acyl-ghrelin and the G-
protein Ras (Dekker et al. 2010), to larger enzymes like the endothelial nitric-oxide 
synthase (Yeh et al. 1999). To comply with the different sub-cellular localization of 
its substrate, APT1 can S-palmitoylate itself and the attached palmitate serves as a 
hydrophobic tag, transiently driving the enzyme near the membranes, where it can 
interact with a wider range of substrates (Kong et al. 2013; Vartak et al. 2014; Won 
et al. 2018). Nevertheless, APT1 does not deacylate any protein indiscriminately 
and the catalytic efficiency can also vary, depending on the type, location or 




Interestingly, the analysis of APT1 sequence let to the identification of a homolog 
with 64% sequence identity, lysophospholipase II (LYPLA2) or APT2 (Toyoda et al. 
1999). Like its homolog, APT2 is also able to hydrolyse a variety of substrates, 
although it is still unclear whether their activity is mutually exclusive or redundant 
(Tomatis et al. 2010; Kong et al. 2013; Adachi et al. 2016; Vujic et al. 2016; Abrami 
et al. 2017; Won et al. 2018). For instance, a study showed that double APT1/APT2 
pharmacological inhibition significantly reduces the hydrolysis rate of one of their 
substrates, the G-protein Ras, compared to the single APT1 knockdown (Dekker et 
al. 2010). However, this study could not exclude a compensatory mechanism from 
other unidentified hydrolases. Certainly, the two enzymes are diverse enough to 
allow isoform-selective inhibition (Won et al. 2016). 
Satou and colleagues showed that both APT1 and APT2 are able to deacylate 
ghrelin in ghrelin-expressing murine cell lines (Satou et al. 2010). Interestingly, cell 
culture media from murine hepatocytes HepG2 cells, contained detectable levels of 
APT1, but not APT2; moreover, the secreted APT1 was fully functional, as it was 
able to deacylate synthetic acyl-ghrelin in vitro. The authors suggested that APT1 
may also be released in the bloodstream, where it may exert a major role in 
deacylating circulating ghrelin, while APT2 activity may be only restricted to the 
intracellular space (Satou et al. 2010), although this hypothesis has not been 
confirmed in vivo yet (see chapter 6). 
 
 Unacylated Ghrelin  
The unacylated form of ghrelin (sometimes referred to as des‐acyl ghrelin, DAG), 
has been considered for a long time nothing more than an inactive form of acyl-
ghrelin (Kojima et al. 1999). One study even reported that all circulating ghrelin in 
human plasma is actually acylated, and its unacylated form may be an artifact of 
sample handling (Blatnik et al. 2012). However, two studies in 2004 showed that 
unacylated ghrelin is able to inhibit the effects of its acylated counterpart on 
glucose metabolism and insulin sensitivity, when injected at the same time as acyl-
ghrelin in human healthy subjects (Broglio et al. 2004; Gauna et al. 2004). 
Moreover, intravenous unacylated ghrelin administration overnight, reduces 
hyperglycaemia, inhibits lipolysis and increases post-prandial insulin levels, either 
in normal weight and obese diabetic subjects (Benso et al. 2012; Özcan et al. 2014).  
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Similar effects, that are opposite to that of acyl-ghrelin, were also shown in rodents 
(Inhoff et al. 2008; Fernandez et al. 2016; Dallak 2018) and other species (Gauna 
et al. 2005; Matsuda et al. 2006). Furthermore, our group recently reported the first 
evidence that unacylated ghrelin is able to counteract the pro-cognitive effects of 
acyl-ghrelin in mice (Hornsby et al. 2020). To do so, we used GOAT KO mice, that 
are not able to convert unacylated ghrelin to acyl-ghrelin therefore causing an 
accumulation of the unacylated ghrelin in the circulation. These mice display 
significant memory impairment in a “spatial memory” task, and show reduced 
markers of AHN and cell function, like c-FOS, Ki67 and dendritic spine arborisation. 
Interestingly, a 7-day treatment with acyl-ghrelin fully rescued the behavioural 
performance and the recovery persisted as long as 21 days after the last injection, 
suggesting that acyl-ghrelin effects on memory may result in long-term promotion 
of hippocampal functions (Hornsby et al. 2020). Collectively, this evidence suggests 
that unacylated ghrelin is more than an inactive product, and it should be 
investigated in parallel with its acylated form. 
 
Kumar et al. showed that the antagonistic effects of unacylated ghrelin were dose-
dependent in rodents, suggesting that unacylated ghrelin may be an endogenous 
competitive inhibitor of acyl-ghrelin (Kumar et al. 2010). However, no receptor for 
unacylated ghrelin has been identified thus far, and most literature agrees that 
unacylated ghrelin does not bind the acyl-ghrelin receptor (Gauna et al. 2005; 
Kumar et al. 2010; Lear et al. 2010). Indeed, a recent study showing GHS-R 
crystalised structure, demonstrated that unacylated ghrelin is not able to bind nor 
activate the receptor in vitro (Shiimura et al. 2020). Consistently, unacylated 
ghrelin administration has been shown to affect insulin signaling in GHS-R KO mice 
(Delhanty et al. 2010). This study, together with the knowledge that unacylated 
ghrelin is the major circulating form of ghrelin (Hosoda et al. 2000a), suggests that 
unacylated ghrelin should be considered a hormone distinct from acyl-ghrelin, that 
it may bind to an endogenous unidentified receptor with discrete functions (Gauna 
et al. 2005; Kumar et al. 2010; Lear et al. 2010) and that does not bind GHS-R. 
However, not all studies agree on this matter. Some suggest that acyl- and 
unacylated ghrelin may act synergically in their effects, as have been shown for 
inhibition of cancer cell proliferation (Cassoni et al. 2004), induction of 
adipogenesis in vivo (Thompson et al. 2004), and inhibition of apoptosis in 
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cardiomyocytes (Lear et al. 2010), endothelial cells (Baldanzi et al. 2002), and 
pancreatic β-cells (Granata et al. 2007). Interestingly, all those effects were 
prevented by inhibiting or deleting GHS-R, suggesting that unacylated ghrelin may 
indeed bind the receptor. This contrast may be explained in several ways. Firstly, 
it is possible that the administered dose of unacylated ghrelin was too high and 
non-physiological in some of these experiments. Indeed, two studies performed on 
human cell lines reported that unacylated ghrelin is able to stimulate GHS-R when 
administered between high nanomolar to micromolar range – approximately 1,000 
to 100,000 fold higher than unacylated ghrelin concentration in the plasma (Gauna 
et al. 2007; Heppner et al. 2014). Secondly, it has been recently described that 
GOAT is able to re-acylate unacylated ghrelin to acyl-ghrelin locally in several 
tissues, as will be better described in section 1.4.4. Since this is a relatively recent 
finding, most of the previous literature – affirming that unacylated ghrelin acts as 
an agonist of GHS-R – did not take in consideration the possibility of in-situ re-
acylation, nor did they quantify GOAT expression and activity in their samples. 
Therefore, it cannot be excluded that in those experiments where unacylated 
ghrelin was added to the cells, it was acting as a precursor, rather than an agonist, 
enriching the existing pool of the “active” acyl-ghrelin. This hypothesis would also 
explain why some researchers found a strong positive correlation between 
unacylated ghrelin administration and GHS-R activity. Thirdly, different methods 
of stabilizing acyl-ghrelin and unacylated ghrelin in samples may have affected the 
outcomes. It has been shown that acyl-chain degrades quickly, once the hormone 
is extracted from blood, suggesting that its stabilization with serine protease 
inhibitors, like AEBSF, is essential to determine the correct ratio between acyl-
ghrelin and unacylated ghrelin in samples (Blatnik and Soderstrom 2011; Delhanty 
et al. 2015). Ultimately, whilst the unacylated ghrelin receptor is unknown, it 
cannot be excluded that unacylated ghrelin may bind GHS-R in an allosteric 
modulatory site or may influence its activity in a different way, either by 
competitive inhibition or indirectly via a different receptor. Indeed, GHS-R has 
been shown to dimerise with several other known and unknown proteins on cell 





Growth hormone secretagogue receptor (GHS-R) was first identified in 1996, as the 
mediator of growth hormone response in the hypothalamus and pituitary gland 
(Howard et al. 1996). Indeed, GHS-R has been detected in the brain, as it will be 
better described in section 1.4.4. 
The GHS-R gene is highly conserved in mammals, with 90% sequence homology 
between human, rat, pig, and sheep (Palyha et al. 2000), and consist of two exons 
and one intron that undergo alternative splicing, so that two distinct forms of the 
receptors have been identified (figure 1.3). The full mRNA transcript codifies for 
GHS-R1a, a 366 amino acid G-protein coupled receptor (GPCR), comprising seven 
transmembrane domains (TM1 to TM7), three intracellular and three extracellular 
loops (Howard et al. 1996; Holst et al. 2003). GHS-R1a crystal structure has been 
recently resolved (Shiimura et al. 2020), showing two main structural differences 
compared to other GPCR receptors. Firstly, the ligand-binding compartment is split 
into two pockets, cavity I and II. Authors suggested that ghrelin enters both cavities, 
although selective mutations of the amino acid residues inside the pockets showed 
that cavity I is essential for recognition of the ghrelin peptide sequence. 
Interestingly, mutations in cavity II do not affect ghrelin’s binding, but rather 
inhibit GHS-R1a constitutive activation (Shiimura et al. 2020), although it is not 
clear whether this process is dependent on ghrelin access/binding to cavity II. 
Second, the two transmembrane segments, TM6 and 7, that surround the ligand 
cavity, are unusually sloped and the gap between them is occupied by large 
hydrophobic chains, essential for recognition of the ghrelin acyl moiety (Shiimura 
et al. 2020). Interestingly, TM6 and 7 have been previously shown to mediate 
GPCRs conformational change to their active form (Zhou et al. 2019), therefore 
authors suggested that the interaction between ghrelin’s acyl chain and this region 
may contribute to the receptor transition to its ligand-activated conformation 
(Shiimura et al. 2020), as hypothesised in a previous study (Ferré et al. 2019). 
Differently, the GHS-R1b isoform is generated when the splicing site between exon 
1 and 2 is skipped and a short 24 amino acids sequence is included in the final 
transcripts, due to an intronic stop codon (Howard et al. 1996). This results in a 
truncated receptor, with 289 amino acids, of which the first 265 are shared with 






GHS-R gene consists of two exons and one intron and can produce two products by 
alternative splicing. Upon receptor activation, the 1a isoform is able to produce an 
intracellular signal thanks to the transmembrane domains TM6 and TM7, which 
are not present in the 1b isoform. Yellow boxes show possible primers/probes 
recognition sequences: exon-exon for GHSR-1a and exon-intron for GHS-R1b 
(overlapping with GHS-R precursor mRNA) (created with BioRender.com).  
Figure 1.3 GHS-R gene alternative splicing 
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Because of this alternative splicing, designing specific probes/primers for GHS-R1b 
isoform (figure 1.3, yellow boxes) is challenging, due to sequence overlapping with 
GHS-R pre-mRNA, therefore GHS-R1b mRNA expression has been poorly 
investigated in literature so far, as will be better described in section 6. 
Interestingly, while GHS-R1a receptor is mostly located in the cellular membrane, 
GHS-R1b protein – detected using an antibody specific for the short intronic 
sequence – has been largely found in the ER (Chow et al. 2012) and in the nucleus 
(Smith et al. 2005), suggesting that its activity on the plasma membrane may be 
dependent on the regulation of its translocation. Since GHS-R1b is lacking the 13 
amino acids that form TM6 and TM7, the two domains involved in signal 
transduction (Zhou et al. 2019), GHS-R1b is not able to induce any of the GHS-R1a 
known intracellular pathways.  
 
All GPCRs are able to form homo‐ or heterodimers and, although not required for 
their function, dimerisation plays an important regulatory function (Kasai and 
Kusumi 2014). GHS-R1a mostly functions as a homodimer (see section 1.2.9) (Holst 
et al. 2005), however it can also heterodimerise with GHS-R1b in transfected 
human cells, and this association reduces GHS-R1a trafficking to the cell membrane 
(Chow et al. 2012), prevents ghrelin-dependent conformational changes of the 
GHS-R1a subunit and decreases its constitutive activity (Leung et al. 2007; Mary et 
al. 2013; Navarro et al. 2016), therefore suggesting that GHS-R1b acts as dominant 
negative regulator of GHS-R1a (Leung et al. 2007). Interestingly, the 
heterodimerisation has been shown to occur with the same efficiency as the 
homodimerization (Leung et al. 2007) and the two forms of the receptor have been 
found to be co-expressed in healthy tissues (Gnanapavan et al. 2002; Carraro et al. 
2004), as well as several cancerous tissues and cell lines (Korbonits et al. 2001; 
Jeffery et al. 2002; Cassoni et al. 2004; Barzon et al. 2005), suggesting a tissue- or 
cell type-dependent differential expression. 
 
Since its discovery, it was clear that the acylation of ghrelin is essential for the 
binding with its receptor. In particular, it has been shown that as little as 10 
picomoles of octanoylated acyl-ghrelin is enough to activate GHS-R1a signaling in 
GHS-R-transfected murine cells, with 2.5 nanomolar inducing 50% of the 
receptor’s signaling capacity (EC50) (Kojima et al. 1999). Another study performed 
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in silico using synthetic human ghrelin peptides and synthetic human GHS-R1a 
receptor, showed an EC50 of 32 nanomolar (Bednarek et al. 2000), suggesting that 
GHS-R1a activation may be somehow more efficient in a living system. 
Interestingly, shorter ghrelin peptides are also able to activate the receptor, as long 
as the first 4 (Matsumoto et al. 2001) or 5 (Bednarek et al. 2000) amino acids at the 
N-terminal (Gly1-Ser2-Ser3-Phe4-Leu5-NH2) are present, suggesting they are 
essential for GHS-R1a activation. Indeed, this sequence is highly conserved among 
most species (Tine et al. 2016). As for the acylation itself, it has been reported that 
GHS-R1a does not discriminate between Ser2 or Ser3 being acylated (Bednarek et 
al. 2000), although the L-configuration of the Ser3 seems to be necessary for the 
receptor’s function (Matsumoto et al. 2001). Moreover, other bonds, like the 
thioether in lieu of the O-ester, retain GHS-R1a activity in vitro, and conveniently 
increase the stability of the acyl chain, suggesting these modifications may be 
adapted for the generation of acyl-ghrelin-based drugs with longer stability 
(Bednarek et al. 2000; Matsumoto et al. 2001). Ghrelin acylated with shorter or 
longer carbon chains, is also able to activate GHS-R1a, although the canonical eight-
carbon chain is the most efficient compared to longer chains (C11 to C16), both in 
vitro (Matsumoto et al. 2001) and in vivo (Heppner et al. 2012). 
 
GHS-R1a has been shown to have strong, ligand-independent, constitutive activity. 
When GHS-R1a is expressed in a human cell line that does not express ghrelin, 
approximately 50% of its maximum activity can be detected – measured as the 
increase in intracellular calcium induced by the activation of the receptor (Holst et 
al. 2003). It is generally believed that ghrelin production is not produced in the 
brain, as will be better described in section 14.4. Since accessing the brain from the 
blood is generally a highly restricted process, as described in section 1.4.1, it has 
been hypothesised that ghrelin may not be able to reach its receptor in the deepest 
regions of the brain, such as the hippocampus. If that were the case, GHS-R1a 
activation in those areas would be mediated only by its own constitutive activity 
(Wellman and Abizaid 2015) or by the activation of its dimerisation partners (see 
section 1.2.9) (Kern et al. 2015). However, this theory is in contrast with studies 
where ghrelin administration in rodents was seen to specifically increase GHS-R1a 
activity in deep brain structures, such as the hippocampus (Diano et al. 2006) and 
the substantia nigra (SN) (Bayliss et al. 2016a).  
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Overall, these evidences highlight that GHS-R1a kinetics is very complex, and 
further studies are needed to clarify the exact dynamic of its interaction with acyl-
ghrelin in vivo. 
 
 GHS-R1a dimerisation and signaling 
GHS-R1a belongs to the rhodopsin family, or class A, of GPCRs, membrane proteins 
that are involved in a variety of intricate signaling networks, mediated by the small 
intracellular G proteins. GPCRs dimerisation is often the first step for induction of 
intracellular signals after ligand binding (Weiss and Schlessinger 1998; Kasai et al. 
2011). As with most GPCRs, GHS-R1a can form homo- and heterodimers that have 
been predicted to be essential for its function (reviewed in Wellman and Abizaid 
2015). As a homodimer, it has been hypothesised that the two GHS-R1a subunits 
have negative co-operativity: one molecule of acyl-ghrelin binds to the first 
subunit, then a conformational change in the receptor occurs preventing another 
molecule from binding on the other subunit (Holst et al. 2005). Without the ligand, 
GPCR monomers are associated in their intracellular portion to the heterotrimer 
Gα/Gβ/Gγ, with Gα bound to guanosine diphosphate (GDP). After the dimerisation 
and binding of the ligand, the receptor undergoes conformational changes that 
induce the exchange of GDP with guanosine triphosphate (GTP), followed by 
disassociation of two subunits, Gα-GTP and Gβ/Gγ, that activate specific signaling 
pathways (second messengers) (recently reviewed in Kontou et al. 2021).  
 
Several G proteins have been identified, of which at least 16 Gα, 5 Gβ, and 11 Gγ 
subunits in humans, whose sequence is highly conserved among mammals 
(Hurowitz et al. 2000). In the hypothalamus, GHS-R1a homodimers regulate 
hunger and food intake, primarily through the Gαq/11 subunit and the second 
messenger phospholipase C (PLC) (figure 1.4, point 1) (Howard et al. 1996). PLC 
cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol-
triphosphate (IP3) and diacylglycerol (DAG), then IP3 reaches its receptor in the ER, 
causing the mobilization of intracellular Ca2+ from stores (figure 1.4, point 2). Ca2+ 
also acts as a second messenger, engaging several enzymes such as the 




CaMKII phosphorylates a variety of intracellular substrates involved in memory 
and learning (Halt et al. 2012; Park et al. 2016) including the AMP-activated kinase 
(AMPK) (Anderson et al. 2008; Andrews et al. 2008). Interestingly, Sirtuin1 
(SIRT1), an enzyme activated during CR and involved in glucose and lipid 
metabolism (Rodgers and Puigserver 2007; Cohen et al. 2009a), is an important 
regulator of AMPK phosphorylation in the hypothalamus, via the p53 transcription 
factor (Velásquez et al. 2011); in turn, pAMPK enhances SIRT1 activity in 
promoting mitochondria activity (Cantó et al. 2009) (figure 1.4, point 3).  
 
pAMPK acts as energy sensor in the hypothalamus (Minokoshi et al. 2004; López et 
al. 2010) and its expression significantly increases shortly after ghrelin treatment 
(López et al. 2008). Moreover, exogenous pAMPK administration in mice increases 
food intake (Andersson et al. 2004) and mediates the beneficial effects of ghrelin 
in the brain (Andrews et al. 2009; Bayliss et al. 2016a; Huang et al. 2019b), heart 
(Zhang et al. 2013) and liver (Qin et al. 2014). Once activated, pAMPK is involved 
in a complex signaling circuit. First, it phosphorylates the regulator-associated 
protein of the mammalian target of rapamycin (Raptor), which binds to the 
mammalian target of rapamycin (mTOR) complex – whose main function is to 
favour cell growth by inducing protein synthesis in response to high energetic 
status – ultimately resulting in mTOR sequestration and inhibition (Gwinn et al. 
2008). Second, pAMPK phosphorylates the Unc-51 like autophagy-activating 
kinase 1 (ULK1), favouring autophagy (Lee et al. 2010) and promoting the recycling 
of damaged proteins and organelles in response to low energetic status (Kuma and 
Mizushima 2010). Moreover, in its function as energy sensor, pAMPK also regulates 
mitochondrial homeostasis, as it will better described in section 1.3.6.  
 
After PIP2 cleavage, DAG remains anchored to the plasma membrane and recruits 
the phosphoinositide 3-OH kinase (PI3K) complex that phosphorylate a series of 
proteins, including the protein kinase B, also known as Akt, and the pro-autophagic 
extracellular regulated protein kinases 1 and 2 (ERK1/2) (Camiña et al. 2007). Akt 
phosphorylates the mitogen‐activated protein kinase (MAPK) that regulates cell 
differentiation and survival (Peltier et al. 2007), and activates the mTOR complex, 
ultimately favouring cell growth (figure 1.4, point 4) (Kumar et al. 2005; Zeng and 
Zhou 2008), while ERK1/2 (Kim et al. 2014) contributes to LC3 cleavage and 
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initiate the autophagic machinery (figure 1.4, point 5). Interestingly, AMPK and 
ERK pathways, have been shown to antagonise each other in several cell types 
(Hwang et al. 2013; Kawashima et al. 2015), suggesting that the balance between 
the pro-autophagic state (mTOR OFF) and the protein synthesis (mTOR ON) after 
ghrelin-induced activation of GHS-R1a, is a finely regulated process. The exact 
mechanism has not yet been clarified; however, it is possible that the configuration 
of GHS-R1a determines the shift between the two pathways, or that each signaling 
cascade is upregulated in specific cell types.  
 
GHS-R1a signaling has also been shown to be mediated by other G proteins. For 
instance, when the receptor binds to Gαs, its activation leads to the mobilisation of 
the enzyme adenylate cyclase (AC), and the formation of second messenger 3',5'-
cyclic adenosine 5'-monophosphate (cAMP) and its downstream effector, protein 
kinase A (PKA) (Kohno et al. 2003). Other subunits that have been associated to 
GHS-R1a include Gαi, that inhibits AC, reducing the formation of the cAMP and 
resulting in modulation of GABA release from the hypothalamic neurones, to 
regulate of food intake (Soto et al. 2015), and Gα12/13, involved in cytoskeleton 
remodelling and cell migration (Lin et al. 2009). Lastly, GHS-R1a, when bound to 
acyl-ghrelin, can interact with the small intracellular protein β-arrestin that 
prevent coupling with G proteins, “arresting” its activation (desensitization), and 
recruiting the clathrin complex that promotes receptor internalization for 
recycling or degradation (Holliday et al. 2007).  
It is not clear how the receptor regulates its binding to different G proteins. 
Interestingly, GHS-R1a signaling seems to be functionally biased, meaning that 
there is an intrinsic mechanism of ligand selection – where the receptor selectively 
prefers one ligand over another in certain conditions – and preferentially activates 
a specific signaling pathway. Although the exact mechanism is not clear, it has been 
hypothesized that it may be dependent on cell type, maturation stage, or ligand 
availability (Sivertsen et al. 2011; Damian et al. 2015; M’Kadmi et al. 2015; Ramirez 






(1) Upon GHS-R1a dimerisation, Gαq/11-GTP subunit activates PLC, that process 
PIP2 into IP3 and DAG. (2) PIP2 induces the release of Ca2+ from the ER, activating 
Ca2+-sensitive kinases, such as CAMKII. (3) One of CAMKII main targets is pAMPK, 
whose activation is favoured by the SIRT1 pathway (and vice versa). (4) pAMPK is 
involved in an intricated signaling pathway that ultimately inhibits mTOR signaling 
and stimulates autophagy via ERK1 and ERK2. (5) However, another pathway may 
be initiated via DAG, which stimulated a kinases cascade mediated by PI3K and Akt, 
ultimately leading to the activation of mitogenic signals such as MAPK and mTOR. 
(5) Since PI3K activation is also able to mediate autophagy via phosphorylation of 
ERK1/2, the balance between mTOR activation/inactivation may be crucial to 
determine the outcome (created with BioRender.com). 
  
Figure 1.4 GHS-R1a neuronal signaling pathways 
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It has been shown that GHS-R1a dimerise with the dopamine receptor D1R 
(sometimes referred to with the name of its gene, DRD1), and this interaction is 
very important, since dopaminergic signaling is associated with food reward 
(Hernandez and Hoebel 1988; Wise 2006) and memory formation (Packard and 
White 1989; Centonze et al. 2001). In particular, acyl-ghrelin has been shown to 
increase dopaminergic signaling in a human neuroblastoma cell line, once 
dimerisation with D1R has induced a shift in the G protein coupled to GHS-R1a, 
from Gαq/11 to Gαi/o (Jiang et al. 2006). Another study showed that, upon 
dimerisation with GHS-R1a, D1R shifts from Gαs to Gαq, in mice hippocampal 
primary cells, allowing dopamine to activate Ca2+ signaling in the absence of ghrelin 
(Kern et al. 2015). Interestingly, the authors also reported improved spatial 
memory functions in mice after injection with a D1R agonist, effect that is 
abrogated in GHS-R1a KO mice. Moreover, they showed co-localisation of D1R and 
GHS-R1a receptors in the mouse brain, most abundant in the dentate gyrus (DG) of 
the hippocampus (Kern et al. 2015), the main area involved in neurogenesis and 
memory formation, as it will be better described in section 1.4.3. GHS-R1a/D1R 
dimers have been detected in several other brain areas, including: substantia nigra 
and VTA, that regulate motor activity and whose impairment has been associated 
to Parkinson’s disease; and prefrontal cortex and hippocampus, associated with 
cognition and learning, notably involved in Alzheimer’s disease (Jiang et al. 2006). 
Moreover, GHS-R1a dimerises with a second dopamine receptor, D2R, resulting in 
PLC activation via the Gβγ subunit and mobilization of intracellular Ca2+ 
Interestingly this induces an anti-orexigenic effect, that has been shown to occur 
only when GHS-R1a is not bound to ghrelin, therefore mediating dopamine 
response to food intake (Kern et al. 2012).  
The dimerisation of GHS-R1a with the 5-hydroxytryptamine (serotonin) 5-HT2C 
receptor has been shown to significantly reduce ghrelin signaling, suggesting that 
serotonin may act as a negative regulator of food intake (Schellekens et al. 2013; 
Schellekens et al. 2015). Interestingly, GHS-R1 deficient mice exhibit increased 
serotoninergic activity in the ARC, but decreased in the paraventricular nucleus 
(PVN), both areas associated to feeding and stress response (Patterson et al. 2010). 
Moreover, ghrelin central administration to wild type mice increases mRNA 
expression of serotonin receptors in the amygdala (Hansson et al. 2014), 
suggesting a region-specific modulation of the serotoninergic signalling. 
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GHS-R1a also dimerises with other GPCRs, such as the melanocortin3 receptor 
(MC3), known for its hypothalamic orexigenic effect that are amplified by its 
dimerisation with GHS-R1a (Rediger et al. 2011); and the oxytocin receptor (OTR), 
that regulates mood and socialisation, to whom surprisingly the GHS-R1a receptor 
has been shown to act as a negative regulator, by increasing its internalisation 
(Wallace Fitzsimons et al. 2019). 
Lastly, it has been recently shown that the liver-expressed antimicrobial peptide 2 
(LEAP2) is a competitive inverse agonist of GHS-R1a, and acts by stabilizing the 
inactive conformation of the receptor, therefore preventing acyl-ghrelin binding 
(Wang et al. 2019; Li et al. 2020). Interestingly, peripheral ghrelin administration 
in mice reduced LEAP2 mRNA in the liver as well as the circulating protein (Ge et 
al. 2018), suggesting the existence of a feedback regulation between the two 
hormones. Consistently, peripheral LEAP2 administration in mice blocks acyl-
ghrelin effects on general metabolism, such as food intake and GH release (Ge et al. 
2018), while intra-cranial administration in rats completely abolishes 
hypothalamic neurone activation and also prevent ghrelin-mediated regulation of 
blood glucose and body temperature (Islam et al. 2020). Thereby, LEAP2 has been 
suggested for clinical use as an anti-obesity drug; indeed, obese subjects display 
high LEAP2 and low acyl-ghrelin in plasma after fasting (Mani et al. 2019). 
However studies performed in mice using synthetic GHS-R1a inhibitors, report 
contradictory results and suggest that high LEAP2 levels not only prevents ghrelin-
induced food intake, but may also cause a form of ghrelin resistance (reviewed in 
Andrews 2019), hence discouraging its use in patients. On the contrary, LEAP2-
neutralizing antibodies increase endogenous acyl-ghrelin activity and GH release 
(Ge et al. 2018), thus representing a potential therapeutic strategy to increase 
ghrelinergic tenor in the brain. 
Overall, these studies highlight the complexity of GHS-R1a signaling, which 
depends on a combination of factors: circulating ligands, the receptor’s constitutive 
activity, and the dimerisation with other GPCRs, ultimately activating dozens of 
different second messengers and intracellular pathways. The complexity of GHS-
R1a signaling explains the multitude of functions in which ghrelin is involved: stem 
cell proliferation (Chung et al. 2013), cell differentiation (Gong et al. 2020); 
autophagy (Ferreira-Marques et al. 2016); gene expression and protein synthesis 
(Goto et al. 2006).  
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1.3 Mitochondrial network and homeostasis 
 
 Mitochondria network remodelling 
Mitochondria are double membraned intracellular organelles, that originated one 
billion years ago when the aerobic bacterium SAR11 clade Rickettstiales, initiated 
an endosymbiotic relationship with an ancestral anaerobic eukaryotic cell. The 
bacterium slowly evolved into the organelle known as mitochondrion, while the 
host cell acquired the bacteria’s ability to autonomously use oxygen for energy 
supply (Sagan 1967; Thrash et al. 2011). Nowadays, each eukaryotic cell contains 
thousands of mitochondria that form a highly dynamic network, constantly 
changing in number, morphology, connectivity, and subcellular localization, 
adapting to the energetic need of the cell. In neurones, the size and shape of these 
networks depends on highly regulated processes (recently reviewed in Fenton et 
al. 2021): fission/fusion, axonal transport, biogenesis and mitophagy. 
 
Mitochondria fission and fusion are modulated by a large family of GTPases, known 
as dynamin-related proteins. One of them, dynamin-related protein 1 (DRP1) is a 
ubiquitous cytoplasmic protein (Imoto et al. 1998) whose activation induces a shift 
toward mitochondria fission (Shin et al. 1997; De Vos et al. 2005; Fonseca et al. 
2019). DRP1 interacts with microtubules components such as tubulin polymers 
(Strack et al. 2013) and actin (Ji et al. 2015) that are assembled around the 
organelles, more specifically at the mitochondria-ER contact site (Friedman et al. 
2011). With their guidance, DRP1 translocates on the outer mitochondrial 
membrane (OMM) where it binds to specific proteins (Ji et al. 2017) and lipids on 
the surface of the mitochondria, like cardiolipin (Stepanyants et al. 2015), that act 
as markers to flag the position of the fission site. Then DRP1 polymerises into ring-
like structures around the organelles (Smirnova et al. 1998) and its GTPase domain 
cleaves the lipidic layer of the OMM, initiating mitochondrial fission (Kamerkar et 
al. 2018), while the proteins intervening in the fission of the IMM are less known. 
DRP1 requires specific post-translational modifications to activate the fission 
process. Notably, phosphorylation at serine residue 616 (s616) by cellular kinases 
such ask ERK1/2 results in activation of its GTPase activity (Kashatus et al. 2015), 
while phosphorylation at s637 by cAMP/PKA signaling inhibits it, suppressing 
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mitochondrial fission (Chang and Blackstone 2007). Many other, less studied, post-
translational modifications have been identified. Phosphorylation at s40/44 by 
glycogen synthase kinase 3β (GSK3β) promotes fission and has been associated 
with oxidative stress vulnerability in AD (Yan et al. 2015); GSK3β can also 
phosphorylate s693, with the opposite effect of reducing mitochondrial 
fragmentation and increasing cell survival after oxidative stress (Chou et al. 2012); 
phosphorylation at s656 by cAMP/PKA inhibits fission, similarly to s637 (Cribbs 
and Strack 2007); lastly, phosphorylation at s585 by cyclin-dependent kinases 1 
(CDK1)/cyclin B complex, mediates mitochondria division during mitosis in vitro 
(Taguchi et al. 2007). Ultimately, DRP1 can also be bound to small ubiquitin-like 
proteins or SUMO (small ubiquitin-like modifiers), affecting DRP1 localization and 
membrane translocation (Figueroa-Romero et al. 2009). All these processes are 
tightly regulated depending on cell type and developmental stage, further 
highlighting the complexity of DRP1 signaling and the sophistication of 
mitochondrial network remodelling and functioning. 
 
Opposite to fission, the pathways that lead to mitochondrial fusion are less 
understood. The main enzymes involved are the dynamin family GTPases 
mitofusin 1 and 2 (Mfn1/2) anchored to the OMM, and OPA1 on the inner 
mitochondrial membrane (IMM). First, parental mitochondria are directed in 
proximity to the ER membranes, where the reaction occurs (Abrisch et al. 2020), 
and the OMMs are tethered, probably via Mfn1 (Ishihara et al. 2004). Indeed, in 
Mfn1-deficient cells, mitochondria are fragmented and fail to bind each other (Chen 
et al. 2003). Interestingly, Mfn2 is believed to have distinct functions, since 
depletion of Mfn2 in HeLa cells causes the formation of larger mitochondrial 
fragments (Eura et al. 2003). Once the OMMs are fused together, OPA1 mediates 
the fusion of the IMMs (Ban et al. 2017), and the mitochondrial content of the 
parental organelles are mixed, completing the fusion process. Interestingly, OPA1 
is also required for the formation and stability of the IMM lipidic invaginations, 
named cristae, suggesting its role in structurally supporting the internal 





Microtubules play a fundamental role in mitochondrial dynamics, guiding the 
organelles towards and away from the mitochondria-ER contact site where fission 
and fusion occur. Moreover, fission generates smaller mitochondria that can be 
more easily delocalised at further sites inside the cells (e.g., synapses and 
dendrites) or transported to lysosomes for degradation. Inside the neurones, 
mitochondria are transported along the axon, in a process known as 
“mitochondrial axonal transport”, by the “motor proteins” kinesin, with direction 
from the soma to the axon, and dynein, that moves in the opposite direction (Pilling 
et al. 2006). The motor proteins bind the mitochondria membranes thanks to a 
family of adaptor proteins: TRAK1 and TRAK2 (sometimes referred to as their 
drosophila ortholog Milton), bind the OMM directly (van Spronsen et al. 2013), 
while Miro1 and Miro2 link TRAKs to the motor proteins, in a Ca2+ dependent way 
(López‐Doménech et al. 2018). Moreover, actin is essential for anchoring the 
mitochondria at the synapses and dendrites (Gutnick et al. 2019), where a very 
intense ATP production occurs, in order to sustain the – energetically very costly – 
neuronal electrical activity (Howarth et al. 2012). 
 
The processes described so far regulate size, content, and shape of the 
mitochondrial network, therefore remodelling the existing pool of organelles. On 
the contrary, biogenesis is a process that generates new mitochondria, and 
involves numerous enzymes, whose exact signaling pathway has not yet been 
entirely clarified. Firstly, the new mitochondrial proteins are either recruited from 
the pre-existing mitochondria, that redistribute their content via fission, or 
synthetised in the cytoplasm, from mRNA transcripts that are transcribed in the 
nucleus, and later transported inside the organelles (Miller and Hamilton 2012). 
Important players of this pathway are large transmembrane complexes of the 
mitochondrial import machinery, such as the translocase of the outer membrane 
(TOM) and the translocase of the internal membrane (TIM23). In particular, the 
TOM complex consists of seven components, three of which – TOM20, TOM22 and 
TOM70 – face the cytosolic side of the OMM (Ahting et al. 1999) and are therefore 
often used as markers to study mitochondrial morphology or number (Gelmetti et 
al. 2017; Fonseca et al. 2019). TOM and TIM enzymes mediate the internalisation 
of thousands of newly synthetised proteins from the cytosol into the mitochondrial 
matrix (Yamamoto et al. 2009; Waegemann et al. 2015), where the new proteins 
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are further processed and sorted into the relevant mitochondrial compartment. 
Interestingly a small number of proteins is produced within the mitochondrion by 
local transcription and replication of mitochondrial DNA-encoded genes. Indeed, 
each mitochondrion contains thousands of copies of mitochondrial DNA (mtDNA) 
(Wiesner et al. 1992), exclusively inherited from the maternal oocyte (Giles et al. 
1980), that also need to be replicated during biogenesis. Each molecule consists of 
a double strand DNA, free of introns, that encodes 37 of the over 1300 genes that 
are necessary to the mitochondria (Anderson et al. 1981). MtDNA is loosely packed 
in large DNA-protein complexes, highly conserved among species, called nucleoids 
(Satoh and Kuroiwa 1991). During biogenesis, nucleoids are disassembled and a 
dedicated mitochondrial replication complex mediates mtDNA replication in the 
mitochondrial matrix, independently from the cell cycle, in either proliferating and 
post-mitotic cells (Magnusson et al. 2003).  
 
Protein redistribution, synthesis and mtDNA replication, are precisely timed and 
finely controlled processes and their main regulator is the peroxisome proliferator-
activated receptor coactivator 1α (PGC1α) (Puigserver et al. 1998). Cytosolic 
PGC1α is activated by either phosphorylation via pAMPK (Zong et al. 2002) or 
deacylation via SIRT1 (Nemoto et al. 2005), then it translocate to the nucleus where 
it binds to the nuclear receptor peroxisome proliferator-activated receptor gamma 
(PPAR-γ) (Puigserver et al. 1998). Furthermore, AMPK phosphorylates and 
activates the histone acetyltransferase 1 (HAT1), creating a more relaxed 
chromatin-DNA structure (Marin et al. 2017) that favours the transcription of 
several transcription factors. Two of these, nuclear factor erythroid 2-related 
factors 1/2 (NRF1/2), activated by PPAR-γ, induce the expression of several 
nuclear encoded mitochondrial proteins, including the transcription factor A 
(TFAM) (Virbasius et al. 1993; Wu et al. 1999), one of the main components of 
mitochondrial nucleoids, that is involved in the final steps of mtDNA replication 
(Kaufman et al. 2007). Another important target of the PGC1α/PPAR-γ complex are 
the mitochondrial uncoupling proteins (UCP) (Kelly et al. 1998), a superfamily of 
enzymes inserted in the IMM that exert a variety of functions, from thermogenesis 




Ultimately, mitochondrial biogenesis increases the energetic production of the cell, 
but also reduces oxidative stress by replacing malfunctioning mitochondria that 
have been degraded. Indeed, mitochondrial protein synthesis (Williams et al. 
1987), biogenesis (Irrcher et al. 2003), and PGC1α expression (Pilegaard et al. 
2003) are significantly increased in the muscle during physical exercise. Contrarily, 
impaired mitochondrial biogenesis has been associated to numerous diseases, 
including neurodegeneration (Golpich et al. 2017), while PGC1α signalling has 
been shown to be neuroprotective against oxidative stress and cell death (St-Pierre 
et al. 2006), further establishing the importance of these organelles in regulating 
cell homeostasis, especially in neurones.  
 
 Electron transport chain and ROS 
Mitochondria are involved in numerous processes, such as calcium homeostasis 
(Lee et al. 2018b), lipid metabolism and myelin stability (Viader et al. 2013), 
apoptotic signaling (Joza et al. 2001), axonal transport (Chamberlain and Sheng 
2019), and synaptic transmission (Lee et al. 2018a). However, their principal role 
is the maintenance of the bioenergetics of the cell by coupling redox catabolic 
processes, such as Krebs cycle and glycolysis – that collects the energy produced 
from glucose and lipid metabolism – with molecular oxygen acquired through 
respiration, in a process known as oxidative phosphorylation (OXPHOS), that 
produces over 90% of the total ATP in the cell (Keilin 1925; Chance and Williams 
1956). This process occurs in the IMM, in a large enzymatic complex known as the 
electron transport chain (ETC) (figure 1.5) (Mitchell 1961), comprising four 
transmembrane proteins (complex I to IV) and two small electron transporters, 
ubiquinone (CoQ) and cytochrome c (cytC). These enzymes can alternatively accept 
and donate electrons (figure 1.5, blue arrows) to generate a proton (H+) gradient 
(figure 1.5, green arrows), that increases the difference of electric potential (ΔΨm) 
(figure 1.5, orange arrow) between the inside and outside of the IMM - also known 
as mitochondrial membrane potential (MMP). An elevated MMP, activates the ATP 
synthase (sometimes referred to as complex V), a large rotating ion channel, 
sensitive to H+ concentrations. When the channel is open, the H+ freely transit 
through the IMM following a concentration gradient and releasing a high amount 




Interestingly, the lipidic cristae of the IMM form small pockets that significantly 
increase its area, so that the IMM is approximately 5 times wider that the OMM 
(Sjöstrand 1977; Perkins et al. 1997). Cells with more energetic demands, such as 
muscle cells and neurones, show even more cristae, significantly increasing the 
number of ETC complexes and, consequently, ATP production (Varanita et al. 
2015). With such intense activity, the number of redox reactions occurring inside 
the cell is very high, resulting in the formation of reactive oxidative species (ROS), 
commonly known as free radicals, produced when an oxygen molecule (O2) is 
reduced from a single electron “leaking” from the respiratory chain, and becomes 
the ROS precursor superoxide ion (·O2¯¯ ) (figure 1.5) (reviewed in Turrens 2003). 
This process is highly dependent on the MMP: the higher the MMP, the higher the 
number of leaking electrons from the ETC (Nobes et al. 1990). Interestingly, 
although this process was originally thought to be random, there are now 
evidences showing that only 5% of the leak occurs through the lipidic layer 
(Brookes et al. 1997), while the remaining leak is controlled by a class of integral 
enzymes, the adenine nucleotide translocases (ANT) (Brand et al. 2005). Indeed, 
the electron transport process is not 100% efficient and, under physiological 
conditions, between 0.2 and 2% of the electrons in the ETC are used to generate 
ROS, more specifically at the CI and CIII (Brand 2010) (figure 1.5). ROS produced 
in this process act as second messenger, taking part in signaling pathways such as 
cell growth (Simon et al. 1998), proliferation and differentiation (Feng et al. 
2019b), in numerous cell types including neurones (Tsatmali et al. 2006; Huo et al. 
2009), where they also regulate synaptic plasticity (Betzen et al. 2009) and Ca2+-
mediated LTP in the hippocampus (Huddleston et al. 2008). Among other things, 
ROS have been shown to activate the AMPK pathway during hypoxia, resulting in 
activation of protective mechanisms, such as autophagy, and inhibition of mTOR 
(Emerling et al. 2009). 
The amount of ROS generated during mitochondrial respiration determines which 
of these pathways is activated; however, high amount of ROS are dangerous for the 
cells since they are able to oxidize cellular lipids and proteins, resulting in 
inflammation and cell toxicity (figure 1.5) (Gargalovic et al. 2006; Kagan et al. 




              
    (Full legend in the next page)  
Figure 1.5 Mitochondrial ETC and ROS production 
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Figure 1.5 Mitochondrial ETC and ROS production (full legend) 
Mitochondrial ETC consists of four transmembrane complexes (I to IV), two 
electron transporters (CoQ and cytC), and the ATP synthase (V). Hydrogen ions (H+, 
green arrows) are actively pushed through the IMM, producing a gradient that 
generates a variation in the MMP (ΔΨm, orange arrow). The electrons (blue arrows) 
move through the complexes and reduce oxygen to produce water. ROS are 
produced when a single electron ‘escapes’ the ETC, forming the superoxide ion. 
Oxidation of biological substrates and mtDNA mutations may induce mitophagy 
and, ultimately, cell death via apoptosis. Endogenous antioxidants and quality 






 Mitochondrial quality control 
Antioxidant molecules are strongly present in nature, therefore they could be 
introduced with the diet, such as the case of vitamin E (Mattill 1927). Moreover, 
cells are equipped with diverse antioxidant systems that dispose of the ROS 
produced in excess (figure 1.5, bottom left). Most of these systems are modulated 
by the nuclear factor erythroid 2-related factor 2 (NRF2): upon oxidative stress 
NRF2 – physiologically present in its inactive form in the cytoplasm – is 
phosphorylated and translocates to the nucleus, where it binds to antioxidant 
response elements (AREs) in the DNA (Murphy and Park 2017). NRF2 increases 
the expression of numerous antioxidant proteins such as superoxide dismutases 
(SOD) (McCord and Fridovich 1969), enzymes involved in glutathione synthesis 
(Meister and Anderson 1983) and the heme oxygenase 1 (HO-1) (Alam et al. 1999). 
Moreover, NRF2 induces the expression of the genes involved in mitochondrial 
biogenesis such as PGC1α (Gureev et al. 2019), the mitochondrial transcriptional 
factor A (TFAM) and NRF1, further contributing to reducing oxidative species in 
the cell (Athale et al. 2012; Gureev et al. 2019). 
If endogenous production exceeds the antioxidant capability of the cell, ROS may 




In the cells, ROS are mostly responsible for mtDNA mutations (Aruoma et al. 1989; 
Kowaltowski and Vercesi 1999; Hollensworth et al. 2000). As previously 
mentioned, the number of mitochondria per cell can vary considerably, however, 
the number of mtDNA copies per cell is maintained relatively constant – within a 
certain range – in each cell type. Mostly cell types in culture have between 1000 
and 5000 copies, while cells extracted from human biopsies show quite some 
variability, with the highest copy number – 400,000 – being found in oocytes – 
whose mitochondria are transmitted entirely to the progeny and therefore need to 
sustain the development process of the embryo (Wai et al. 2010). Because of the 
large number of copies, random mutations during mtDNA replication are very 
frequent (Gorman et al. 2015), ultimately leading to mitochondria carrying 
different version of the genome in the same cell. This phenomenon, called 
heteroplasmy, is still largely unknown and has been shown to be silently present 
in most of the global population (Irwin et al. 2009; Payne et al. 2013; Ye et al. 2014), 
whilst it can seldom be associated to mitochondrial diseases (Ye et al. 2014). 
Although mtDNA undergo mutations more frequently than nuclear DNA, 
mitochondrial function is not affected as much – probably due to a redundancy 
effect, where healthy mtDNA copies compensate for the defective ones (Wallace 
and Chalkia 2013). However, in the long term, the accumulation of ROS-induced 
mtDNA mutations can reduce mitochondrial efficiency and lead to cellular toxicity 
(Taylor et al. 2003) and even more ROS production (Vives-Bauza et al. 2006; Indo 
et al. 2007; Park et al. 2009), initiating a vitious cycle of oxidative stress and 
mitochondrial impairment. 
 
To rescue mitochondrial damage after ROS overproduction, cells activate various 
quality control processes. For instance, mixing the existing pool of mitochondria 
via fusion/fission, results in redistribution of the mutated mtDNA copies among 
hundreds of organelles (Mouli et al. 2009), so that ultimately each mitochondrion 
would contain mostly wild type mtDNA copies. Moreover, interleaved in the IMM 
there are several proteases of the AAA superfamily (ATPases Associated with a 
variety of cellular Activities) (figure 1.5), whose function is to mediate proteolytic 
degradation of unfolded, oxidated or defective proteins of the ETC (Langer et al. 
2001), while the cytoplasmic proteasomal machinery removes defective proteins 
in the OMM (Karbowski and Youle 2011). 
43 
 
An important protection mechanism is mediated by the UCP family. When the MMP 
raises significantly, it also increases the chance of proton leak and, consequently, 
the production of ROS (Korshunov et al. 1997). In this situation, a molecule or 
pathway able to induce a membrane depolarisation (reduction of the MMP), should 
significantly reduce proton leaking, preventing ROS from being produced.  
UCPs are ion transporters whose main function is to dissipate the proton gradient 
generated during mitochondrial respiration, by providing an alternative route for 
H+ to pass through the IMM (reviewed in Hass and Barnstable 2021). This could 
result in diverse outcomes, depending on the cell type and the UCP isoform.  
The first uncoupler to be discovered, UCP1, was cloned from rodents in 1985 and 
is expressed exclusively in brown adipocytes (Bouillaud et al. 1985; Jacobsson et 
al. 1985). It was originally named thermogenin, since its function is to convert the 
proton gradient into heat (instead of ATP) and to regulate body temperature (Klaus 
et al. 1991). Interestingly, its homologues in plants, StUCP (Laloi et al. 1997) and 
AtUCP (Nogueira et al. 2011), are also involved in thermogenesis and stress 
response in cold weather, suggesting a high degree of conservation across species 
and kingdoms.  
Identified in rodents a decade later, UCP2 (Fleury et al. 1997; Gimeno et al. 1997) 
is present at low levels in most tissues (Pecqueur et al. 2001), but is especially 
abundant in proliferating cells that rely on glycolysis as a main energetic source, 
such as stem cells (Zhang et al. 2011), and activated T cells (Rupprecht et al. 2012). 
Contrary to UCP1, UCP2 does not have a thermogenic function; instead, it has been 
shown to be particularly responsive to ROS, and to exert a protective function 
against oxidative damage in several cell types. In PC12 neuronal cells, 
overexpression of UCP2 significantly reduces cell death after H2O2-induced 
oxidative stress (Horvath et al. 2003). Similarly, retinal cells of transgenic mice 
expressing human UCP2 showed much greater survival rate, after injection in the 
eye of the excitotoxic kainic acid (that overstimulates neurones resulting in death) 
compared to wild type animals, and even more compared to UCP2 KO models 
(Barnstable et al. 2016). Interestingly, UCP2 has been shown to increase 
mitochondrial fission and degradation after severe stress, such as hypoxia in lung 
cells (Haslip et al. 2015) or ischemia in kidney tissue (Qin et al. 2019), further 
supporting its ubiquitous role in counteracting oxidative insult.  
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Other, less characterised members of the human UCP family are: UCP3 (Vidal-Puig 
et al. 1997), expressed in the heart and skeletal muscle, where it facilitates FA 
transport inside mitochondria during biogenesis (Hilse et al. 2018); UCP4 (Mao et 
al. 1999), almost exclusively expressed in the brain and associated to neuronal 
development (Smorodchenko et al. 2009) and neuroprotection (Cho et al. 2017); 
UCP5, also known as BMCP1 (Sanchis et al. 1998), expressed in several organs, 
including the brain, where it has been found to be neuroprotective (Kwok et al. 
2010); and UCP6, or KMCP1, first identified in the kidney, that show a strong 
sequence homology to UCP5, although it has not been reported to have any 
uncoupling activity (Haguenauer et al. 2005).  
Ultimately, these data show that mitochondria uncoupling may represent a strong, 
cell-specific, protection strategy against oxidative stress and related damage.  
 
However, if the oxidative stress is prolonged, cells activate one last protective 
mechanism called mitophagy, a combined effect of fusion, fission and lysosomal-
mediated autophagy that specifically isolate and degrade impaired mitochondria 
(Twig et al. 2008), in order to prevent the spread of oxidised proteins and lipids 
within the organelle network. Several mitophagic pathways have been recently 
identified in mammals (Di Rita et al. 2018; Yamada et al. 2019). The best 
characterised process – described only ten years ago (Jin et al. 2010; Narendra et 
al. 2010) – is mediated by the phosphatase and tensin homolog (PTEN)-induced 
kinase 1 (PINK1) and the cytoplasmic E3 ubiquitin ligase, Parkin. In physiological 
conditions, PINK1 is mostly located in the cytosol. However, its protein sequence 
contains a mitochondrial transport region (MTS) that allows its relocation at the 
OMM (Silvestri et al. 2005; Lin and Kang 2008), where the TOM complex mediate 
its import and the TIM23 anchors PINK1 to the IMM (Lazarou et al. 2012). There, 
PINK1 is cleaved sequentially by the mitochondrial processing peptidase (MPP) 
(Greene et al. 2012) and the presenilin-associated rhomboid-like (PARL) (Deas et 
al. 2011) and the resulting shorter peptide is quickly degraded via proteasome 
(Yamano and Youle 2013). Indeed, using the most common laboratory techniques, 
PINK1 is barely detectable inside the healthy cells, unless it is stabilized or 




The aforementioned process requires intact mitochondria. Indeed, ROS and 
heteroplasmy may cause severe mitochondrial damage, resulting in the reduction 
of the MMP (Chinopoulos et al. 1999; Ye et al. 2014), that initiate the mitophagic 
pathway. More specifically, when the membrane is depolarized PINK1 is not 
cleaved and accumulates at the OMM where it is stabilized with the kinase domain 
accessible to cytosolic substrates (Zhou et al. 2008). Once activated by auto-
phosphorylation (Aerts et al. 2015), uncleaved PINK1 recruits cytosolic Parkin at 
the OMM (Matsuda et al. 2010; Vives-Bauza et al. 2010). Parkin is a cytoplasmic E3-
ubiquitine ligase, ubiquitously expressed, whose function is to ligate a chain of 
poly-ubiquitin on the surface of defective proteins, targeting them to the ubiquitin-
proteasome system (UPS) for degradation (Imai et al. 2000; Shimura et al. 2000; 
Zhang et al. 2000). Parkin ligase activity relies on its ubiquitin-like domain, that is 
usually kept inactivated by intramolecular interactions (Chaugule et al. 2011; Ham 
et al. 2016). After it is recruited to the mitochondrion, full length (but not cleaved) 
PINK1 phosphorylates Parkin’s ubiquitin-like domain (Kondapalli et al. 2012; 
Shiba-Fukushima et al. 2012; Kazlauskaite et al. 2014), freeing it from its auto-
inhibition (Gladkova et al. 2018). At the same time, PINK1 phosphorylates free 
ubiquitin molecules (Kane et al. 2014; Koyano et al. 2014), making them accessible 
to Parkin’s catalytic domain. Once activated, Parkin transfers small chains of poly-
phospho-ubiquitin to numerous substrates in the OMM, forming transitory 
thioester bonds with the substrates (Iguchi et al. 2013; Zheng and Hunter 2013). 
Noteworthy targets of Parkin are: Mfn1/2, whose ubiquitin-induced degradation 
results in the inhibition mitochondrial fusion and induction of fission, concurring 
to separate the damaged mitochondrial components from the rest of the network 
(Gegg et al. 2010); and Miro, whose degradation causes the arrest of mitochondrial 
axonal transport (Wang et al. 2011). Moreover, poly-ubiquitinated substrates 
mobilise ubiquitin-binding autophagic receptors, such as p62 that binds the 
microtubule-associated-protein 1 light chain 3 (LC3) on the autophagosome 
surface, causing the two organelles to merge (Geisler et al. 2010). Lastly, LC3 is 
cleaved at the C-terminus, forming LC3-II (Kabeya et al. 2004), the 
mitochondrion/autophagosome combined content is released inside the lysosome 




Interestingly, this process may also involve smaller mitochondrial portions. 
Indeed, mitophagy has been shown to be preceded by extensive DRP1-mediated 
mitochondrial fission (Gomes and Scorrano 2008) that generates uneven 
subpopulations of organelles. This occurs when damaged proteins or mutated 
mtDNA nucleosomes are separated by the rest of the organelles and embedded in 
smaller mitochondrial-derived compartments (MDCs), some of which exhibits low 
MMP and are selectively targeted for degradation (Twig et al. 2008). A second 
independent mechanism is a membrane-budding process that generate 
mitochondria-derived vesicles (MDVs) that could also be transported to the 
lysosomes for selective mitophagy (Soubannier et al. 2012). However, this specific 
pathway has been shown to be independent of DRP1 and to also mediates 
communication among organelles (Sugiura et al. 2014), suggesting it may also be 
implicated in mitochondrial quality control. 
Ultimately, mitophagy is an essential process for maintaining mitochondrial health 
and cell survival. Indeed, mutations in key proteins of the mitophagic pathway are 
associated to familiar PD and it will be better described in chapter 4. 
 
When all the quality control pathways fail to repristinate mitochondrial function, 
cells trigger the apoptotic signalling mediated by enzymes of the B cell lymphoma 
2 (BCL2) family. In particular, BCL-associated X protein (BAX) is incorporated in 
the OMM and oligomerises with BCL2-homologous antagonist/killer (BAK) (Chen 
et al. 2005; Kuwana et al. 2005) in specific sites, stabilising DRP1 on the OMM and 
inducing apoptotic mitochondrial fragmentation (Wasiak et al. 2007). BAX/BAK 
oligomerisation also results in abnormal increase in mitochondrial permeability, 
MMP dependent (Gottlieb et al. 2003), and OPA-1 mediated cristae remodelling 
that provokes the extrusion of damaged materials from the organelles (Scorrano et 
al. 2002; Yamaguchi et al. 2008). The electron transporter cytC is released from the 
IMM and binds the cytoplasmic apoptotic protease activating factor 1 (Apaf1) to 
form a large structure called apoptosome (Zou et al. 1997), ultimately resulting in 
the activation of the caspase-9/caspase-3 apoptotic pathway (Li et al. 1997).  
In a separate process, severe mitochondrial damage causes high levels of Ca2+ in 
the mitochondrial matrix, triggering the opening of membrane-spanning 
mitochondrial permeability transition pores (mPTP) on the IMM. mPTP act as a 
release valve to reduce Ca2+ overload (Elrod et al. 2010) and induce cristae 
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remodelling (Bernardi et al. 2015) via a not yet well identified mechanism that may 
occur within the same BAX/BAK pathway (Scorrano et al. 2002).  
Ultimately, the release of mtDNA fragments – from either BAX/BAK pores or mPTP 
– may induce severe inflammation via translocation of the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kβ) (Giampazolias et al. 2017) and 
activation of the pro-inflammatory cytokine interferon 1 (IFN-I) response (Saito et 
al. 2019), ultimately leading to cell death in several organs (Oka et al. 2012; Ding et 
al. 2014), including the brain (Patrushev et al. 2006; Kalani et al. 2018).  
Notably, the pharmacological inhibition of mPTP with cyclosporin A has been 
shown to mitigate mitochondrial dysfunction (Bernardi et al. 2015). Similarly, cells 
lacking both BAX and BAK genes are resistant to pro-apoptotic compounds and 
mitochondrial toxins (Wei et al. 2001).  
Indeed, targeting mitochondrial-mediated cell death has been pointed out as a 
prospective clinical strategy against several age-related neurodegenerative 
disorders (Wu et al. 2019; Dey et al. 2020; Shevtsova et al. 2021). 
 
 Free radical theory of ageing 
Ageing is traditionally defined as the progressive deterioration of physiological 
capacities – or rather the accumulation, with time, of cellular and molecular 
changes associated to diminished responsiveness (resilience) to environmental 
stresses and increased vulnerability to diseases.  
The molecular mechanisms of ageing are still highly debated among scientists, 
although one of the theories with most consensus is the mitochondrial theory of 
ageing, that points to ROS accumulation as the major contributor to the process. 
This theory, originally known as the “free radical theory of ageing”, was formulated 
in 1956, after the first scientific evidences showed that the concentration of highly 
active oxidative species – physiologically produced in every living systems – 
increase with increasing metabolic activity and correlates with reduced lifespan, 
similarly to what happens after long exposure to radiations (Harman 1956). 
Although originally contested from the scientific community, this theory was soon 
confirmed by numerous studies. Oxidative damage – measured as the amount of 
oxidized nucleosides – has been shown to significantly increase in several areas of 
the human brain, in both nuclear DNA and mtDNA (Mecocci et al. 1993), while 
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extensive mtDNA mutations have been detected by single cell qPCR in the SN of 
aged healthy humans (Kraytsberg et al. 2006).  
Combining a serious of indirect evidences, this theory – later renamed 
“mitochondrial theory of ageing” – largely anticipated the role of oxidative stress 
and DNA damage in ageing and cancer, pointing at mitochondria’s ROS as the major 
cause of ageing and age-related disorders (Harman 1972; Barja 2019).  
Interestingly, the increment in life expectancy resulting from the CR regime is 
frequently suggested as opposing the ageing process attributed to the 
mitochondrial free radical theory of ageing (Barja 2007; Afanas’ev 2010). Indeed, 
a significantly diminished mitochondrial ROS production, per unit of O2 consumed, 
seems to occur during CR, without impairing ATP production (López-Lluch et al. 
2006). This evidence suggests that O2 consumption and ROS production are 
independently regulated and that a CR regimen – or CR mimetics such as acyl-
ghrelin – may prevent oxidative stress without affecting cellular metabolism, 
therefore representing a valid therapeutic strategy against mitochondrial ageing. 
On the contrary, some studies show that CR may actually increase ROS production 
and that pharmacological treatments with anti-oxidant compounds may have 
detrimental effects in the long-term, such as pro-tumorigenesis and reduced 
lifespan (reviewed in Ristow and Zarse 2010).  
It has been hypothesised that CR-mediated increase in ROS – although subtle – 
would induce the cells to activate an adaptive response to oxidative stress, 
ultimately leading to increased resilience in the long term. Opposite to Harman’s 
theory, this hypothesis named “mitochondrial hormesis” or just “mitohormesis”, 
suggests that a defined amount of intracellular ROS is required at all times, in order 
to promote cell health and prevent age-related disorders (Tapia 2006).  
This theory does not completely overcome Harman’s, rather it complements it by 
highlighting the fragility of all the biological systems. Indeed, ageing – just like any 
other disease and biological process – is just the result of an imbalance between 
the numerous factors constantly stimulating our systems, pulling in different 
directions. Hence, improving our understanding of this balance, is the key to 




 In vitro models of oxidative damage and neurodegeneration 
The neural processing of information is metabolically very expensive: the brain 
uses approximately 20% of the whole body oxygen consumption, despite being 
only the 2% of the total weight (Kety 1957), therefore the OXPHOS process is 
particularly important in neurones. However, ROS production exponentially 
increases with age and since neurones are post-mitotic cells, hence survive many 
decades with little renewal, ROS will accumulate with time, ultimately resulting in 
neuronal cells being more susceptible to oxidative stress than other cell types.  
Complex V impairment, with consequential loss of efficiency of the ETC system and 
ROS hyperproduction, have been associated with accelerated ageing (Warnsmann 
et al. 2021), and mtDNA mutations were found to accumulate in the brain of aged 
subjects with brain diseases (Bender et al. 2006). Moreover, ROS are considered to 
be key components in the aetiogenesis of several age-related neurodegenerative 
diseases, such as PD (Floor and Wetzel 1998; Yamamoto et al. 2007; Ikawa et al. 
2011; Burbulla et al. 2017) and AD (Smith et al. 1998; Padurariu et al. 2010; 
Angelova et al. 2015; Mota et al. 2015). Interestingly, specific neuronal sub-
populations show increased susceptibility to oxidative stress. This is the case of 
dopaminergic neurones in PD, and the hippocampal neurones of the CA1 in AD, as 
it will be better described in chapter 4 and 5, respectively. 
 
The maintenance of a healthy population of mitochondria is essential for cell 
survival and to prevent age-related neuronal disorders. However, studying 
mitochondrial health directly in the brain of the patients is challenging, and animal 
models cannot fully recapitulate the complexity, length (several decades) and 
pathogenesis of human cognitive disorders. In the last twenty years, researchers 
have been focusing on in vitro systems such as human stem cells-derived neurones. 
These neurones originate from human pluripotent stem cells that can be guided 
towards maturation using either chemicals or genetic engineering. Hundreds of 
protocols are currently available for differentiation into specific cell types such as 
dopaminergic neurones (Zhang et al. 2014), cortical neurones (Hirabayashi et al. 
2004), astrocytes (Krencik and Zhang 2011), retina cells (Mandai et al. 2017) and 




In practice, stem cell-derived neurones currently represent one of the best models 
of human brain maturation – much closer, genetically and functionally, than animal 
models. However, in order to recapitulate specific disease-relevant phenotypes, it 
is often necessary to treat the cells with a toxin or drug that would induce such 
phenotype – sometimes even in cells that are already carrying disease-relevant 
mutations (Mertens et al. 2018) – therefore removing the “slow accumulation” 
element of neurodegenerative diseases from the system.  
Several toxins can be used to induce mitochondrial damage and to simulate in vitro 
the accumulation of intracellular stress naturally occurring during ageing. For 
instance, long exposures to mitochondrial toxins, like the uncoupler carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP) that causes membrane depolarization 
(reduction of MMP), induce severe mitochondrial damage, as can be determined by 
measuring specific mitochondrial markers, such as TOM20, cytC, and OPA1 (Geisler 
et al. 2010). Similarly, drugs such as rotenone could be used to induce PD-like 
symptoms in mice and PD-like molecular changes in cells, as it will be better 
described in chapter 4. 
In these models, MMP can be taken in consideration as a measure of mitochondrial 
health. Several MMP probes, such as the MitoTrackerTM Orange and many others, 
have been developed for research purposes based on the principle that positively 
charged fluorescent molecules that are able to cross the OMM (lipophilic), would 
accumulate in the intermembrane space (IMS), proportionally to the amount of its 
charge (the extent of the depolarisation) (Smith et al. 2003; Perry et al. 2011b; 
Logan et al. 2016). Most of these probes act as molecular sensor of oxidative stress: 
once in the IMS, they are oxidised by the ROS produced by actively respiring cells 
and emit a specific fluorescent signal. Once fixed, the intensity and localisation of 
the stain inside the cells allows indirect measure of mitochondria oxidative activity 
– the stronger the fluorescence, the higher the MMP – while preserving the cellular 
3D structure (Agnello et al. 2008). 
Following oxidative stress, disruption of the MMP can also induce changes in 
mitochondrial gene expression and protein synthesis (Guantes et al. 2015), 
ultimately reducing or inhibiting physiological processes such as mitochondria 
fission/fusion and biogenesis. Hence, molecular markers such as phosphorylated 
DRP1 (Cereghetti et al. 2008; Xu et al. 2016) or PGC1α (Carré et al. 2010; Davinelli 
et al. 2013), could also be taken in consideration to evaluate mitochondrial health. 
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Moreover, several protocols and commercial kits are available to analyse other 
aspects of mitochondrial health, both in vitro and in vivo, such as ATP production 
(Wibom et al. 1990; Shepherd et al. 2006; Salin et al. 2016) and oxidative stress 
(Sano et al. 1998; Roberts and Morrow 2000; Valgimigli et al. 2001; Giustarini et al. 
2009; Marrocco et al. 2017). Lastly, a common way to quantify mitochondria 
activity consists of monitoring the oxygen concentration in the media of cultured 
cells or isolated mitochondria using specific oximeters, such as the Seahorse FX 
analyser (Wu et al. 2007).  
In sum, each of the aforementioned protocols give helpful insights into 
mitochondrial health and function; however, due the complexity of the system and 
the variability of the models, a combination of diverse methodology is required in 
order to trace a comprehensive picture of mitochondria health in vitro. 
 
 Ghrelin regulates mitochondrial health via pAMPK 
Since the discovery of its involvement in memory and brain function, an increasing 
number of studies have shown that acyl-ghrelin is also a key-mediator of 
mitochondrial health in several tissues. Acyl-ghrelin binds to GHS-R1a and induces 
AMPK phosphorylation via Ca2+-sensitive kinases, as shown in section 1.2.9. 
Indeed, acyl-ghrelin increases AMPK phosphorylation – quantified as the ratio 
between pAMPK and total AMPK – in the SN of intraperitoneal-injected mice, as 
well as in cultured dopaminergic cell line SN4741 (Bayliss et al. 2016a).  
As previously mentioned, in the hypothalamus, AMPK serves as a cellular energy 
sensor and its phosphorylation is regulated by a group of metabolic hormones, 
including ghrelin, leptin and insulin (Andersson et al. 2004; Minokoshi et al. 2004). 
Once activated, pAMPK phosphorylates a series of targets involved in cell 
metabolism, such as the acetyl-CoA carboxylase (ACC), whose main function is to 
regulate lipid oxidation and provide mitochondria with FA during biogenesis (Hu 
et al. 2003) (figure 1.6, point 1). 
 
pAMPK also phosphorylates DRP1 at different sites, to modulate the remodelling 
of mitochondrial networks (figure 1.6, point 2): in case of an energy shortage, 
pAMPK would favour DRP1 phosphorylation at the anti-fission site s637, resulting 
in the organelles fusing in a large tubular network in order to maximize energy 
production (Wikstrom et al. 2013); on the other side, a more severe oxidative 
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stress would preferentially trigger mitochondria fission, with pDPR1 s616 
interacting with Mfn1/2, resulting in the containment of damaged mitochondria 
and their consequential degradation (Zheng et al. 2018). Notably, two studies 
performed in mice reported that either a life-long 40% CR regime (Khraiwesh et al. 
2013), or treatment with a CR mimetic compound (Liu et al. 2015) increases total 
DRP1 expression as well as the number, size and surface area of mitochondria, in 
the liver and brain respectively. These data suggest that CR affects DRP1 by 
favouring mitochondrial fission (phosphorylation at s616), however more studies 
are needed to determine if this effect is mediated by acyl-ghrelin. Preliminary 
studies from our group, showed that acyl-ghrelin treatment of SN4741 mouse 
neuronal cells significantly increase s616 phosphorylation (unpublished). 
Interestingly, it has been recently shown that activation of the ERK1/2 pathway 
results in preferential DRP1 phosphorylation at s616 and reduced MFN1 
oligomerisation, overall increasing mitochondrial fission (Pyakurel et al. 2015; 
Prieto et al. 2016). Since acyl-ghrelin is a strong activator of the ERK pathway, via 
pAMPK, in several tissues and models (Zhang et al. 2007; Liang et al. 2012; Wang 
et al. 2012b; Waseem et al. 2014; Wang et al. 2020), it is reasonable to hypothesise 
that acyl-ghrelin is indeed the mediator of CR-induced DPR1 phosphorylation at 
s616. However, more studies need to be performed to investigate the role of the 
GHS-R/pAMPK/ERK pathway in mitochondrial fission and fusion balance. 
 
As mentioned in section 1.2.9, pAMPK works along with SIRT1 to mediate 
mitochondrial health (Cantó et al. 2009). One of the key target of  pAMPK/SIRT1 
pathway, is PGC1α that then translocates to the nucleus and induces the expression 
of numerous enzymes of mitochondria biogenesis, like the nuclear respiratory 
factor 1 (NRF1) involved in mtDNA replication and cell growth (Bergeron et al. 
2001) (figure 1.6, point 3). Accordingly, acyl-ghrelin injection in rodents, promotes 
mitochondrial respiration and increases mitochondrial number in NPY neurones 
in the hypothalamus, and this effect is abrogated in AMPK KO mice (Andrews et al. 
2008). Interestingly, CR has also been shown to increase mtDNA copy number and 
to stimulate mitochondrial biogenesis via PGC1α; moreover using an in vitro model 
of CR, in which cell nutrients were reduced although maintained balanced, MMP 
and ROS generation were both significantly reduced, without negatively affecting 






Acyl-ghrelin binds to GHS-R1a resulting in phosphorylation of AMPK and 
activation of numerous downstream pathways involved in mitochondrial health. 
Three significant targets of pAMPK are: (1) ACC, involved in lipid metabolism; (2) 
DRP1, whose phosphorylation state determine the balance between fission and 
fusion; (3) PGC1α, resulting in increased mitochondria biogenesis; (4) UCP2 and 
(5) NRF2, resulting in reduced oxidative stress. (6) Moreover, pAMPK pathway also 
results in repression of pro-inflammatory factors. (7) Lastly, if the oxidative stress 
persists, acyl-ghrelin favours PINK1/Parkin mediated autophagy (created with 
BioRender.com). 
  
Figure 1.6 AMPK-mediated ghrelin effects on mitochondria homeostasis 
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In rodents, peripheral injected acyl-ghrelin increases UCP2 mRNA levels in NPY 
neurones in the hypothalamus of wild type animals, while ghrelin-mediated 
increase in mitochondrial number is abrogated in UCP2 KO animals (Andrews et 
al. 2008) (figure 1.6, point 4), suggesting that UCP2-mediated MMP uncoupling 
may also represent a potential molecular mechanism behind ghrelin-mediated 
neuroprotection. 
The acyl-ghrelin/pAMPK pathway has also been shown in vitro to phosphorylate 
NRF2, which separates from its cytoplasmic inhibitor Keap1, translocates to the 
nucleus and increases gene expression of anti-oxidant enzymes (Wang et al. 2020) 
(figure 1.6, point 5), and prevents activation of immune cells, as reported from the 
reduction of the microglial marker IBA1 and the astrocytic GFAP (Bayliss et al. 
2016a). Moreover acyl-ghrelin reduces the expression of pro-inflammatory 
cytokines, such as the plasminogen activator inhibitor type 1 (PAI-1) and the 
tumour necrosis factor α (TNF-α), by inhibiting the inflammatory pathway 
mediated by the nuclear factor kappa-light-chain-enhancer of activated β-cells 
(NF-kβ) (Ding et al. 2008; Moon et al. 2009) (figure 1.6, point 6). 
Lastly, acyl-ghrelin preserves cellular health, by inducing PINK1/Parkin- mediated 
degradation of damaged mitochondria in conditions of extreme oxidative stress, 
via the AMPK/PGC1α pathway (Wang et al. 2021), although the exact conditions 
that determine the shift between a pro-survival response and induction of 
mitophagy, have not been entirely clarified yet (figure 1.6, point 7). 
 
In summary, CR and acyl-ghrelin act as cellular regulators of mitochondrial 
homeostasis, aiming at both preserving/increasing them and degrading them 
when they are dysfunctional. Moreover, these evidences strongly point to pAMPK 
as being the key mediator of the ghrelinergic axis activity on mitochondrial 
function in the brain. Since mitochondria are involved in every possible mechanism 
in the body, more studies are needed to further characterise the role of the 
ghrelinergic axis in mitochondrial health, and to determine whether it is possible 





1.4 The ghrelinergic system in the human brain 
 
 Brain accessibility 
Ghrelin mRNA is undetectable in the brain, therefore most, if not all, of the ghrelin 
in the brain is transported from the stomach via the circulation. In order to interact 
with GHS-R in the brain, circulating peptides need to cross the blood-brain-barrier 
(BBB) (figure 1.7 A), a highly stringent structure formed by three elements: 
endothelial cells from the capillary side, with numerous tight junctions that 
determine its selectivity; “end-feet” astrocytes that surround the external wall of 
the capillary, which are involved in the formation and maintenance of the barrier; 
and pericytes that provide structural support (Ballabh et al. 2004). Banks and 
colleagues showed that intracranial-injected radio-labelled human acyl-ghrelin is 
able to cross the BBB in mice, in both blood-to-brain and brain-to-blood directions, 
through a saturable system – most likely an active transport – while human 
unacylated ghrelin enters the brain by non-saturable transmembrane diffusion 
(Banks et al. 2002). These data were later supported by other studies (Diano et al. 
2006; Pan et al. 2006), suggesting that the BBB plays a major role in determining 
ghrelin concentration in the brain. 
Another source of circulating factors in the brain is the cerebrospinal fluid (CSF), a 
colourless liquid that fill the five ventricle cavities in the brain parenchyma, and 
surround its surface providing mechanical protection and nurture (Cushing 1914). 
The CSF is separated from the stroma by a distinct semi-permeable barrier, the 
blood-cerebrospinal fluid barrier (BCSFB), which consists of two distinct elements. 
First, the choroid plexus (CP) is a layer of cube-shaped epithelial cells adjacent to 
the lateral ventricles (figure 1.7 B) (Scott et al. 1974). CP cells produce the CSF, 
which is constantly filtered bidirectionally from and to the blood via “fenestrated” 
capillaries, that contain small pores to facilitate the exchange of molecules (Brown 
et al. 2004). Interestingly, the ependymal cells of the CP express tight junctions that 
prevent molecules to cross freely from and to the blood, therefore making the 
ependymal cells of the CP the main regulators of the CSF content (Dandy 1918; 
Davson 1966; Brown et al. 2004). Second, the circumventricular organs (CVO) are 
specialised structures in the third and fourth ventricles, containing an exclusive 





(A) The blood brain barrier (BBB) regulates transport of substances from the brain 
capillaries, to specialised astrocytes surrounding the endothelium. (B) Adjacent to 
the ventricles, the choroid plexus (CP) mediates transport from fenestrated 
capillary and the CSF, produced by the ependymal cells. (C) Lastly, the 
circumventricular organs (CVO), are specialised structures that share 
characteristics of both the BBB (tight junctions, specialised astrocytes) and the CP, 
(fenestrated capillaries, transport to the CSF) (created with BioRender.com).  
Figure 1.7 Anatomy of the cerebrovascular barriers 
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Opposite to the CP, the blood vessels of the CVO are fenestrated only for a short 
tract, while for the rest of it they resemble a traditional BBB, with astrocytes 
creating a barrier around the vases (Morita et al. 2016). The CVOs come into 
contact with several areas of the brain, including the inferior portion of the 
hypothalamus, the median eminence (ME), where the BCSFB is highly permissive 
to allow hormones and peptides produced there to be secreted directly into the 
circulation (Morita et al. 2016). A recent study showed that a fluorescent analogue 
of acyl-ghrelin peripherally injected in mice, is internalised by the ependymal cells 
of the CP and by a specific subset of hypothalamic tanycytes (Uriarte et al. 2019). 
The authors synthesised several fluorescent variants of the hormone – truncated 
or mutated peptides that simulate the high variability of GHRL products – then 
measured their uptake efficiency. Their data show that both the tanycytes and the 
ependymal cells of the CP have very low-selectivity for the different variants of the 
fluorescent hormone, granting the access to all ghrelin molecules whose N-
terminal sequence was intact (Uriarte et al. 2019). These data suggest that the 
BCSFB may also play an important role in controlling ghrelin access to the brain.  
 
There are two main differences between the BBB and the BCSFB. First, the BCSFB 
is more permeable than the BBB, due to the fenestrated capillaries; second, while 
the CSF only flows between the ventricles and on the surface of the brain, the 
microcirculation – filtered by the BBB – goes deeply into the brain parenchyma 
reaching areas not directly accessible to the CSF (reviewed in Pardridge 2016; 
Mastorakos and McGavern 2019). Interestingly, different doses of circulating acyl-
ghrelin have been shown to affect its brain localisation: a low dose of fluorescent 
acyl-ghrelin, peripherally injected in mice at rest, showed higher preference for the 
hypothalamus and was barely detectable in the CSF. Conversely, either a centrally 
injected or a peripherally injected high dose of fluorescent acyl-ghrelin was able to 
reach a wider number of regions and was measurable in the CSF (Cabral et al. 2014; 
Uriarte et al. 2019). Indeed, a new model has been proposed (Perello et al. 2019) 
to describe ghrelin accessibility to the brain: a small increase in circulating ghrelin, 
such as pre-prandially, would allow a quick, direct, and loosely selective access to 
the hypothalamus and the ARC – via the tanycytes of the ME – where ghrelin would 
exert its main orexigenic effects. On the contrary, a higher and steady increase of 
acyl-ghrelin in the blood, like during prolonged CR or pharmacological 
58 
 
intervention, would increase uptake from both the BCSFB – increasing the peptide 
concentration in the CSF – and the BBB, allowing it to reach a wider number of 
targets, deeper in the brain parenchyma. For instance, a subcutaneous ghrelin 
injection of 60pmol/g in wild type mice has been shown to activate the neurones 
in the ARC and promote food intake without significantly affecting other brain 
areas, while a much higher dose of 300pmol/g activates neurones of the 
paraventricular area (which also express GHS-R1a) to modulate food-related 
stress response, independently from the ARC (Cabral et al. 2016). The hypothesis 
that ghrelin can access numerous brain structures, depending on its plasma 
concentration, is consistent with the fact that GHS-R1a is expressed almost 
ubiquitously in the brain (this will be discussed in section 1.4.4), including areas 
that are usually less accessible to circulating peptides, such as the hippocampus. 
Moreover, this theory debunks the hypothesis from Wellman and colleagues 
(Wellman and Abizaid 2015), previously described, that GHS-R1a-mediated effects 
in the hippocampus are solely caused by its constitutive activity. 
 
Another possibility is that ghrelin distribution in the brain may prioritise areas that 
are most active, therefore its transport would be based on need, rather than 
location. This hypothesis originates from the fact that ghrelin crosses the BBB via 
a saturable mechanism (Banks et al. 2002) and it would most likely require specific 
signals to access certain areas of the brain. However, it is also possible that 
regulating the expression of GHS-R1a in specific areas of the brain, – rather than 
regulating the amount of ghrelin that is transported there – would be enough to 
determine ghrelin’s activity in that area. Indeed, a recent study showed that ghrelin 
transport across the BBB occurs independently from the amount of GHS-R1a 
expressed from the target cells (Rhea et al. 2018). This suggests that the regulation 
of ghrelin transport is not influenced by signals coming from the brain 
parenchyma, rather occurs independently from it: after ghrelin is distributed in the 
brain, according to its plasma concentration and brain permeability, the regulation 
of GHS-R1a expression could be an additional mechanism of regulation in certain 
areas or cell types. Interestingly, it has been shown that GHS-R1a is internalised 
approximately 20 minutes after ghrelin’s binding in order to protect the receptor 
from overstimulation, a mechanism that is shared by several other GPCRs (Tolle et 
al. 2001; Camiña et al. 2004). Approximately 360 minutes after agonist removal, 
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GHS-R1a levels on the cell membrane are restored and the cycle can start again 
(Camiña et al. 2004). The quick internalisation reduces the ability of the cell to 
further respond to ghrelin in the short term – indicating that the need for ghrelin 
of that cell has been fulfilled.  
Overall, these evidences show that the mechanisms that regulate ghrelin entry into 
the brain have a major role in determining its activity, and that paradigms like CR 
or diseases that may modify its plasma concentration, are able to influence the 
extent of ghrelin’s presence, and therefore its function in specific brain areas. 
 
 Human hippocampus anatomy and structure 
The human hippocampus is a 4-4.5cm long and 1-2cm thick arched bilateral 
structure (figure 1.8), localised under each hemisphere’s cortex in the medial 
temporal lobe. It is part of the limbic lobe, a C-shaped region on the medial surface 
of the hemispheres that surrounds the midbrain, identified in 1878 by Paul Broca 
and named from the Latin limbus, that means edge, since this region represent the 
curved rim of the cortex (Broca 1878). 
The term hippocampus, first used in the XIV century (Arantius 1587), is ancient 
Greek for seahorse, due to its resemblance with the sea creature with whom it 
shares an arched physiognomy. Indeed, the hippocampus folds on itself during 
development, although this process remains incomplete in most mammals and 
only reaches its maximum extent in humans: the rat hippocampus remains dorsal 
to the thalamus, while in humans it curves beneath (Tilney 1939). Interestingly, the 
size of the hippocampus, compared to body weight, generally increases in higher 
species, with the largest being found in primates (Stephan 1983). Due to its 
connection with memory and learning, it has been hypothesised that the size of the 
hippocampus in the different species may correlate with increased cognitive 
abilities. However, some highly evolved species such as dolphins and whales, have 
a small hippocampus if considered in proportion to the size of their brain (Patzke 
et al. 2015). Moreover, certain hippocampal areas such as the CA1 and the dentate 
gyrus, are much larger in humans and monkeys, in relation to the size of the whole 
hippocampus, compared to rodents and other species (Stephan and Manolescu 






(A) Representation of a single human hippocampus, with the CA and the DG folding 
on each other. (B) The typical “C-like” aspect of the GCL (dark grey) on coronal 
sections at different positions (from i to v). (C) Coronal section from the 
hippocampus body (iii) (adapted with permission from Duvernoy et al. 2013, 
Springer licence number 4967160485075) (continues in the next page).   
Figure 1.8 Structure of the human hippocampus 
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   Figure 1.8 Structure of the human hippocampus (continuation) 
(A) 1 body; 2 head; 3 tail; 4 terminal segment; 5 digitationes; 6 vertical digitation; 
7 uncus; 8 band of Giacomini; 9 margo denticulatus. (C) 1 alveus; 2 stratum oriens; 
3 stratum pyramidale, or pyramidal layer; 3 stratum lucidum; 4 stratum radiatum; 
5 stratum lacunosum; 6 stratum moleculare; 7 vestigial hippocampal sulcus; 8 
stratum moleculare, or molecular layer; 9 stratum granulosum, or granular layer; 
10 polymorphic layer; 11 fimbria; 12 margo denticulatus; 13 fimbrio-dentate 





On the medial axis (antero-posterior), the human hippocampus can be divided in 
three segments: head, or anterior segment; body, middle segment; and tail, 
posterior segment (figure 1.8 A) (Duvernoy et al. 2013). On the lateral axis (left-
right) it consists of two layers, or laminae: the Cornu Ammonis (CA) or 
hippocampus proper, and the dentate gyrus (DG) or fascia dentata. The two 
laminae are folded inside each other, so that, in coronal sections, they appear as 
two intersecting “C” letters separated by the hippocampal sulcus (figure 1.8 B and 
C). From the intersection of the two laminae, several layers of distinct cells can be 
identified in coronal sections (figure 1.8 C, layers 1 to 10). The largest and most 
evident one is the pyramidal cell layer (figure 1.8 C, layer 3), whose cells are easily 
recognisable by their large triangular soma and dense ramifications. The 
heterogeneity of this region led anatomists to divide it in 4 distinct parts: the CA1 
is a large area that continues from the subiculum (Latin for support), a wide 
structure that seem to physically sustain the hippocampus in place and whose 
fibers connect it directly to the entorhinal cortex; the CA2 is a small transition 
region with densely packed cells; the CA3 corresponds to the curve of the lamina 
and is rich in non-myelinated mossy fibers originating in the DG; lastly the CA4 – 
sometimes called hilus or the end-blade of the hippocampus – is the region 
underlying the DG curvature and is scarcely dense of cellular soma but rich of 




The DG lamina is also divided in 3 layers: the thick molecular layer (figure 1.8 C, 
layer 8) that mostly receive fibers from the entorhinal cortex via the perforant 
pathway; the granule cell layer (figure 1.8 C, layer 9), or GCL, that contains plenty 
of small, round and densely packed neuronal cell bodies, which form the smaller ‘C’ 
in coronal sections; lastly, the polymorphic layer (figure 1.8 C, layer 10), a very thin 
layer that contains the initial part of the GCL cells’ axons – those mossy fibers that 
will then cross the CA4 and CA3. 
Lastly, between the DG and the CA, there is often another visible layer, the 
hippocampal sulcus, that sometimes forms vestigial cavities (figure 1.8 C, layer 7) 
(Duvernoy et al. 2013). Ultimately, the CA and the DG form two continuous laminae 
on the longitudinal axis, resulting in the hippocampus being essentially the same 
throughout its length. 
 
 Hippocampus and mnemonic functions 
The first evidence that connected the human hippocampus to mnemonic function 
dates back to 1953, when a surgeon performed a bilateral temporal lobe resection 
on patient H.M., relieving him of an uncurable epilepsy, but causing a severe 
memory loss (Scovielle and Milner 1957). Since then, many studies investigated 
the role of hippocampus on memory formation, consolidation and recall in rodents 
(Aggleton et al. 1999; Clark et al. 2000; Prusky et al. 2004), primates (Zola et al. 
2000; Nemanic et al. 2004), and humans (McKee and Squire 1993; Pascalis et al. 
2004; Kirwan et al. 2010; Lad et al. 2019). 
The totality of the information coming from the environment, are collected by 
specialised sensorial organs associated to specific cortical structures: for instance, 
the parietal cortex is mostly activated upon reception of visual signals (Sakata and 
Kusunoki 1992), the temporal cortex after auditory signals (Scheich et al. 1998), 
and so on. Then all the signals converge to the entorhinal cortex, and later to the 
hippocampus, where information most recently acquired are “stored” for short-
term recall – opposite to older “long-term” memories that are stored in the cortex 
(Duvernoy et al. 2013). 
The human hippocampus has been associated to the processing of space (Hassabis 
et al. 2009) and time (Umbach et al. 2020); decision-making processes (Bach et al. 
2014); episodic memory, such as recall of autobiographic memory (personally 
experienced events, set in a precise space-temporal context) (Chadwick et al. 2010) 
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and the emotions associated to them (Zhu et al. 2019); visual and odour recognition 
(Levy et al. 2003); pattern separation for overlapping memories, for example 
recognition of details across different memories (Chadwick et al. 2011); and many 
more. Significantly, the hippocampus has been shown to be the main regulator of 
coordinating separate elements from divergent type of memories, into one whole 
representation (Backus et al. 2016). Moreover, the hippocampus has also an 
important function in regulating endocrine processes such as stress management, 
fear and anxiety, for instance in post-traumatic stress disorder (Astur et al. 2006; 
Milad et al. 2007). 
The hippocampus ability to create and retain new memories, mostly involves the 
neuronal progenitor cells in the GCL layer, that are able to generate new neurones 
through lifetime (Boldrini et al. 2018; Moreno-Jiménez et al. 2019). These cells are 
involved in memory and plasticity, but also mood and anxiety. Interestingly, 
antidepressant drugs like serotonin reuptake inhibitors and tricyclic 
antidepressant, specifically stimulates neuronal progenitors of the GCL in the brain 
of patients with major depressive disorder (Boldrini et al. 2009; Anacker et al. 
2011), suggesting that targeting these cells may have beneficial effects on the 
hippocampal function. 
 
Despite the consistency of its anatomical structures, the three main hippocampal 
regions – head, body, and tail – have been suggested to be noticeably different when 
it comes to their function. Fifty years ago, a study showed that the dorsal and 
ventral regions of the mouse hippocampus have distinct input and output 
connections (Swanson and Cowan 1977). Since then, numerous studies performed 
in mice by selectively lesioning individual hippocampal regions, reported that the 
ventral segment modulates emotional behaviour and affective processes, including 
stress response (Henke 1990) and fear (Maren and Holt 2004), while the dorsal 
area is involved in cognitive and mnemonic function, including navigation and 
spatial processes (Moser et al. 1995). Interestingly, Bast and colleagues identified 
a third functionally distinct region in the intermediate segment, involved in 
translating cognitive and spatial knowledge into motivation and action (Bast et al. 
2009), although the existence of such region is still debated. 
Several studies confirmed this regionalisation in the human hippocampus, where 
the most posterior (dorsal) segment – the tail – has been associated to spatial 
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navigational strategy and visuo-spatial cognition (Brunec et al. 2018) and showed 
greater connectivity with medial and lateral parietal cortex (Adnan et al. 2016; 
Vogel et al. 2020); whereas the most anterior (ventral) region – the head – is 
associated to imagination and episodic memory (Barry et al. 2019), and is highly 
connected to temporal and orbitofrontal cortex (Adnan et al. 2016), that is also 
involved in social and motivational behaviours (Vogel et al. 2020). 
However, few studies using electrophysiological recordings in rodents (Kjelstrup 
et al. 2008) and fMRI imaging in humans (Collin et al. 2015), suggest that the 
hippocampus longitudinal axis is functionally organized along a gradient, rather 
than being arranged in discrete regions. Moreover, left and right hippocampi in 
human seem to have differential activations. 
Studies performed in patients with unilateral temporal lobotomy, identified a 
correlation between the right hippocampus and patients’ visuo-spatial memory 
abilities – the ability to recall objects and their location (Smith and Milner 1981), 
while the lobectomy of the left hippocampus has been associated to impaired 
working memory capacity and verbal or narrative memory (Frisk and Milner 
1990). Subsequent fMRI studies confirmed this hypothesis: for instance, recalling 
a complex driving route through a city, preferentially activates the right posterior 
hippocampus (Maguire et al. 1997), while recall of verbal material (Greicius et al. 
2003) and the acquisition of new conceptual information (the acquisition of rules 
that can guide behaviour in novel situations) (Kumaran et al. 2009), mostly activate 
the left posterior hippocampus. 
 
Overall, the hippocampus multifaceted role in memory and cognition, makes it 
significantly relevant in the study of ageing and neurodegeneration.  
Interestingly, structural abnormalities have been observed in a variety of 
neuropsychiatric diseases: unilateral decrease of the hippocampal volumes has 
been reported in major depression (Bremner et al. 2000) and bipolar disorder 
(Swayze et al. 1992); bilateral volume loss was reported in schizophrenia (Heckers 
2001) and alcoholism (Sullivan et al. 1995); while increased volume was reported 
in some genetic disorders like X-fragile syndrome (Reiss et al. 1994). Ageing has 
also been associated to a slight decrease of the hippocampal size (Convit et al. 
1995b), although there are contradictory evidences on this matter (Sullivan et al. 
2005). Indeed, the human hippocampus shows selective vulnerability to age-
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related diseases that are unique to humans. For instance, spatial and episodic 
memory impairments are the first symptoms of AD, whose main feature is cellular 
damage to the medial temporal lobes, including the hippocampus (Moss et al. 1986; 
Laakso et al. 1996). Moreover, hippocampal cell loss is also present in other 
neurodegenerative disorders, like PD (Laakso et al. 1996; Camicioli et al. 2003), 
and Huntington (Rosas et al. 2003).  
Ultimately, the hippocampus plays a pivotal role in human cognition and memory 
and its impairment in certain disease makes it a valuable pharmacological target. 
 
 The ghrelinergic system in the human brain 
Acyl-ghrelin has been shown to affect memory and attention, two cognitive 
functions that are associated to the hippocampus. However, there is general 
consensus that acyl-ghrelin is not produced in the brain (Kojima et al. 1999; Banks 
et al. 2002; Wortley et al. 2004; Grouselle et al. 2008; Kageyama et al. 2008; Yang 
et al. 2008a; Sakata et al. 2009; Furness et al. 2011; Cabral et al. 2017) – with the 
possible exception of two regions: the hypothalamus, whose neurones show dense 
ghrelin+ vesicles in presynaptic terminals (Russo et al. 2017), and its tiny 
neighbour, the septum pellucidum (Cowley et al. 2003). Since septal neurones 
project to the hippocampus (Huh et al. 2010), it may be hypothesised that ghrelin 
reaches hippocampal GHS-R1a following release from presynaptic septal 
neurones, in which it may be endogenously produced. Nevertheless, ghrelin 
production in the septum was not confirmed by other studies. 
Notably, numerous researches report that acyl-ghrelin crosses both BBB and 
BCSFB, as shown in section 1.4.1. Eventually, the latest proposed model of acyl-
ghrelin accessibility to the brain (Perello et al. 2019), states that central ghrelin is 
exclusively produced peripherally, and later transported in the brain so that its 
availability in the deepest areas of the parenchyma is almost exclusively dependent 
on its plasma concentration (see section 1.4.1). 
 
Notably, another regulatory mechanism has recently emerged that could represent 
a turning point in understanding the ghrelinergic activity in the brain. As 
mentioned in section 1.2.5, GOAT is the only enzyme known to catalyse ghrelin 
acylation, and ghrelin is the only known substrate of GOAT. Since ghrelin is not 
produced in the brain, and numerous evidences show that peripheral GOAT 
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expression perfectly matches that of ghrelin (Sakata et al. 2009; Lim et al. 2011), it 
seems unlikely that GOAT would be expressed in the brain. However, recent studies 
detected GOAT mRNA in the mouse hippocampus; even more interestingly, using 
mouse hippocampal slices and a fluorescent acylation reporter, GOAT – most likely 
located in the plasma membrane – was able to re-acylate ghrelin in-situ (Murtuza 
and Isokawa 2018). These data significantly change the previous knowledge about 
the dynamics of the ghrelinergic axis; indeed, the fact that unacylated ghrelin is 
subject to cell target-mediated activation, provides a novel potential mechanism 
for manipulating ghrelinergic activity in the brain. 
This process has also been shown to occur in peripheral tissues. For instance, our 
collaborators recently reported that the pro-adipogenic effect observed after bone 
marrow infusions with unacylated ghrelin, was completely abolished in GOAT KO 
mice, whilst the same effect reported after acyl-ghrelin infusion was not dependent 
on the presence of GOAT (Hopkins et al. 2017). These data suggest that the effect 
itself, apparently attributed to unacylated ghrelin, is actually dependent on ghrelin 
being re-acylated by GOAT in the tissue. 
Another study showed that the administration of unacylated ghrelin to cultured 
cardiomyocytes increases their uptake of MCFA, that are essential for several 
metabolic functions but are also important for ghrelin acylation itself. Indeed, the 
authors detected GOAT expression in these cells, hinting at the possibility that 
unacylated ghrelin is converted to acyl-ghrelin in the cytoplasm of these cells (Lear 
et al. 2010). 
Noteworthily, full length GOAT proteins were detected in the crude protein fraction 
from plasma of fasted mice and rats (Stengel et al. 2010) and in human plasma 
(Stengel et al. 2013). The authors suggest that GOAT released depends on the 
individual’s energetic status: its plasma concentration significantly increases in 
rodents after 24 hours of fasting (Stengel et al. 2010), and correlates with acyl-
ghrelin plasma levels in obese and anorexic patients (Stengel et al. 2013). However, 
to the best of my knowledge, no study was performed to determine whether 
circulating GOAT is fully functional. Besides, since GOAT is a transmembrane 
protein, its release is most likely mediated by small lipidic vesicles (Hopkins et al. 
2017), that could represent an obstacle for GOAT binding with circulating 
unacylated ghrelin in the blood. Indeed, unacylated ghrelin represents 70 to 90% 
of the total circulating ghrelin, as shown in section 1.2.7, suggesting that GOAT re-
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acylation activity in the circulation may be poorly efficient, or may undergo strict 
regulation. 
Whilst ghrelin acylation has been confirmed to occur in the brain, and possibly in 
the circulation, hardly any information is known about its deacylation. APT1 mRNA 
transcript has been almost ubiquitously detected in rodents (Allen Cell Types 
Database - RNA-Seq; Wang et al. 1999; Won et al. 2017), whilst APT1 protein has 
been found in various cell types, including neurones (Duncan and Gilman 1998; 
Toyoda et al. 1999). Notably, APT1 has also been shown to be expressed on 
circulating macrophages, hinting to the possibility that acyl-ghrelin may be 
deacylated in the circulation. 
 
Lastly, several authors reported that GHS-R is highly expressed in the brain, by 
using a combination of in situ detection of mRNA and immunoreactivity assays or 
using fluorescent GHSR-GFP mice. Specifically, GHS-R1a was abundantly detected 
in the ARC of the hypothalamus, the SN, the DG of the hippocampus, the VTA and 
the dorsal raphe nucleus, while almost no expression was detected in the striatum 
(Howard et al. 1996; Bennett et al. 1997; Guan et al. 1997; Gnanapavan et al. 2002; 
Diano et al. 2006; Zigman et al. 2006; Albarrán-Zeckler and Smith 2013; Mani et al. 





1.5 Aims of the project 
PD and AD are age-related neurodegenerative diseases, and represent the most 
common cause of dementia, affecting several million people worldwide. 
Acyl-ghrelin is a versatile hormone that has been shown to illicit numerous 
protective functions in the body. More specifically, it has been shown to exert a 
neuroprotective function in mouse models of both PD and AD, making it a potential 
therapeutic compound against neurodegeneration and dementia. 
Furthermore, ghrelin-mediated activation of its receptor, GHS-R1a, induces the 
pAMPK pathway and mediates mitochondrial function, contributing to the 
maintenance of the cellular homeostasis. 
 
Despite numerous evidences reporting ghrelin neuroprotective effects in rodents 
and in vitro, very little is known about this pathway in humans. This thesis will try 
to compensate the lack of information, by characterising the ghrelinergic axis in 
post-mortem brains of healthy and diseased patients, whilst testing the hypothesis 
that ghrelin reduces oxidative stress and modulates mitochondrial homeostasis in 
human neuronal cells. 
 
The main aims of this thesis are: 
- To characterise the expression of the key enzymes that participate in the ghrelin 
axis (GHS-R1a, GOAT and APT1) in the aged healthy human hippocampus and in 
human stem-cell-derived mature neurones. 
- To determine whether the ghrelinergic axis may be impaired in the hippocampus 
of patients affected by PD and PD with dementia, and to characterise how ghrelin 
modulates mitochondrial health in vitro, using human stem-cell derived neurones 
treated with rotenone. 
- To investigate the ghrelinergic axis in the hippocampus of patients affected by AD 
at early or late stages, and to characterise mitochondrial health in human stem-cell 







2 Materials and methods 
 
 
2.1 Human brain tissue   
 
 Aged, PD and PDD subject 
The PD and PDD brain tissues used in this thesis, were donated to the UK 
Parkinson’s Disease Society Tissue Bank at Imperial College, London, with ethical 
approval (07/MRE09/72). 
 
Fixed frozen post-mortem hippocampal tissue slices (6-8µM thick) were received 
onto Superfrost + glass slides. Upon arrival, tissue was stored at -70°C and sections 
from across the anterior-posterior extent of the hippocampus were visually 
determined, before being used in IHC and BaseScope, as described in sections 2.7 
and 2.9 respectively.  
A total of 17 subjects were included in the analysis: healthy controls (n=5), with no 
evidence of degenerative disease or cognitive decline, participants diagnosed with 
PD (n=7) and participants diagnosed with PDD (n=5) as shown in table 1. 
 
Un-fixed post-mortem hippocampal tissue slices (5µM thick) were received in 
Eppendorf tubes (approximately 25mg per tube). Upon arrival, tissue was stored 
at -70°C. AllPrep extraction kit was used to extract RNA and proteins from each 
tube, as described in section 2.3. 
A total of 18 subjects were included: healthy controls (n=6), participants diagnosed 




 fixed-frozen  fresh 
 Case Gender Age pmi (h)  Case Gender Age pmi (h) 
ctr 
C08 F 93 9  PDC92 M 79 25 
C025 M 35 22  PDC91 M 85 29 
PDC016 F 93 13  PDC107 F 87 15 
PDC022 M 65 12  PDC88 F 96 24 
PDC026 F 80 23  PDC86 M 89 18 
    
 PDC87 F 92 24 
      
 
     
PD 
PD081 M 73 19  PD239 M 81 8 
PD086 F 87 22  PD261 M 84 21 
PD022 F 76 14  PD275 M 79 22 
PD051 M 80 7  PD247 F 88 12 
PD074 M 85 17  PD184 M 71 24 
PD107 F 76 n/n  PD86 F 87 22 
PD109 M 72 9  
 
   
PD101 F 79 41      
 
    
     
PDD 
PD28 M 82 14  PD28 M 82 14 
PD63 F 80 10  PD93 F 81 22 
PD079 F 78 22  PD99 M 82 10 
PD093 F 81 22  PD79 F 78 22 
PD099 M 82 10  PD122 M 92 21 
PD076 M 61 14  PD106 M 75 3 
PD078 M 79 24      
 
Table 1 Human brain samples from PD and PDD patients 







 Young, aged, early AD and late AD subjects 
Human brain tissue donated to Brains for Dementia Research (BDR) (London – City 
and East NRES committee 08/H0704/128+5) was used in this thesis, and ethical 
approval obtained for all our analysis (07/MRE09/72).  
 
Fixed-frozen paraffin-embedded (FFPE) post-mortem hippocampal tissue slices, 
mounted onto Superfrost + glass slides, were received from Edinburgh BDR brain 
bank. Upon arrival, tissue was stored at +4ᴼC before being used in IHC, as described 
in section 2.6. 
A total of 20 subjects were included: healthy young controls (ctr) (n=5), healthy 
aged ctr (n=5), participants diagnosed with early AD (n=5) and late AD (n=5), as 
shown in table 2. 
 
Un-fixed post-mortem hippocampal tissue were received frozen in OCT medium 
blocks from Oxford and Newcastle BDR banks. Upon arrival, tissue was stored at -
70°C, then cryo-sectioned and 25mg of tissue per each block was stored in 
Eppendorf tubes, also stored at -70°C before use. AllPrep extraction kit was used 
to extract RNA and proteins from each tube, as described in section 2.3.  
A total of 20 subjects were included: healthy young ctr (n=5), healthy aged ctr 






 FFPE  fresh 
 Case Gender Age pmi (h)  Case Gender Age pmi 
young 
ctr 
SD038/17 M 34 99  039/13 M 41 1d 
SD029/17 M 40 103  103/13 F 48 2d 
SD026/16 F 37 126  156/13 M 45 2d 
SD022/16 M 39 86  099/11 F 41 2d 
SD031/15 F 40 89  167/11 F 43 2d 
SD061/13 F 40 77      
          
aged 
ctr 
SD030/19 M 82 56  2006/17 M 100 3d 
SD042/18 F 73 74  2006/53 M 71 2d 
SD030/18 M 63 115  2006/57 M 85 2d 
SD011/18 F 61 80  2006/116 F 89 1d 
SD046/17 F 65 76  2005/115 M 93 2d 
SD036/17 M 71 71      
          
early 
AD 
SD001/17 F 76 29  2006/051 M 79 4d 
SD025/19 M 86 123  2003/84 F 89 5d 
SD023/19 M 77 7  2005/63 F 88 3d 
SD016/19 F 79 19  2002/54 M 87 2d 
SD008/18 F 69 94  2002/65 F 90 1d 
SD001/18 M 72 103      
          
late 
AD 
SD031/19 F 90 52  91/1250 F 73 1d 
SD005/19 M 74 75  RI 92/1087 F 90 54h 
SD004/19 M 66 49  RI 91/1112 F 64 65h 
SD037/18 M 72 103  RI 92/1125 F 70 144h 
SD021/18 F 90 76  RI 91/1313 F 83 42h 
SD012/18 F 85 80      
 
Table 2 Human brain samples from young, aged, early AD and late AD patients 




2.2 ReNcells ™ VM  
 
 Plate coating and cell reviving  
ReNcells™ VM are neural stem cells obtained from the ventral mesencephalon of 
the developing human brain. This cell line was generated by transduction with the 
transcription factor c-myc that confers extended lifespan and stable genotype and 
phenotype (Donato et al. 2007). Moreover, ReN cells can replicate for a large 
number of cycles, without undergoing genomic instability (appendix 1). 
Cells were purchased from Merck Millipore (SCC008), stored in liquid nitrogen at 
low passages (between 4 and 7). In order to maintain the cells in proliferation, 
fresh growth factors, EGF and bFGF, should be added every 48 hours at least. 
However, cells are very sensitive to changes in their environment, so low plating 
densities or increased cell death, would spontaneously trigger cell differentiation. 
 
Cells were grown as a monolayer in a laminin-coated plastic dish.  
Laminin (AMSbio 3400-010-02) was stored at -70ᴼC after purchase. Before use, one 
tube (1mg/1ml) of laminin was thawed at +4ᴼC, then resuspended in 9ml of 
DMEM/F12 (Gibco), for a final concentration of 20µg/ml (coating media). This 
solution was always kept in ice during use, then stored at +4ᴼC for up to 1 week. 
Once resuspended, laminin solution could be used up to 2 times. 
The day before cell plating, the appropriate volume of coating media was added in 
every plate (table 3), then plates were incubated at +37ᴼC and 5% CO2 for 24 hours. 
After incubation, laminin was removed from the plate and stored at +4ᴼC for a 
second use. Plate was washed twice with 1xPBS (Gibco), then fresh proliferating 
media (APM) was added. Cells were removed from liquid nitrogen, and quickly 
thawed in the water bath at +37ᴼC, until almost all ice was thawed. Then the content 
of each vial was gently transferred into a coated T75 plate with APM, without 
vortexing or centrifuging to prevent cell death. Then plates were immediately 
moved at +37ᴼC and 5% CO2, overnight. 
Complete APM was prepared as shown in table 4 and kept at +4ᴼC for up to 4 weeks. 




















T75 75 6,5 3 15-20 20x10e6 
T25 25 3 1 7-10 9x10e6 
6wp 9,5 1 0,5 1,5-2 n/a 
96wp 0,32 0,05 n/a 0,1 n/a 
 




 Cell growth and passaging 
The next day, half of the media was removed, and the same volume of fresh APM 
was added. ReN cells, as most cultured cells, release in the culture media variable 
amounts of soluble factors. Interestingly, in the case of ReN-derived neurones, 
some of those factors prevent cells to undergo cell death. Indeed, ReN cells die 
when the whole media is entirely replaced with fresh one, even in the presence of 
growth factors. To overcome this issue, I developed a protocol where only half 
media is replaced during cell growth, all the way until maturation. 
 
When ReN stem cells reached 70-80% confluence, they were passaged as follow. 
Cell monolayer was quickly washed with 1xPBS (Gibco), and immediately treated 
with 1-3ml of trypsin/EDTA solution (Gibco), using the volumes shown in table 3. 
Cells were incubated at +37ᴼC and 5% CO2 for 2 minutes, then quickly removed 
from incubator and gently agitated to favour cell detachment. 10ml of APM (per 
1ml of trypsin) was quickly added to neutralise its enzymatic activity. Then all cells 
were collected from the surface and transferred in a 15ml tube to be centrifuged at 
300g for 5 minutes at RT. Supernatant was removed and pellet was resuspended 
in fresh APM, then plated in a newly coated flask. For differentiation, cells were 
counted using a haemocytometer and plated as described in section 2.2.4. 
In order to maintain the cells in a proliferative state, they were passaged as follow: 
1in3 dilution, in order to have them 70% confluent the next day; or 1in20 dilution, 
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to reach confluency in 3 days (i.e., Friday to Monday). These dilutions were 
optimised to ensure the maximum cell cycle efficiency. Indeed, if cells were seeded 
at lower densities, the increased room between the cells would trigger 
differentiation and cell death. 
Lastly, due to the short half-life of the growth factors in the media and in order to 
prevent spontaneous differentiation, half media was changed every other day with 
freshly added growing factors. Indeed, leaving the cells in the same media for 
longer than 60-70 hours would trigger the differentiation process. 
 
 Cells freezing and storage 
ReN cells can grow for a short number of passages before they start to 
spontaneously differentiate in neurones (data not shown). Proliferating ReN cells 
can be stored in liquid nitrogen for several years, whilst neither differentiating nor 
mature ReN neurons can be revived after frozen (data not shown), hence the 
survival of the clone is entirely dependent on the stem cells. 
ReN cells freezing media was purchased by Merk Millipore (SCM007) then quickly 
thawed at RT (never at +37ᴼC). Each confluent T75 plate of ReN stem cells was 
washed once with 1xPBS, then incubated with the appropriate volume of 
trypsin/EDTA, collected and centrifuged, as described in the previous section. For 
the freezing process to be more efficient, as much supernatant as possible must be 
removed from the pellet. Then, the pellet can be resuspended in 1ml of freezing 
media, per each 70% confluent T75 plate that was processed. Since freezing media 
contains high concentrations of DMSO, that is toxic for the cells at RT, it is important 
to move them as quickly as possible at lower temperatures. More specifically, the 
cryovials were moved to -80ᴼC using a freezing container (i.e., Mr Frosty, Thermo 
Fisher 5100-0001) filled with isopropanol, to ensure a gradual reduction of the 








 ReN neurones differentiation  
Before inducing neuronal differentiation, cells need to be passaged at a density 
between 60,000 and 600,000 cells/ml. Lower seeding density (60,000) were used 
for long-term cultures (i.e., 28 days) and for imaging analysis to allow better cell-
cell resolution. However, due to large cell death observed in the first days of the 
protocol, very few cells are expected towards the end of the differentiation 
protocol; hence higher seeding density (600,000) were required for experiments 
including quantitative analysis (qPCR, WB). 
 
24 hours after plating, APM was removed and cells were quickly washed once with 
differentiation media (ADM), then the media was entirely replaced with ADM 
(table 4). The day in which the APM was entirely replaced by ADM was marked as 
the day 0 of the differentiation process (day in vitro 0, DIV0). Half media was 
changed every other day until DIV14, to counteract the increase of media pH 
caused by the cell death. After DIV14, cell number was stabilised, hence half media 
was changed twice a week (i.e., Monday and Friday), until the end of the 
differentiation protocol. 
 
❖ Differentiation Media (ADM) 
Advanced DMEM/F12 (Gibco 12634)   47.5ml 
1% Penicillin-Streptomycin (Gibco)    0,5ml 
4mM glutamine (Gibco)     1ml 
1xB27 supplement (Gibco 17504-044)   1ml 
50µg/ml gentamicin (Gibco 15750037)   50µl 
10U/ml (50µg/ml) Heparin (Sigma H3393)   50µl 
 
⬧ Sterile-filter the media (22µm filter) and store at +4ᴼC for up to 1 week 
 
❖ Proliferation Media (APM) 
ADM        50ml 
20ng/ml bFGF (preprotech AF-100-18B)   10µl 
20ng/ml EGF (preprotech AF-100-15)   10µl 
 




 ReN neurones treatment and AβOs preparation 
After confirming that ReN neurones express neuronal maturation markers, as well 
as GHS-R1a (that starts being detectable around DIV22-24) (chapter 3), the next 
experiments were designed as follow. First, cells were pre-treated with acylated or 
unacylated ghrelin every day for 5 days, from DIV24 to DIV28; this pre-treatment 
intended to recreate the effects of a short-term CR, without affecting the nutrient 
composition of the media. Then, neurones at DIV28 were treated for 24 hours with 
either rotenone or amyloid-β oligomers (AβOs), at two different concentrations – 1 
or 10µM – in order to induce mild oxidative stress and simulate the earlier stages 







Since only half of the media can be removed from each well, as described in section 
2.2.2, stock solutions of each compound are prepared containing double the 
concentration (2x) needed.  
Following supplier’s guidelines, acylated ghrelin (Tocris) and unacylated ghrelin 
(Tocris) were resuspended in water, while rotenone (Sigma) was resuspended in 
DMSO; all three compounds were stored at -20ᴼC in small stock aliquots of 100µM. 
Before use, compounds were resuspended in ADM at 2µM (and 20µM rotenone), 
before being diluted 1in2 with the cell media that was already contained in the well. 
 
AβOs were prepared as described in Dr. Klain’s lab protocol (Lambert et al. 2001). 
Briefly, 1µg of full-length Aβ peptide (1-42) (Aβ42) was resuspended under a 
chemical fume hood in 1ml ice-cold 1,1,1,3,3,3‐Hexafluoro‐2‐propanol (HFIP), a 
highly volatile fluorinated solvent that allow slow monomerization of the structure. 
Figure 2.1 ReN Neurones treatment timeline 
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After 1 hour incubation at RT with the lid of the reaction tube firmly closed, the 
solution was placed on ice for 1 hour before being aliquoted on ice to prevent 
evaporation. Each aliquoted tube was then left over-night at RT with the lid open 
under a chemical fume hood to allow complete evaporation of the solvent – that is 
highly toxic. To ensure complete evaporation, the next morning each tube was fast-
spinned through a speed vacuum for 10 minutes with the lid open. At the end of 
this process, Aβ monomers appeared as a small transparent film, barely visible at 
the bottom of each tube. Aβ pellets were frozen at -80°C and thawed as needed.  
The day before treatment, one or more tubes were thawed and quickly 
resuspended with freshly opened DMSO to a 100µM concentration. After a gentle 
vortex to ensure the pellet was lifted from the tube, the DMSO was further diluted 
to a final concentration of 2µM (for 1µM treatments) or 20µM (for 10µM treatment) 
in ADM. To allow slow and controlled oligomerisation, the pellet was incubated at 
+4°C for 16-18 hours.  
For every new batch of Aβ42 powder purchased, we tested the oligomerisation 
process to exclude any batch-to-batch variation. The validation was performed by 
our collaborators and consisted of high-resolution scanning of the oligomers using 
atomic force microscopy (AFM), to determine particle size and shape (Gazze et al. 
2021). Only batches that produced oligomeric particles of circular shape and 
regular size (approximately 10nm of diameter) were used for cell treatment, whilst 




2.3 Protein and nucleic acids extraction  
 
 AllPrep (QIAGEN) extraction kit from cells and tissues 
The Qiagen AllPrep DNA/RNA/Protein mini kit (80204) enables the simultaneous 
extraction and purification of genomic DNA, total RNA, and total protein from the 
same sample, ensuring high level of efficiency and great purity.  
The protocol was performed according to manufacturer’s instructions.  
 
- Tissue rupture 
The cell pellet or up to 30mg of tissue was transferred in a tissue disruptor tubes 
from the QIAmp Fast DNA kit (Qiagen, 51404). Then 600μl buffer RLT was added 
per sample and the tubes were vortexed for approximately 30 seconds until 
complete homogenisation. The lysate was then centrifuged at 20,000 x g for 3 
minutes at RT and transferred to an AllPrep DNA spin column. This was centrifuged 
for 30 seconds at 8,000 x g at RT and stored at 4°C for later DNA purification. The 
flowthrough was used for RNA and protein purification. 
 
- RNA isolation 
430μl of 100% ethanol was added to the flow-through and mixed well by pipetting, 
then added to a RNeasy spin column and centrifuged for 15 seconds at 8,000 x g at 
RT. The flow-through was transferred to a separate tube and stored at 4°C for later 
protein purification. 700μl buffer RW1 was added to the RNeasy spin columns, 
centrifuged and the flow-through discarded. Subsequently, 500μl of buffer RPE was 
added and centrifuged. This was repeated a second time, with a longer 2 minutes 
centrifuge at 8,000 x g at RT to thoroughly wash the spin column. The spin column 
was placed in a new 2ml collection tube and centrifuged at full speed for 1 minute 
to spin dry. The RNeasy spin column was placed in a new 1.5ml collection tube and 
30μl of RNase-free water was added directly to the column membrane, then 
centrifuged for 1 minute at 8,000 x g at RT to collect the eluted RNA. RNA was 






- Protein isolation 
1000μl of buffer APP was added to the flow-through from the RNA purification 
step, mixed vigorously and incubated at RT for 10 minutes to precipitate the 
protein. This was centrifuged 20,000 x g for 10 minutes, and the supernatant 
carefully decanted. 500μl of 70% ethanol was added to the protein pellet and 
centrifuged at 20,000 x g for 1 minute. As much liquid as possible was removed and 
the pellet left to dry at RT for 5-10 minutes. 5% Sodium dodecyl-sulfate (SDS) 
(Sigma, 436143) was prepared by dissolving 5g of SDS powder in 100ml of water. 
The protein pellet was re-suspended in approximately 250μl 5% SDS and stored at 
-20°C.  
 
- DNA isolation 
500μl of buffer AW1 was added to the AllPrep DNA spin column (set aside in the 
first step), then centrifuged for 15 seconds at 8,000 x g and the flow-through 
discarded. Next, 500μl buffer AW2 was added and centrifuged for 2 minutes at 
20,000 x g. The tube was centrifuged for an additional 1 minute at 20,000 x g to 
spin-dry. Finally, the DNA was eluted by the addition of 100μl of buffer EB (pre-
heated to 70°C), incubated for 2 minutes and centrifuged at 8,000 x g for 1 minute. 
 
 Protein quantification  
Protein quantification was performed using the Pierce BCA assay kit (Thermo 
Fisher, 23227).  
Briefly, a standard curve was generated using the albumin standards provided in 
the kit, diluted with 5% SDS (2.00, 1.50, 1.00, 0.750, 0.500, 0.250, 0.125, 0.025, 
0.0μg/μl). 25μl of sample/standard was added per well in duplicate. A blank well 
was added using the buffer diluent. Working reagent was made by combining 
reagent A + B (50:1), then 200μl was added per well. The plate was then incubated 
for 30 minutes at 37°C and absorbance read at 562nm using a plate reader 
(PolarStar Omega plate reader). Sample concentrations were calculated by 







2.4 Quantitative real-time PCR 
 
 DNase treatment 
DNase treatment was conducted to minimise gDNA contamination, according to 
manufacturer’s instructions (DNA-free TM kit; Ambion cat: AM1906).  
5μl 10X DNase I buffer and 1μl rDNAse I was added to each RNA sample and mixed 
gently. Samples were incubated in a water bath at 37°C for 30 minutes. 0.1 volume 
DNase inactivation reagent was added to each sample and mixed well, incubated at 
RT for 2 minutes with occasional mixing. Samples were centrifuged at 10,000 x g 
for 1.5 minutes and transferred to a fresh tube.  
 
 Reverse transcription  
Extracted and purified RNA were reverse-transcribed to cDNA using the Primer 
Design nanoScript2 RT kit. 
900ng of RNA were used per sample. 1μl of the oligo-dT primers and 1μl of the 
random nonamer primers were added per sample and made up to 10μl total 
volume with RNAse/DNAse-free water. Samples were heated to 65°C using a 
thermal cycler (BioRad T100), then quickly stored on ice. The rest of the reagents 
were added according to table 5. A “no-RT” sample was prepared as a control for 
gDNA contamination. All samples were then placed in a thermal cycler (BioRad 
T100) with the following conditions: +20°C for 5 minutes, +42°C for 20 minutes, 
+75°C for 10 minutes, +4°C until collection. Samples were then stored at -40°C. 
 
Reagent RT sample No-RT sample 
nanoscript2 4x buffer 5μl 5μl 
dNTP mix 1μl 1μl 
Nanoscript2 enzyme 1μl --- 
water 3μl 4μl 
TOTAL 10μl 10μl 
 




 SYBR green qPCR 
Each cDNA sample was made into a 1:5 dilution with water. A 10μl reaction volume 
was used with universal SYBR-green (Primer Design, PPLUS), as shown in table 6. 
Primer sets were used at 1μM concentration. Samples were processed in a BioRad 
CFX96 Real-Time PCR Detection System, with the following conditions: +95°C for 
2 minutes followed by 40 cycles of +95°C for 10 seconds, +60°C for 30 seconds, 
+72°C for 15 seconds. Melt curve analysis was also performed (appendix 2). Results 
were quantified using the ΔΔCt method, normalised against the reference genes (β-
actin and β2-microglobulin, β2M), and presented as fold change. Statistical analysis 
was performed using the ΔCt values. 
 
ΔCt = Ct (gene of interest) – Ct (reference genes) 
ΔΔCt = ΔCt (treatment) – ΔCt (vehicle) 
Fold change = 2-ΔΔCt 
 
Reagent Volume (μl) 
Sample (1:5) 2.5 
Primers (1μM) 2.5 
SYBR-green master mix 5 
TOTAL VOLUME 10 
 




 Primer’s optimisation 
Primer’s optimisation was performed as described elsewhere (Bustin et al. 2009). 
Briefly, each primer was tested to determine the optimum melting temperature, by 
applying a temperature gradient to the plate (+50°C to +70°C). Then cDNA from 
the control samples, was used to determine the optimal cDNA dilution (range 
between 1:2 and 1:20). In my investigations, all primers were found to be optimal 
at the temperature of +60°C. The melting curves show no primer dimer formation 
(appendix 2). All primer sequences are shown in appendix 2. 
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2.5 Western blot 
 
 SDS-page 
Moulding glass plates were cleaned with 70% ethanol and rinsed with water before 
use, then constructed into the gel frame. The separating gel with the appropriate 
percentage of acrylamide, was then prepared according to table 7 with 10% 
ammonium persulfate (APS) (Sigma, 215589) and TEMED (Sigma, T9281) added 
immediately before casting. Water-saturated butanol (Sigma, 28154) was added 
on top of the gel to ensure an even gel edge. The gel was then left until complete 
polymerisation (approx. 15-30 minutes), then the butanol removed and rinsed 
with water. The stacking gel was prepared according to table 7, and added on top 
of the separating gel, with a comb inserted to form the lanes. Once fully 
polymerised, the comb was removed, and the wells rinsed with water. The gel was 
then assembled in the Mini-PROTEAN tetra system (Bio-Rad) electrode assembly 
clamping frame and filled with running buffer (1.5M Tris-HCl pH 8.8, 0.4% SDS).  
20 μg of each protein sample was combined with 4X sample loading buffer (BioRad, 
1610747) and made up to a final volume of 25μl with water, boiled at 100°C for 5 
minutes before being carefully loaded into the 50 corresponding wells. 5μl of 11-
245kDa protein molecular-weight marker (NEB, P7712S) was also added. The 
whole assembly was connected to a powerpack Basic (BioRad) and run at 150V for 
approximately 1 hour or until bands had sufficiently resolved.  
 
reagent 
Separating gel Stacking 
gel 7.5% 10% 12% 15% 
Water 5ml 4.2ml 3.5ml 2.5ml 1.75ml 
4x Tris and SDS 2.5ml 2.5ml 2.5ml 2.5ml 0.75ml 
30% acrylamide 2.5ml 3.3ml 4ml 5ml 0.5ml 
10% APS 100µl  100µl 100µl 100µl 100µl 
TEMED 10µl 10µl 10µl 10µl 10µl 
 




 Transfer and visualisation 
Polyvinylidene difluoride (PVDF) membrane (BioRad, 1620177) was first washed 
in methanol for 1 minute, then water for 2 minutes and then incubated for 30 
minutes in transfer buffer (25mM Tris, 190mM Glycine, 20% Methanol w/v). Also, 
two pieces of Criterion size Extra thick blot paper (BioRad, 1703967) and the gel 
was incubated in transfer buffer at this time. One piece of blot paper was laid down 
in the Trans-Blot Turbo transfer system (BioRad) and a roller used to reduce air 
bubbles. The membrane was laid on top of this, with the gel carefully on top of the 
membrane and another piece of blot paper applied on top of this, with a final gentle 
rolling to reduce air bubbles. The transfer machine’s lid was locked into place and 
run at 15V for 75 minutes.  
Once the transfer was complete, the membrane was incubated in 5% bovine serum 
albumin (BSA) (Sigma, A9418) dissolved in TBS-tween20 (20mM Tris, 150mM 
NaCl 0.1% Tween 20) (TBS-T) for 1 hour. The appropriate concentration of 
primary antibodies was then added (table 8), diluted in 5% BSA-TBS-T together 
with the membrane and sealed in a small plastic bag, incubated overnight on a 
rocker at +4°C. The next day, the membrane was washed (5x5 minutes washes) 
with TBS-T. This was repeated for the appropriate secondary antibody. 
Enhanced chemiluminescence detection using the Amersham ECL Select (GE 
Healthcare, RPN2235) was added to the membrane to visualise the protein bands. 
The ECL select solution was prepared using a 1:1 combination of reagent A and 
reagent B. Typically, 500μl was added per whole membrane, incubated for 2 
minutes, and visualised using the BioRad ChemiDoc XRS. 
 
 Densitometric quantification: Image J  
The quantification of the WB data was performed using the open-source software 
Fiji (by ImageJ). Briefly, each band was flagged as a region of interest (ROI) of fixed 
size. Then the software measured the optical density of the target protein bands 






 ImmPACT DAB (Vector lab) immunohistochemistry 
3,3'-diaminobenzidine (DAB) is oxidized in the presence of peroxidase and 
hydrogen peroxide resulting in the deposition of an alcohol-insoluble precipitate 
at the site of enzymatic activity. The reaction product is insoluble, stable, and not 
light sensitive so stained samples may be preserved for extended periods of time 
without losing sensitivity and quality of prepared tissue samples. 
The ImmPACT DAB Peroxidase (HRP) (Vector Lab) yield a typical brown coloured 
product and is 2-4 folds more sensitivity than the original DAB substrate kit. 
To investigate the distribution of the two major enzymes of the ghrelinergic system 
in the aged brain, DAB-immunohistochemistry (IHC-DAB, or simply IHC) was 
performed using anti-GOAT or anti-APT1 antibodies (table 8) on wither fixed 
frozen tissue from PD and PDD patients, or formalin-fixed paraffin-embedded 
sections of human hippocampus from early and late AD. 
 
  Fixed-frozen tissue (PD) 
Sections were removed from -80°C freezer, air dried for 1-3 minutes then draw 
around the section with a hydrophobic pen (ImmEdge™ PAP Pen, Vector lab). Once 
the moisture was disappeared from the tissue, each slice was covered with 250µl 
of 10% NBF, then incubated for 1 hour at RT. This extra-fixation step was necessary 
due to the frailty of the tissue, in order to prevent detaching in the following steps.  
After incubation, tissue was washed twice in 1xPBS, then incubated with 1% H2O2 
in PBS-triton (1xPBS + 0.1% Triton100) (PBS-T) for 8 minutes to inactivate 
endogenous peroxidases. Sections were quickly washed twice in 1xPBS, then a 
specific antibody-binding was prevented by incubating the tissue with 10% normal 
Donkey serum (NDS) (Sigma Aldrich, St Louise, USA) in PBS-T for 20 minutes at RT. 
None of the antibody used in this thesis required antigen retrieval. Sections were 
incubated with the appropriate primary antibody in PBS-T overnight at +4°C, at the 
concentrations shown in table 8. 
The following day, sections were washed twice in 1xPBS, then incubated with 
biotinylated secondary antibody (against the host species of the primary) at 1:500 
dilution in PBS-T for 1 hour at RT. In the meantime, the avidin-biotin complex 
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(ABC) solution was prepared, following manufacturer’s guidelines (Vectastain® 
ABC Kit PK-6100, Vector lab). Sections were washed twice in 1xPBS and promptly 
incubated with pre-mixed ABC solution for 1 hour at RT. After two more washes in 
1xPBS, ImmPACT DAB (Vector lab) was prepared and applied quickly. During the 
first steps of antibody optimisation, colour development was observed under optic 
microscope to determine the optimal incubation time (10 seconds to 2 minutes). 
All the antibodies used in this thesis were found to be optimally detectable after 40 
seconds incubation with DAB. Then sections were quickly placed in warm tap 
water to stop further colour development. Counterstain was performed using Gill’s 
Haematoxylin, diluted 1in2 with distilled water, for 30 seconds at RT. After few 
more washes sections were increasingly dehydrated: 70% for 3 minutes; 100% 
twice for 5 minutes; then Histoclear twice for 1 minute. Lastly, the glass was 
covered with the Entellan mounting media and left to dry overnight before 
inspecting. 
 
 FFPE tissue (AD) 
FFPE tissue requires an additional de-paraffination step, at the beginning of the 
protocol, since the wax seal physically impede the antibodies to reach their targets 
on the tissue. 
To remove the paraffine, sections were placed into preheated oven at 60°C for 30 
minutes. Then slides were incubated in Xylene, a paraffine solvent, under fume 
hood for 30 minutes. After the incubation, sections were re-hydrated with 
decreasing concentrations of ethanol (100% → 95% → 70%) for two minutes each, 
then placed in tap water. Antigen retrieval was performed with warmed citraconic 
anhydride 0.05% (0.5g in 1ml ddH2O) in the steamer (100%) for 1 hour. Sections 
were removed from the steamer and quickly placed into warm tap water, then the 
area surrounding the tissue was marked with the hydrophobic pen and sections 
were moved in 1xPBS. 
Once the paraffine was removed from the tissue, sections were incubated in H2O2, 






 Cell count: QuPath 
Using a Zen Axio microscope system (ZEISS) (Bioimaging facility, Cardiff 
University), stained sections were scanned with a 40x objective (400x 
magnification), and the resulting images (>100 per section) were automatically 
stitched from the microscope software in order to produce a single file (>1GB of 
size). The files were then acquired using the open-source QuPath software. The DG 
area was manually drawn in each section, and the positive cells manually counted 






 ICC protocol 
ReN neurones maturation was assessed by investigating the expression of specific 
maturation markers.  
Briefly, ReN neurones were grown in 96 well plates, then fixed at different stages 
of differentiation with 10% NBF for 15 minutes at RT. Fixed cells were washed 
several times with 1xPBS, then blocked with 5% NDS at RT for 1 hour. Primary 
antibodies were applied, and cells were incubated overnight at 4°C (table 8). The 
following day, cells were washed in 1xPBS, then incubated with secondary 
antibody for 1 hour at RT in the dark. Excess antibody was removed, and cells were 
stained with the nuclear dye Hoechst, diluted 1:5000 in 1xPBS for 5 minutes. 
Immunofluorescence examination and imaging were carried out on a Zen LSM710 
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2.8 Mitochondria homeostasis assays 
 
 MitoTracker™ orange (Thermo Fisher) 
MitoTrackerTM Orange CMTMRos (Thermo Fisher) is a useful tool for in vivo 
characterisation of mitochondrial mass and oxidative activity. It consists of a 
fluorescent dye that is internalised in live cells, due to its lipophilic nature, and is 
incorporated in the mitochondria matrix where it accumulates proportionally to 
their membrane potential.  
ReN neurones were treated in a 96-well plate, as shown in figure 2.1. Then at DIV28 
were treated with MitoTracker following the manufacturer instruction and 
incubated 30 minutes in the dark. After incubation cells were fixed with 10% NBF 
containing 1:5000 Hoechst, for 15 minutes in the dark. After few 1xPBS washes, 
cells were imaged immediately on a Zen LSM710 confocal microscope (ZEISS). 
Analysis were performed with the open-source software Cell Profiler, using a 
specific pipeline designed to detect mitochondria in fixed neurones and recently 
published from our group (Rees et al. 2020).  
 
 CellTiterGLO™ (Promega) 
ATP cellular content was detected with the CellTiterGLO™ luminescent assay 
(Promega), consisting of a single reagent that is applied directly to live cells. The 
reagent contains a lysis buffer that can break the cellular membrane and induce the 
release of intracellular ATP in in the luciferase-containing.  
Fluorescence was measured using a plate reader and reported as fold change 











2.9 BaseScope™ Assay 
 
 RNA-ISH in fixed-frozen human tissue 
The BaseScope™ Assay in situ hybridization (ISH) technology (ACDbio/biotechne) 
is a powerful tool to detect gene expression in situ, within the spatial and 
morphological context of the tissue section (Wang et al. 2012a). The proprietary 
probe is designed to allow significant signal amplification and increased sensitivity 
and reproducibility, for the detection of the target RNA with single-cells resolution. 
In this thesis I used a variant of the original protocol, designed to improve tissue 
stability, and prevent detaching, whilst allowing high quality stain in old and fragile 
human brain tissue (Carisì et al., in preparation). Briefly, tissue sections were 
removed from the freezer and one extra-fixation steps were performed, similarly 
to what shown in section 2.6.2. Then, BaseScope protocol was carried out by 
incubating the tissue with H2O2, to inhibit endogenous peroxidases, and with a 
proprietary protease that contributes to the antigen unmasking. Finally, 
oligonucleotide probes were hybridised onto the tissue, targeting either GHS-R1a 
mRNA or the housekeeper gene peptidyl-propyl isomerase B (PPIB) as positive 
control, and revealed by secondary detection to yield small, fuchsia-coloured dots, 
counterstained with Gill’s Haematoxylin.  
 
 Analysis: QuPath  
As previously described, a Zen Axio microscope system (ZEISS) (Bioimaging 
facility, Cardiff University) was used to scan the sections. The resulting files were 
then acquired using the QuPath software, the DG area was manually drawn, and 
the dots manually counted, as previously described in section 2.6.4. GHS-R1a dots 










2.10 Statistical analysis 
The experiments in this thesis were performed with a variable number of biological 
replicates, indicated in each figure legend with the letter n. In situ experiments on 
human brains were performed using 1 tissue section per sample (donor), except 
for the BaseScope assay that was performed on three tissue sections per sample. In 
vitro experiments included two or three biological replicates, with each replicate 
including three distinct wells on the same plate (three technical replicates). 
Statistical analyses were performed using the GraphPad Prism 8.0 software. 
Outliers were detected using the ROUT method, setting the maximum desired false 
discovery rate at Q=1%. 
Data distribution was assessed using D’Agostino-Pearson’s normality test. For 
normally distributed data, statistical differences between two groups were 
identified by using a two-tailed unpaired Student's t-test. When comparing more 
than two groups, a one-way ANOVA test, followed by Tukey’s post-hoc test, was 
used to determine statistical differences. Data displaying non-Gaussian 
distribution (non-parametric) were analysed with the Kruskal-Wallis test, 
followed by Dunn’s multiple comparison test to determine statistical differences. 
All data are presented as mean ± standard error of the mean (SEM). P values of 
<0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****) were considered significant. 
More details regarding the number of biological repeats and the specifics of each 







3 Ghrelinergic system in human 





 Ghrelinergic system and cognition during ageing 
The ageing process consists in a progressive accumulation of intracellular 
molecular changes and oxidative stress, to a point where the cells are no longer 
able to defend themselves from stress and damage. In humans, ageing is typically 
accompanied by reduced immune response and increased tissue inflammation 
(Fagiolo et al. 1993; Bruunsgaard et al. 2001; de Gonzalo-Calvo et al. 2010), 
hormonal dysfunctions (Simon et al. 1992; Andrawis et al. 2000; Díez et al. 2003; 
Collins et al. 2019), and reduced appetite (Chapman 2004; Pilgrim et al. 2015; 
Giezenaar et al. 2016). Brain function is also affected, since aged individuals 
manifest impaired sleep (Ehlers and Kupfer 1989), reduced CSF production (May 
et al. 1990), and a decline in overall brain activity (Cummins and Finnigan 2007). 
Mostly healthy aged adults experience a subtle decline in episodic and working 
memory – functions that are supported by cortical and medio temporal circuits 
(Bailey et al. 2013; Votruba et al. 2016). Indeed, some studies report progressive 
brain atrophy during ageing, especially involving the frontal lobe and the 
hippocampus (Convit et al. 1995a; Enzinger et al. 2005), whose size reduction 
correlates with mild impaired cognitive functions (Kalpouzos et al. 2012). 
Moreover, the aged brain show increased inflammation and T cells infiltration in 
rodents (Dulken et al. 2019), monkeys (Batterman et al. 2021), and humans 
(Gemechu and Bentivoglio 2012; Dulken et al. 2019), due to increased vascular 
permeability, although the exact mechanism of this process is still debated: Yang 
and colleagues suggested a shift from ligand-specific receptor-mediated transport, 
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that physiologically occurs in the healthy brain, to a non-specific transcytosis (Yang 
et al. 2020), while Dulken and colleagues suggested the existence of defined 
molecular signals that are able to guide the T-cells in precise brain locations 
(Dulken et al. 2019). Interestingly, a study recently showed that aged mice 
undergoing CR for 8 weeks, have significantly reduced immune cell infiltration in 
the aorta and other peripheral arteries, in addition to reduced production of pro-
inflammatory cytokines (Trott et al. 2018). Although this study did not take in 
consideration T cell infiltration in the BBB or BCSFB, this report suggests a 
potential additional protective mechanism by CR in the aged brain. 
Along with a general deterioration of physiological functions, the ghrelinergic axis 
has also been shown to be impaired in ageing. Aged mice exhibit reduced plasma 
acyl-ghrelin compared to younger animals (Takeda et al. 2010). Similarly, plasma 
acyl-ghrelin levels in normal weight healthy elderly subjects (range 60 to 90 years 
of age) are significantly lower than in younger subjects (range 20 to 40 years) 
(Rigamonti et al. 2002; Akamizu et al. 2004; Schutte et al. 2007; Spitznagel et al. 
2010). This is consistent with the aforementioned studies showing that the elderly 
show a physiological decrease in appetite, sleep and memory – functions that are 
modulated by acyl-ghrelin activity (Chapman 2004). 
 
As previously mentioned, several studies performed in rodents reported that 
central administration of acyl-ghrelin improves memory retention, increases 
dendritic spine density, and stimulates synapse formation, highlighting the 
importance of ghrelin in regulating memory and hippocampal function (recently 
reviewed in Buntwal et al. 2019). Interestingly, acyl-ghrelin levels in plasma seem 
to directly correlate with cognitive function in both young and aged humans. Xu 
and colleagues measured cognitive function in 150 individuals aged 18-65, in the 
three months following a mild brain injury, reporting a significant correlation 
between cognitive decline and reduced plasma acyl-ghrelin level (Xu et al. 2014). 
A similar study, performed in a cohort of 260 subjects between 60 and 85 years of 
age, identified a positive correlation between total ghrelin plasma level (AG+UAG) 
and memory performance in both diabetic and non-diabetic subjects (Sang et al. 
2018), while Ngo and colleagues showed that acyl-ghrelin levels in plasma of 
amyotrophic lateral sclerosis patients, inversely correlates with the severity of the 
disease (Ngo et al. 2015). These evidences suggest the use of acyl-ghrelin detection 
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in plasma as a predictive biomarker for brain and cognitive deterioration. Likewise, 
it has been shown that total ghrelin is significantly decreased in the plasma of 
epileptic patients, and its level can be partially restored after treatment (Greco et 
al. 2005; Dag et al. 2010); interestingly, these studies also showed that total ghrelin 
can be isolated and measured from salivary samples, since ghrelin has been shown 
to be produced in salivary glands (Aydin et al. 2005), hence suggesting ghrelin 
extracted from saliva could represent a more easily obtainable, although equally 
effective, biomarker. 
Yet, some studies reported contradicting results. Spitznagel and colleagues 
measured acyl-ghrelin plasma level in a small group of 35 elderly subjects (age 
range 60-85), adjusting the values for waist-to-hip ratio, cholesterol, and fasting 
insulin levels of the subjects (on the ground that previous reports correlated these 
three variables to ghrelin levels). Their research showed that increased plasma 
acyl-ghrelin levels – normalised for the variables above – is associated with poorer 
cognitive and memory functions (Spitznagel et al. 2010). For this particular study, 
the authors refer to their results as “partial inverse correlation”, because of the 
complex normalisation that may have biased the results. Few other conflicting 
results have been published: one reported worse overall cognitive performance in 
twenty-one young subjects (range 20-40 years) injected with two doses of 
100µg/km of acyl-ghrelin, over a 3 minutes time period (Kunath et al. 2016); 
another study reported enhanced memory performance, although only for food-
related pictures, in twenty young subjects (range 20-30 years) after two 500µg/kg 
acyl-ghrelin injection, over a 15 minutes time period (Malik et al. 2008). The 
variability in the methods used, as well as the small number of participants, may 
explain the many discrepancies among different studies.  
Most importantly, hardly any studies in literature have focused on unacylated 
ghrelin levels, and this could lead to the exclusion of significant information from 
the greater picture. Indeed, our group recently showed that peripheral 
administration of unacylated ghrelin in mice, reduces AHN – the main process 
underlying memory formation – (Hornsby et al. 2020), confirming previous reports 
in which unacylated ghrelin has been shown to counteract the beneficial effects of 
acyl-ghrelin in several animal models (Matsuda et al. 2006; Kumar et al. 2010; 
Stevanovic et al. 2014; Fernandez et al. 2016). Moreover, we also showed that 
acylated/unacylated ghrelin (AG:UAG) ratio is impaired in the plasma of PD with 
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dementia patients, but not in cognitively normal PD subjects (Hornsby et al. 2020), 
as will be better discussed in chapter 4. This suggests that, measuring AG:UAG ratio 
– rather than acyl-ghrelin levels by itself – may better represent the changes 
occurring to the ghrelinergic system during ageing. 
 
Another important element often missing from ghrelin research, is the 
investigation of the enzymes involved in the ghrelinergic axis – GHS-R1a, GOAT and 
APT1. Indeed, these enzymes are essential in determining circulating AG:UAG ratio, 
hence affecting ghrelinergic signalling in the brain. Notably, acyl-ghrelin relocates 
from the circulation to the brain, where it binds GHS-R1a in several regions, 
including the hippocampus, the occipital cortex, and the hypothalamus, as shown 
in section 1.4.4. Sun and colleagues studied the expression levels of GHS-R1a mRNA 
in the mouse brain during ageing (range 1-30 months of age). While they were able 
to detect significant decrease of plasma total ghrelin and close-to-significance 
decrease of acyl-ghrelin, they could not identify any significant change in GHS-R1a 
mRNA in total brain extracts, at any age (Sun et al. 2007b). Singularly, while GHS-
R1a mRNA expression is physiologically very low in fat tissue of young mice, its 
expression increases during ageing and is associated with impaired thermogenesis 
and pro-inflammatory response (Lin et al. 2011) – in contrast with the well-known 
anti-inflammatory properties of acyl-ghrelin (as shown in section 1.3.6) – 
suggesting a GHS-R-dependent, ghrelin-independent mechanism of 
thermoregulation and inflammation in fat tissue during ageing (Ma et al. 2011). 
GOAT has also been shown to be expressed in the human brain, as well as in rodents 
where it can re-acylate unacylated ghrelin, as shown in section 1.4.4. However, to 
my knowledge, no one has investigated expression of GOAT in the brain during 
ageing – except one single report, showing that GOAT increases in total brain lysate 
of aged chicken (Kitazawa et al. 2015). 
Furthermore, hardly anything is known about APT1 expression, localisation, and 
activity in the human brain. As a result, the goal of this chapter is to investigate and 
compare the expression of GHS-R1a, GOAT and APT1 between the young and the 




 In vivo and in vitro models of brain diseases 
The human hippocampus (sections 1.4.2 and 1.4.3) differs from most of the other 
species not only because of its size and anatomical features, such as 
neurotransmitters distribution and differential connections between different 
areas, but also for its involvement in highly complex cognitive tasks, some of which 
are unique to humans. Indeed, while several other species are capable of complex 
processes such as communication and memorisation, humans can also engage in 
distinctive forms of social cognition, such as elaborating the intentions behinds a 
person behaviour and learning from them, in order to develop a sense of collective 
culture (Tomasello and Rakoczy 2003). This process, known as the “theory of 
mind”, is based on two processes; the “mentalisation”, defined as the ability of 
recognising the others as distinct individual, and the “episodic autobiographical 
memory”, which specifically involves the human hippocampus and defines a 
human’s ability to recall knowledge of the past and to use it to understands other’s 
people intentions (Perry et al. 2011a). So, while on one side the hippocampus 
contributes to our species identity, on the other side its complexity makes it 
selectively vulnerable to diseases that are unmatched in the animal kingdom, like 
neurodegenerative diseases. Indeed, hardly any cases of neurodegenerative-like 
disorders have been ascertained in nature. The closest example is a genetic 
disorder of wild Japanese baby macaques, that causes progressive neurological 
impairment and death at early age (McBride et al. 2018). Other neurodegenerative-
like diseases have been identified in domestic animals, although these are very rare 
and mostly caused by parasite infections or genetic mutations, aggravated by 
centuries of genetic selections (Sisó et al. 2006). Hence, neurodegenerative 
disorders – intended as the consequence of progressive, mostly age-related, 
accumulation of neuronal and cognitive defects – are almost exclusive to humans, 
therefore human, or humanised, models are needed to thoroughly investigate and 
characterise these diseases. 
Nevertheless, the use of genetic mice models to study human neurodegenerative 
disorders has always been favoured due to the difficulty of accessing – or 
successfully reproducing – the human brain, as well as the simplicity in handling 
small animals, such as rodents, that exhibit quicker breeding capability and shorter 
life cycle (18-22 months). 
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As mentioned before, the use of human stem cell-derived neurones steadily 
increased in the last few decades and numerous companies invested in the 
production and commercialisation of human stem cells lines readily available for 
differentiation. One of such models is the ReNcell™ VM stem cell line (from now on 
referred to as ReN cells), generated from the ventral mesencephalon (VM) region 
of a 10-week-old gestational human brain, and immortalised by insertion of the v-
myc transcription factor gene (Donato et al. 2007). Although myc genes are 
oncogenes, hence traditionally associated with uncontrolled tumorigenesis (Dang 
et al. 1999), stem cell transfected with either c-myc or v-myc, have displayed long-
term cell expansion capacity (or “stemness”), while maintaining a stable phenotype 
and without developing karyotypic abnormalities (Villa et al. 2004; Takahashi and 
Yamanaka 2006) (appendix 1). Notably, ReN cells differentiation occurs upon 
removal of the mitogens EGF and FGFb from the culture media, and has been 
extensively characterised (Hoffrogge et al. 2006; Donato et al. 2007; Pai et al. 2012; 
Stevanato et al. 2015; Song et al. 2019). The resulting ReN cells-derived neuronal 
cultures (from here on referred to as ReN neurones) are actually a mixed 
population of post-mitotic cells such as astrocytes, neurones, and oligodendrocytes 
in variable amounts, although specific protocols have been designed to favour 
single cell subtypes, such as dopaminergic (Seiz et al. 2012) or oligodendrocytes 
(Li et al. 2017). Ultimately, the variability of the culture composition and the cell 
frailty – being post-mitotic cells – make their usage challenging, albeit they more 
closely resemble primary cell cultures in term of cell type composition, 
differentiation fate and genomic stability. 
In alternative, one of the most common cell line in neuroscience research is the 
human SH-SY5Y, obtained in 1970 from a bone marrow biopsy of a metastatic 
neuroblastoma, and characterised by high expression levels of tyrosine 
hydroxylase (TH) and dopamine-β-hydroxylase, two key enzymes of the 
catecholaminergic system – hence can synthesize both dopamine (DA) and 
noradrenalin (NA) (Biedler and Schachner 1978). These cells are highly stable, 
easy to handle and can divide numerous times without losing their genetic and 
phenotypic characteristics. Interestingly, SH-SY5Y cells can also be differentiated 
to a more mature neuron-like phenotype, and are especially employed as models 
of PD (Encinas et al. 2000).  
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Alas, SH-SY5Y cell cultures are not entirely neuronal, and some cells exhibit 
epithelial-like characteristics (Ross et al. 1983). Furthermore, their cancerous 
origin may influence differentiation, growth and metabolism; indeed, reports on 
their exact phenotype are contradictory (reviewed in Xicoy et al. 2017). 
 
Lastly, human post-mortem brain tissues are another important research tool to 
investigate brain diseases. However, whilst the mouse brain can be collected, 
sliced, and cultivated alive in culture media for a short amount of time (Hatton et 
al. 1980), human brain can only be collected after death – hence cannot be used as 
an actively responding model. Although it is probably the most reliable source of 
information, being the closest model possible, post-mortem brain tissue has 
numerous disadvantages; firstly, very few people decide to donate their brains 
after death, and very few organs are in good enough conditions to be used for 
research. Indeed, a sudden or violent death may significantly affect cellular 
structure, for instance in case the brain cells suffered a significant lack of oxygen 
before death; moreover, the time window between the subject death and the tissue 
collection, known as post-mortem interval (pmi), may also significantly affect the 
structure of the tissue, producing unwanted molecular changes and increasing 
samples variability (Barton et al. 1993; Harrison et al. 1995; Li et al. 2003). 
Secondly, although different fixation techniques are available, each one of them is 
only suitable for certain type of experiments; for instance, formalin-fixed paraffine-
embedded (FFPE) tissue maintains high structural integrity therefore is 
recommended for in situ detection of macromolecules, however it is challenging to 
use for protein and/or nucleic acids extraction, since the paraffin removal step 
requires harsh solvents that cause the loss of some antigens and impairs the 
integrity of nucleic acids (Wang et al. 2013). On the contrary, fresh-frozen tissues 
– stored at very low temperatures immediately upon collection – present lower 
structural integrity, since freeze-thaw cycles may impact 3D structure of the cells, 
but preserve protein antigens and allow extraction of very high purity RNA/DNA 
(Kelly et al. 2019). 
Ultimately, there are numerous in vivo and in vitro models that can – and are being 
– successfully used in neuroscience research. However, due to the many limitations 
of each of these models, using a combination of in vitro and ex vivo may be more 




Acyl-ghrelin has been shown to exert neuroprotective effects in cellular and animal 
models of neurodegenerative diseases (section 1.2.2), being able to cross both the 
BBB and the BCSFB (section 1.4.1) and to bind and activate GHS-R1a in the brain 
(section 1.4.4). 
Since our group recently reported that acyl-ghrelin is significantly reduced in the 
brain of PD patients diagnosed with dementia, it is imperative to investigate the 
extent to which the enzymes of the ghrelinergic axis – GOAT and APT1 – and ghrelin 
receptor – GHS-R1a – are expressed in the human hippocampus during ageing, in 
order to establish the potential for a pharmacological intervention for 
neurodegenerative diseases. 
 
The aims of this chapter are: 
- To characterise the expression and the spatial localization of ghrelinergic axis 
proteins (GOAT, APT1 and GHS-R1a) in the human hippocampus from healthy 
young and aged subjects. 
- To quantify the expression of these proteins (GOAT, APT1 and GHS-R1a) in order 
to determine their variation between the young and aged human hippocampus. 
- To assess maturation of human stem-cell derived neurones and expression of 






 Ghrelinergic system components are expressed in distinct 
compartments in the aged human hippocampus 
GOAT immunopositive cells are present throughout the human hippocampus and 
the surrounding regions in young (not shown) and aged healthy brain (figure 3.1 
A). The immunopositivity is higher in regions with greater nuclei density, like the 
GCL (figure 3.1 B), and lower in areas with less cells, like the CA4 (figure 3.1 C), 
suggesting that GOAT is proportionally distributed between brain regions. 
In comparison to GOAT, APT1 protein expression does not appear to be uniform; 
instead, the pattern of immunoreactivity is variable across the brain (figure 3.2 A). 
In particular, the highest anti-APT1 immunoreactivity was found in the 
hippocampal sulcus (figure 3.2 B), the CA4 area (figure 3.2 C), and the vestigial 
cavity (figure 3.2 D). APT1 immunopositive cells are scarce in other locations of the 
tissue (not shown), except for the area surrounding vasculature and for the rim of 
ependymal and sub-ependymal tissue contiguous to the ventricles and the cells 
adjacent the choroid plexus (figure 3.2 E, black arrows). These results suggest that 
APT1 is expressed in discrete regions in the aged healthy human brain. 
 
In contrast, studying the distribution of ghrelin receptor is quite challenging since 
the commercially available antibodies are not 100% effective (as described in 
section 6). Therefore, I performed the BaseScope assay in the aged brains: 
oligonucleotide probes targeting GHS-R1a mRNA can be seen on the tissue as small, 
fuchsia-coloured dots, with each dot representing the amplification of a single 
molecule of GHS-R1a mRNA. The puncta were not clearly visible under a 4x 
objective (40x magnification) (figure 3.3 A); however, using a 40x objective (400x 
magnification) the GHS-R1a probe dots were clearly visible around the nuclei. The 
stain was particularly evident in the GCL (figure 3.3 B, black arrowheads), while it 
was less consistently observed in other areas of the hippocampus, such as the CA4 
(figure 3.3 C), suggesting that GHS-R1a is also expressed in discrete patterns in the 






GOAT immunoreactivity detected with IHC-DAB (dark brown, black arrowheads) 
in the aged healthy human hippocampus, seen at (A) 40x magnification and (B, C) 
400x magnification. Nuclei are stained with haematoxylin (purple, red 
arrowheads). (Atlas adapted with permission from Duvernoy et al. 2013, Springer 
licence number 4967160485075) 
  




APT1 stained with IHC-DAB (brown, black arrows) in the aged healthy human 
hippocampus, seen at (A) 40x magnification and (B, C, D) 400x magnification. (E) 
APT1 immunopositive stain is also clearly visible in the rim of the sub-ependymal 
tissue, underneath the choroid plexus and adjacent to the ventricle. Nuclei are 
stained with haematoxylin (purple, red arrows). (Atlas adapted with permission 
from Duvernoy et al. 2013, Springer licence number 4967160485075).   






GHS-R1a mRNA expression (fuchsia dots, black arrows) in the aged human 
hippocampus, detected using BaseScope, is shown at (A) 40x magnification, and (B, 
C) 400x magnification. Nuclei are stained with haematoxylin (purple). (Atlas 
adapted with permission from Duvernoy et al. 2013, Springer licence number 
4967160485075). 
  
Figure 3.3 GHS-R1a mRNA localization in the aged human hippocampus 
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 Ghrelinergic system is intact with ageing 
Anti-GOAT immune-positivity was identified in the GCL of the hippocampus by the 
round aspects, with the brown precipitate of chromogen tightly packed around the 
nuclei (figure 3.4 A, black arrowheads). GOAT immunopositive cells were counted 
inside the GCL (delineated by red lines), then normalised for the area of the region 
in mm2; this was done to account for natural variations in size of the hippocampus 
that may occur between subjects (donors) as well as the natural shrinkage of the 
DG associated with aging (see section 1.4.2). After normalisation, the analysis 
revealed 804.4± 159.5 GOAT positive cells per mm2 of DG in young brains (n=6), 
and 433.3 ± 160.8 cells per mm2 of DG in aged brains (n=4), with no significant 
difference between groups (p=0.1551) (figure 3.4 B). Western Blot protein 
quantification, reported as fold change to GAPDH, confirmed no significant changes 
between young (0.9942 ± 0.1994) (n=5) and aged (0.9616 ± 0.09621) (n=5) 
subjects (p=0.8864) (figure 3.4 D and E). Lastly, quantification of MBOAT4 mRNA 
transcript from tissue lysates, reported as fold change to β-actin, also showed no 
significant difference between young (ΔCt=7.163 ± 0.1743) (n=5) and aged 
(ΔCt=7.025 ± 0.2016) (n=5) subjects (p=0.6187) (figure 3.4 C). These results 
suggest that GOAT expression in the hippocampus does not vary significantly with 
ageing. 
 
APT1 immunopositive cells were identified in the CA4 area of the hippocampus, by 
their star-like morphology (figure 3.5 A, black arrowheads), then normalised for 
the area in mm2 of the CA4. 76.22 ± 17.22 cells per mm2 were counted in young 
brains (n=5), and 134.3 ± 56.62 cells per mm2 in aged brains (n=4), with no 
significant difference between groups (p=0.3132) (figure 3.5 B). Western Blot 
protein quantification, reported as fold change to GAPDH, confirmed no significant 
changes in APT1 between young (1.417 ± 0.1345) (n=5) and aged (1.205 ± 0.2499) 
(n=5) brains (p=0.4784) (figure 3.5 D and E). Lastly, LYPLA1 gene expression from 
tissue lysates, reported as fold change to β-actin, showed no significant difference 
between young (ΔCt=5.941 ± 0.2075) (n=5) and aged (ΔCt=5.780 ± 0.1409) (n=5) 
subjects (p=0.5387) (figure 3.5 C), suggesting that APT1 expression does not vary 






(A, B) Anti-GOAT immunoreactivity in the GCL (circled in red) was determined by 
IHC, quantified, and normalised for the area of the GCL (in mm2); (C) MBOAT4 gene 
expression was measured by RT-qPCR; (D, E) GOAT protein relative quantification 
in the tissue was performed by western blot. ROUT analysis was performed to 
remove any outliers from the groups. Significance was measured with unpaired 
two-tailed t-test (n.s. not significant). Data are reported mean ± SEM.  




(A, B) Quantification of anti-APT1 immunoreactive cells, detected in the CA4 
(circled in red) by IHC and normalised for the area of the CA4 (in mm2); (C, D) 
relative quantification of LYPLA1 gene expression by RT-qPCR; (E, F) relative 
quantification of APT1 protein by western blotting. ROUT analysis was performed 
to remove any outliers from the groups. Significance was measured using an 
unpaired two-tailed t-test (n.s. not significant). Data are reported as mean ± SEM.  
Figure 3.5 Expression of APT1 in the young and aged human brain 
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Lastly, due to the incompatibility of the BaseScope assay with our FFPE sections, 
GHS-R1a mRNA expression was analysed via RT-qPCR. Gene expression in tissue 
lysates, reported as fold change to β-actin, showed no significant difference 
between young (ΔCt=6.867 ± 0.5421) (n=5) and aged (ΔCt=6.447 ± 0.6679) (n=5) 
subjects (p=0.6385) (figure 3.6), suggesting that GHS-R1a mRNA expression is 




GHS-R1a gene expression was measured by RT-qPCR. ROUT analysis was 
performed to remove any outliers from the groups. Significance was measured 





Figure 3.6 GHS-R1a mRNA expression in young and aged human brain 
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 ReN neurones reach maturation and express key enzymes of the 
ghrelinergic axis, after 28 days of differentiation in vitro 
ReN stem cells (DIV0) grow uniformly and consistently, exhibiting typical 
fibroblast-like shape and size (figure 3.7 A). At this stage, cells express “stemness” 
markers such as the neuroepithelial stem cell protein, Nestin (figure 3.7 B) and the 
proliferation antigen Ki67 (figure 3.7 C).  
 
Upon growth factors withdrawal, cells started differentiating; after 4 days into the 
differentiation process (DIV4), they begin to show a more elongated morphology 
(figure 3.7 D) and express neuronal precursor markers such as the microtubule-
associated protein 2 (MAP2) (figure 3.7 E) and the “neuronal nuclei” antigen, NeuN 
(figure 3.7 F).  
 
After 28 days (DIV28), ReN neurones exhibit long prolongments and a mature 
neuronal morphology (figure 3.7 G); moreover, some cells express markers 
associated to specific neuronal phenotypes, such as the vesicular glutamate 
transporter 2 (VGluT2), marker for glutamatergic neurones (figure 3.7 H), and the 
tyrosine hydroxylase (TH) enzyme (figure 3.7 I) of DA/NA neurones. They also 
express more generic markers such as the axonal microtubule protein β3-tubulin, 
that is expressed by all neurones regardless of the cellular sub-type, and the glial 
fibrillary acidic protein (GFAP) expressed by astrocytes (figure 3.7 K).  
More specifically, 32.9% ± 0.417 of the total cells were found to be β3-tubulin+ 
(neurones), while 63.3% ± 3.33 were GFAP+ (astrocytes) (n=3) (figure 3.7 J). No 
overlap between the two stain was detected. The remaining cells (“others”) were 






(A) ReN cells (DIV0) express proliferation markers such as (B) Nestin (green) and 
(C) Ki67 (purple). (D) At day 4 of the differentiation process (DIV4), ReN cells start 
showing elongated morphology and expressing neuronal precursor markers such 
as (E) MAP2 (green) and (F) NeuN (purple). (G) After 28 days (DIV28), ReN 
neurones exhibit mature morphology and express markers of different neuronal 
sub-populations, such as (H) VGlut2 for glutamatergic neurones (red) and (I) TH 
for dopaminergic neurones (green). (J, K) Quantification of neuronal cells 
(immunopositive for β3-tubulin, red), and astrocytes (positive for GFAP, green) 
(n=3). Scale bar 50μM.  
Figure 3.7 ReN cells express neuronal markers during differentiation 
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ReN cells and ReN neurones were investigated for the expression of key enzymes 
of the ghrelinergic system.  
Using the BaseScope assay, no GHS-R1a stain was detected at DIV0 and DIV14, 
while some dots appeared at DIV22 and became more evident at DIV28 (figure 3.8, 
black arrowheads), suggesting that GHS-R1a is expressed in the later stages of 
neuronal maturation, but not in stem cells nor during early differentiation.  
 
Both GOAT and APT1 mRNA expression were detected by RT-qPCR in stem cells 
(DIV0), while mature neurones (DIV28) exhibit 2-times higher (**p=0.0069) and 
4-times higher (***p=0.0009) expression level, respectively, compared to DIV0. 
Similarly, APT1 protein was detected in ReN cells during differentiation, between 
DIV0 and DIV28. On the contrary, GOAT protein was not detectable using WB in 
cell lysates at any of the analysed timepoint, in contrast with the whole brain tissue 
lysate that was used as a positive control (not shown), suggesting a differential 






(A) BaseScope assay of PPIB (housekeeper) and GHS-R1a (black arrowheads) on 
ReN cells at different stage of differentiation. (B) RT-qPCR analysis of LYPLA1 
(APT1) and MBOAT4 (GOAT) gene expression at DIV0 and DIV28 (n=2). (C) 
Western blot of GOAT and APT1 in differentiating ReN cells at different timepoints 
(n=1). Scale bar 50μM. **p=0,0069; ***p=0,0009. 
 
  




One of the major candidates identified as a protective agent against age-related 
diseases in the brain, is the hunger hormone ghrelin, whose complex signalling, 
described in sections 1.2.9 and 1.3.6, is mediated by its receptor GHS-R1a. In 
several mice models, acyl-ghrelin has been shown to exert an important protective 
effect against neurodegeneration as shown in sections 1.2.2. Furthermore, its levels 
in humans are reduced during ageing, as described in section 3.1.1. To better 
understand the extent of this impairment and the potential consequences to brain 
health, my first aim was to characterise the expression of the three key players of 
the ghrelinergic system in the human hippocampus – GOAT, APT1 and GHS-R1a – 
and to determine whether the ghrelinergic system is affected during ageing. 
Moreover, since post-mortem brain tissue can only partially recapitulate the 
complexity of the mature brain, I also differentiated and characterised the human 
ReN stem cell line. I was able to confirm their maturation into neurones by showing 
the expression of relevant maturation markers after 28 days of differentiation in 
vitro (figure 3.7), as previously extensively reported (Donato et al. 2007). These 
data confirm that ReN neurones could represent a comprehensive model of 
neuronal maturation, hence I further investigated the expression of key enzymes 
of the ghrelinergic axis. 
 
 GOAT 
My data show that GOAT is homogeneously expressed in the human hippocampus 
(figure 3.1), as previously reported in rodents (Murtuza and Isokawa 2018). The 
pattern of immunostaining is well defined and tightly concentrated around the cell 
nuclei, consistent with GOAT localisation in the membranes of the ER (Taylor et al. 
2013). Interestingly, GOAT protein and mRNA levels do not vary significantly with 
ageing, in any of my analyses (figure 3.4).  
As previously mentioned, GOAT can acylate unacylated ghrelin in the mouse 
hippocampus (Murtuza and Isokawa 2018). Moreover, several studies reported 
that ghrelin is the only known substrate of GOAT, as shown in section 1.2.5. These 
studies, in combinations with my data about GOAT expression in the aged human 
brain, could indicate that ghrelin is re-acylated in situ, similarly to what occurs in 
rodents. Alas, these data are circumstantial and not sufficient to confirm this 
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hypothesis; moreover, even though the data show that GOAT expression levels are 
maintained throughout ageing, its enzymatic activity may still vary with time (i.e., 
reduced efficiency, inhibition, etc.), therefore it is essential to determine the 
conditions required for its activation. This is impossible to investigate directly in 
the human brain, however it could be possible to measure GOAT activity in vitro 
using GOAT-expressing human stem cell-derived neurones and a fluorescent 
acylation probe, similarly to what shown by Murtuza and colleagues in mouse brain 
slides (Murtuza and Isokawa 2018). ReN neurones could potentially be used for 
this purpose, since my data show GOAT mRNA expression after 28 days of 
differentiation (figure 3.8 B). Strangely, GOAT protein could not be detected in the 
same cells (figure 3.8 C), suggesting that the protein may undergo specific post-
translational regulation. Interestingly GOAT expression in rodents has been shown 
to be enhanced by CR (Reimer et al. 2010; Stengel et al. 2010; Zhao et al. 2010), 
hence future work should investigate whether cultivating ReN neurones in a 
nutrient-restricted media may favour GOAT protein expression. 
 
Additionally, it would be interesting to investigate GOAT cell-specificity. This 
information could be obtained by performing double immunostaining in situ in the 
human brain, for several neuronal-subtype markers – such as GFAP for astrocytes, 
VGlut for glutamatergic neurones or TH for dopaminergic neurones. This 
information could be particularly relevant in the context of specific 
neurodegenerative disorders, in which single cell types are more effected than 
others, such as dopaminergic (DA) neurones in PD. For instance, in the context of 
PD, if GOAT were to be found in a single cell type, such as DA cells, it could predict 
an impairment of the ghrelinergic system specifically in this disease, due to the 
specific degradation of this cell type and subsequent loss of GOAT. On the contrary, 
if GOAT expression were to be found in diverse cell types, a compensatory 
mechanism could occur upon death of affected neurones, allowing regular 
ghrelinergic activity despite the cell loss. Lastly, identifying cell specificity of GOAT 
expression, may also give information about the brain areas where ghrelin could 
be locally re-acylated, hence further extending our knowledge about acyl-ghrelin 




A study reported that following intracranial-delivery, unacylated ghrelin persists 
for a longer period of time in the CSF of mice, compared to acyl-ghrelin – which is 
most likely used or degraded (Banks et al. 2002). This evidence suggests that acyl-
ghrelin deacylation may occur locally and, since unacylated ghrelin is unable to 
activate GHS-R1a (Shiimura et al. 2020), it is vital to characterize APT1 protein 
expression and activity in the brain, to understand the mechanisms that determine 
acyl-ghrelin bioavailability. Indeed, very few studies have shown APT1 mRNA 
and/or protein expression in the CNS.  
In the mouse brain, APT1 mRNA expression was detected by single-cell RNA 
sequencing (Linnarsson lab Mouse Brain Atlas) and RNA in situ hybridisation 
(RNA-ISH) (Siegel et al. 2009; Tatro et al. 2013), while protein expression was 
reported in a single study, using IHC (Tatro et al. 2013). Similarly, I was able to 
detect in vitro APT1 mRNA and protein expression in mature ReN neurones at 
DIV28 (figure 3.8 B and C), suggesting these cells retain the ability of de-acylate 
ghrelin. Interestingly, APT1 protein expression has only been shown once before 
in the human brain, performing WB on the whole brain lysates (Wang et al. 1999), 
while the mRNA was detected in a large study using RNA-ISH to analyse thousands 
of genes simultaneously (Allen Human Brain Atlas). Hence, to my knowledge, the 
data presented in this thesis are the first evidence specifically focusing on showing 
the localisation of APT1 protein in the human hippocampus (figure 3.2). 
Interestingly, my data show that APT1 is distributed in discrete layers of the 
hippocampus (figure 3.2) suggesting a clear and defined pattern of action. The 
highest expression was found in three areas: the CA4 (figure 3.2 C), the 
hippocampal sulcus and vestigial cavity (figure 3.2 B and D), and in the ependymal 
and sub-ependymal tissues of the inferior blade of the lateral ventricles (figure 3.2 
E). Notably, in most of my tissue samples, it was not possible to identify the 
polymorphic layer (figure 1.8 C, layer 10) - a very thin transition layer that runs 
between the GCL and the CA4 - partly because of the reduced size of the layer, and 
partly because it is scarcely populated, being mostly a crossroad for the axons 
originating from the GCL above. Either way, since the anti-APT1 stain looked very 
consistent in that region (figure 3.2 C), I used the term “CA4” to refer to the whole 
area immediately inferior to the GCL, with the assumption that this would include 
the polymorphic layer. 
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A novel element that stands out, is the atypical, branched aspect of the APT1+ cells 
in the CA4 (figure 3.5 A), whose appearances closely resemble those of astrocytes. 
To my knowledge, there is no study specifically focusing on APT1 expression in 
astrocytes in any species, although murine stem-cell derived astrocytes have been 
shown to express both APT1 and APT2 (Kong et al. 2013). Interestingly, based on 
the data from a large mouse RNA-seq database, it seems that APT1 is expressed in 
astrocytic cells in the region of the hippocampus (dropviz.org). However, in order 
to confirm this hypothesis, future work should investigate co-localisation between 
APT1 and specific cellular sub-types, using molecular markers such as GFAP for 
astrocytes, NeuN for neurones, and more. 
 
The hippocampal sulcus is a foetal structure, generated during development. When 
the two hippocampal laminae have completed their folding, the sulcus extremities 
start fusing and the fissure disappears shortly after, except for a small vestigial 
region in the most medial part of the hippocampus (Duvernoy et al. 2013). After 
development, this structure does not retain any function. However, being a 
continuation of the superficial hippocampal sulcus (figure 1.8 C, layer 14) that is in 
contact with the ventricle, it could be possible that the small vestigial cavity, could 
also be filled with CSF. Notably, an enlargement of the cavity has been associated 
with Alzheimer’s disease, consistent with the massive cell loss occurring in the 
brains of the affected patients (De Bastos-Leite et al. 2006). Further studies will be 
needed to clarify its function and the role of APT1 positive cells in this region.  
 
Interestingly, APT1 is also selectively expressed in the rim of the cells immediately 
next to the choroid plexus, suggesting that the enzyme may indeed have a key role 
in determining acyl-ghrelin availability in the CSF. The analysis of APT1 gene 
expression patterns from the mouse brain atlas and other databases, confirmed 
that APT1 mRNA was detected in choroid plexus epithelial cells (mousebrain.org, 
dropviz.org), although to my knowledge no previous studies have acknowledged 
this expression pattern in humans. As shown in section 1.4.1, acyl-ghrelin crosses 
the BBB via a saturable receptor-mediated mechanism, while accessibility of the 




Moreover, peripherally injected fluorescent acyl-ghrelin has been shown to be 
internalised by the ependymal cells of the CP and the hypothalamic pericytes, 
although the exact uptake mechanism has not been investigated (Uriarte et al. 
2019). Since APT1 is known to catalyse ghrelin de-acylation, its presence in 
proximity of the BCSFB may indicate a role as a crossing guard: by de-acylating 
ghrelin before it could access the brain parenchyma, APT1 would represent an 
important key regulator of acyl-ghrelin accessibility in the brain. Interestingly, 
chemoreceptors like Tas1r1 and Tas1r3, that are responsible for ghrelin sensing in 
the gastrointestinal tract, are also expressed in the brain, including in the 
hypothalamic tanycytes and in the CP, suggesting a role in the chemo surveillance 
system of the brain (Santos et al. 2019). Future studies on co-localization between 
APT1, GOAT and ghrelin chemoreceptors in the ependymal and sub-ependymal 
tissues of the lateral ventricles, may suggest an additional role for local 
acylation/deacylation.  
Indeed, as previously mentioned, acyl-ghrelin is quickly de-acylated after intra 
cranial injection (Banks et al. 2002); in order to investigate whether APT1 
enzymatic activity may be responsible for this, a possible approach would be to 
inject fluorescent acyl-ghrelin (McGirr et al. 2011) in the CSF of APT1 KO mice, to 
determine whether APT1 is actively implicated in acyl-ghrelin import in the brain.  
 
Lastly, according to the mouse atlas, APT1 is also expressed in the cells of the 
diagonal band of Broca, a bundle of cholinergic nerve fibers that innervates the 
hippocampus (Senut et al. 1989). These fibers, are considered to be the generators 
for low frequency neuronal waves, called theta rhythms, that occur in the mouse 
hippocampus during active exploration (Green and Arduini 1954). 
 Theta waves play an essential role in learning and memory (Winson 1978; Wang 
et al. 2015a), particularly the formation of new memories associated to experience 
(Feng et al. 2015). Since acyl-ghrelin role in improving hippocampal-dependent 
memory formation in rodents has been extensively reported (Kent et al. 2015), 
future work could investigate the presence of APT1 in these neurones, and its role 





My data show that APT1 protein and mRNA levels, do not vary with ageing in the 
DG of the human hippocampus (figure 3.5). Interestingly, a previous report showed 
that APT1 mRNA is increased in the CA1 and DG of aged mice compared to young 
controls (Tatro et al. 2013); moreover the microRNA miR-138, that has been shown 
to downregulate APT1 expression (Siegel et al. 2009), is highly expressed in the 
mouse hippocampus at the dendritic spines – structures located at the synaptic 
terminals that are involved in the formation of new memories (Tatro et al. 2013). 
Interestingly, this study also reported a positive correlation between miR-138 
expression in the brain, and short-term memory function in the aged mice (Tatro 
et al. 2013). Similarly, a study recently showed that APT1 inhibitor peptides are 
neuroprotective in a mouse model of Huntington disease (Virlogeux et al. 2021). 
Although these studies did not investigate ghrelin levels, the results are in line with 
the well-known beneficial function of acyl-ghrelin on memory formation. 
Unfortunately, I was not able to quantify APT1 immunoreactivity in other areas of 
the brain, such as the ependymal cells next to the choroid plexus, due to technical 
difficulties; future work could utilise diverse assays, such as BaseScope, to quantify 
APT1 in such areas, to determine whether its level may be altered in ageing or in 
the context of neurodegenerative disorders. 
Overall, these data suggest the involvement of local APT1 in determining 
availability of acyl-ghrelin in the brain. More studies are needed to determine its 
role in the cognitive process, and to investigate whether a therapeutic intervention 
aiming at reducing APT1 expression or activity (hence increasing circulating acyl-
ghrelin) could be beneficial for cognitive function. 
 
 GHS-R1a 
GHS-R1a was known to be expressed in the brain (Howard et al. 1996) long before 
the endogenous ligand, ghrelin, was ever discovered (Kojima et al. 1999). 
Numerous studies detected GHS-R1a mRNA in the hippocampus of mice (Zigman 
et al. 2006) and humans (Guan et al. 1997; Gnanapavan et al. 2002). Using the 
BaseScope assay, I was also able to detect GHS-R1a mRNA in the healthy aged 
human brain. More specifically its expression appeared to be restricted to defined 
areas, such as the GCL of the DG (figure 3.3 B), while little to no immunoreactivity 
was detected in the CA4 (figure 3.3 C) and surrounding regions (not shown). This 
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is consistent with previous reports showing GHS-R1a is mostly expressed in the DG 
in rodents (Diano et al. 2006; Hornsby et al. 2016).  
Since all commercially available anti-GHS-R1a antibodies are poorly specific 
(Ratcliff et al. 2019), I was only able to detect the mRNA of the receptor, hence these 
data do not give any information on protein localisation. Notably, using a GHS-R1a-
GFP mice, our group recently showed that GHS-R1a is expressed in mature 
neurones, since GFP immunoreactivity co-localises with NeuN+ cells in the mice 
hippocampus; however, no colocalization was identified with stem cells (Nestin+) 
or astrocytes (GFAP+) (Hornsby et al. 2016), suggesting acyl-ghrelin activity in the 
mouse brain is restricted to determined cell types. This could be addressed in 
future experiments, for instance by multiplexing the BaseScope assay for GHS-R1a 
mRNA with a classic antibody-based immunostaining in situ in the human brain. 
 
Lastly, my data report no significant changes in GHS-R1a mRNA expression level 
with ageing (figure 3.6), although the impossibility to analyse its protein level, 
prevented a more comprehensive analysis. Either way, if confirmed, my data 
showing the intact expression of GHS-R1a in the aged human brain, are highly 
encouraging; indeed, the development of a therapeutic strategy aimed at 
increasing acyl-ghrelin level and activity in the brain could be only possible in the 
presence of a functional ghrelin receptor and depletion of GHS-R1a in the aged or 
diseases brain would discourage the use of such strategy. 
 
 Conclusions 
Ultimately, this chapter shows that the key enzymes of the ghrelinergic system are 
expressed in the human hippocampus, and their expression levels are maintained 
during ageing, suggesting the feasibility of a therapeutical intervention aimed at 
increasing ghrelinergic tenor in the brain. 
Moreover, ReN neurones at DIV28 reach full maturation and express GHS-R1a and 





3.5 Key findings 
 
▪ GOAT is homogeneously expressed in the DG and the CA1 of the human 
hippocampus (figure 3.1). 
▪ GOAT protein and mRNA levels in the DG do not vary with ageing (figure 3.4). 
▪ GOAT mRNA is detectable in ReN neurones (DIV28), but GOAT protein is not 
(figure 3.8). 
 
▪ APT1 is expressed in discrete regions in the human hippocampus – most notably 
CA4, the vestigial sulcus and the rim of tissue next to the CP. Moreover, APT1+ 
cells show an atypical, branched aspect (figure 3.2). 
▪ APT1 protein and mRNA levels in the DG do not vary with ageing (figure 3.5). 
▪ APT1 mRNA and protein are both detectable in ReN neurones (DIV28) (figure 
3.8). 
 
▪ GHS-R1a mRNA is detectable in the DG of human aged hippocampus (figure 3.3). 
▪ GHS-R1a mRNA level does not vary with ageing (figure 3.6). 
▪ GHS-R1a mRNA is not expressed in ReN stem cells, nor at the early stages of the 
differentiation, but it is detectable at DIV22 and DIV28. 
 
▪ Approximately 40% of cultured ReN cells at DIV28, are neurones. Moreover, 
other markers of neuronal maturation, such as VGlut2 and TH are detectable. 
▪ ReN neurones start expressing GHS-R1a around DIV22 of the differentiation 
process. APT1 and GOAT mRNA are both detectable in stem cells and mature 
neurones. Surprisingly, while APT1 protein is detectable throughout the 








4 Ghrelinergic system in





 Pathogenesis, anatomy, and dementia 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
in the world. It is a chronic and progressive disease, characterized by bradykinesia, 
akinesia, resting tremor, postural instability, and muscular rigidity (Parkinson 
1817). Its aetiopathogenesis is unknown and there is currently no cure; most cases 
are sporadic – a combination of genetic susceptibility and environmental risk 
factors – and 1.4 times more frequent in men than women. The onset generally 
occurs after the age of 50, with global prevalence of ~0.5% at age 65, and ~2% at 
age 85. In Europe, where life expectancy is higher than the global average, the 
prevalence reaches ~1.8% and ~2.6%, respectively. Indeed, with a worldwide 
increase of life expectancy in the past 30 years, the number of PD cases has now 
reached 6 million and it is expected to double by 2050 (Dorsey et al. 2018), making 
it one of the highest health care cost burden in modern society. 
The two main pathological changes that occur in the brain of patients are the 
development of abnormal intracellular aggregates known as Lewy Bodies (Gibb 
and Lees 1988), and the loss of dopamine-producing (DA) neurones in the SN pars 
compacta (Yahr and Bergmann 1987). The direct consequence of this selective 
degeneration is the impairment of the motor system (Schultz 1986). However, the 
failure of the dopaminergic system usually precedes the visible symptoms by 
several decades, due to the redundance within the system: in earlier stages, the 
neuronal loss is compensated by the surviving neurones, and the system is 
functionally maintained. When the cell loss is too conspicuous – usually around 
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70/80% – the remaining dopaminergic cells cannot maintain nigro-striatal 
signaling and the first motor symptoms appear (Bernheimer et al. 1973). As a 
consequence, diagnosis of PD usually occurs when the disease has already reached 
an advanced stage of neurodegeneration, contributing to the difficulties in 
identifying an effective therapeutic strategy. The current therapies focus on 
increasing the dopaminergic tenor in the brain, for management and relief of the 
symptoms. The gold standard is the dopamine precursor, 3,4-dihydroxy-L-
phenylalanine (L-DOPA), whose function is to replace the loss of dopamine in the 
brain of affected patients, but its activity is quite limited, and the dosage need to be 
increased constantly to counteract the neurodegenerative process. This molecule 
was identified over 60 years ago (Carlsson et al. 1957), and has not yet been 
replaced, despite that its long-term use has been associated with severe side effects 
and toxicity (Ahlskog and Muenter 2001). 
 
Although motor dysfunctions are more notably associated with the disease, PD 
patients also experience a variety of non-motor symptoms (NMS) (Politis et al. 
2010). Some of them, such as sensorial impairment (i.e. the loss of the sense of 
smell), muscular pain, mood disorders and reduced sleep quality, may anticipate 
the motor symptoms of a few years, but are often missed or misinterpreted 
(Stamey et al. 2008; Postuma et al. 2012). Since L-DOPA is not effective against NMS 
(Fabbri et al. 2017), and in some cases it may even worsen some of them (Eskow 
Jaunarajs et al. 2010), it is believed that the dopaminergic failure is not responsible 
for the NMS, that are most likely associated with a failure of the cholinergic 
autonomic nervous system (reviewed in Wolters 2009). Indeed, synthetic 
cannabinol analogues are being tested for NMS management alongside L-DOPA, 
and preliminary data look promising (Peball et al. 2020). 
Approximately 52% of PD patients also experience significant weight loss (Abbott 
et al. 1992), although the exact causes are uncertain. Some studies report loss of 
appetite (Politis et al. 2010), reduction in sense of taste (Wszolek and Markopoulou 
1998), and variations in energy expenditure at rest (Markus et al. 1992). Moreover, 
PD patients exhibit severe deficits in gastrointestinal function due to a 
malfunctioning in the enteric nervous system and damage of the dorsal motor 
nucleus of the vagus nerve (Halliday et al. 1990). Ultimately, PD patients report 
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attenuated ghrelin-mediated response to food (Song et al. 2017), suggesting an 
impairment in the ghrelinergic axis that will be described in section 4.1.3.  
During the later stages of PD, more severe neurological dysfunctions occur that 
interfere with the daily functioning and impact the life quality of the patients and 
their families (Schrag et al. 2000). These include anxiety (Henderson et al. 1992), 
depression (Barone 2011), pain (Defazio et al. 2008), confusion and hallucinations 
(Mosimann et al. 2006) and severe cognitive deficits, such as language deficit 
(Matison et al. 1982), spatial impairment (Hovestadt et al. 1987), and memory loss 
(Weintraub et al. 2004). It has been estimated that at least 20-40% of the diagnosed 
PD patients, exhibit signs of dementia a few years after diagnosis (Cummings 1988; 
Hobson and Meara 2004; Athey et al. 2005; De Lau et al. 2005), and up to 70% of 
them would develop dementia within 10 years (Portin and Rinne 1987; Aarsland 
et al. 2003; Hely et al. 2005). This condition is defined as Parkinson’s disease with 
dementia (PDD). Due to the high variability of the diagnostic criteria, in 2007 the 
Movement Disorder Society recruited a task force of scientist and clinicians from 
all over the world, to define the first official guideline to clinically identify PDD 
(Dubois et al. 2007; Emre et al. 2007). The PDD diagnosis is based on a numeric 
score attributed to patients’ performances on various cognitive tests, including 
memory, language, and attention, in combination with fMRI scans. Interestingly, 
volumetric MRI studies have shown that brain volume loss is a measure of 
cognitive decline during PD progression (Hu et al. 2001). More specifically, mildly 
impaired PD patients and PDD patients, have shown significant hippocampal 
atrophy compared to cognitively functional PD patients (Weintraub et al. 2011). In 
addition, PDD patients exhibit significant atrophy of the medial temporal lobe, 
particularly in the entorhinal cortex (Kenny et al. 2008; Weintraub et al. 2011), as 
well as parietal-temporal and prefrontal cortex (Jokinen et al. 2009). Since PD with 
mild cognitive impairment often deteriorates in PDD (Janvin et al. 2006), 
hippocampal atrophy has been suggested as a predictive biomarker of cognitive 
decline in PD, possibly anticipating a more severe PDD condition (Weintraub et al. 
2011). 
Due to the increasing average lifespan, and consequently the number of PD cases 
worldwide, the identification of the molecular pathways underlying this disease 




 Molecular pathways and mitochondrial impairment 
Although the exact aetiopathogenesis of PD is unknown, 10–20% of PD patients 
have a family history. Notably, specific PD-causing mutations have been identified 
in the genes of α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), 
phosphatase and tensin homolog (PTEN)-induced novel kinase 1 (PINK1) and 
parkin (PARK2) (Tan et al. 2019). Other genes, such as deglycase 1 (DJ-1) (Bonifati 
et al. 2003) and β-glucocerebrosidase (GBA1) (Swan et al. 2016), have also been 
associated with increased risk of developing the disease. Studies performed on 
these mutations and the molecular pathways regulated by these genes, allowed the 
delineation of a wide, although not yet complete, picture of the molecular 
mechanisms that may be involved in PD and PDD (figure 4.1). 
Four factors are considered the principal contributors to PD at a molecular level: 
activation of the ER stress response (Hoozemans et al. 2007); impairment of the 
intracellular protein degradation systems (McNaught and Jenner 2001; Cuervo et 
al. 2004); oxidative stress and mitochondrial dysfunction (Schapira et al. 1992); 
neuroinflammation and glial cell activation (Ouchi et al. 2005). In order to fully 
understand the disease, it is imperative to consider these elements not as distinct 
pathways, rather as a combination of overlapping events. Because of that, a deficit 
in any one of the pathways is enough to trigger a cascade reaction, affecting 
downstream signalling of the other pathways, ultimately causing DA neurones to 
die (Klemann et al. 2017). 
 
The key molecular player in PD pathogenesis is the formation of Lewy Bodies 
(figure 4.1, point 1) (Lewy 1912), intracellular inclusions made of abnormally 
aggregated α-synuclein protein, associated with others such as ubiquitin (Tofaris 
et al. 2003) and tau (Ishizawa et al. 2003) in variable amounts. α-synuclein is a 
multi-functional protein, mostly located at the synaptic densities, where it is 
involved in vesicles motility and dopamine uptake/release (Wang et al. 2014b). 
Genetic mouse models carrying PD-relevant SNCA mutations, showed an alteration 
in the distribution of presynaptic vesicles that correlates with decrease in 
dopamine release and impairment in neuronal firing properties (Janezic et al. 
2013). Interestingly, in the presence of damaged DNA, normal α-synuclein is 
rapidly recruited to the nuclei where it coordinates DNA repair, restoring 
homeostasis (Schaser et al. 2019). Mutations in the SCNA gene, elicit abnormal 
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aggregation of α-synuclein (Conway et al. 1998), possibly causing a reduction in its 
presence in the nucleus, contributing to cell death (figure 4.1, point 2). 
There are two main intracellular mechanisms of degradation for aberrant or 
excessive proteins; the macro-autophagy or autophagy-lysosome pathway (ALP), 
(figure 4.1, point 3) (De Duve 1963; Takeshige et al. 1992) and the ubiquitin-
proteasome system (UPS) (figure 4.1, point 4) (Hershko et al. 1978; Hershko et al. 
1979). Both clearance processes are activated by misfolded proteins carrying 
unique “tags”, made of covalently bonded polyubiquitin chains. The two systems 
usually target different proteins, however they can also work concurrently; for 
instance, intracellular α-synuclein is preferentially degraded by the UPS system, 
but an increase in protein misfolding will also recruit the ALP pathway in parallel 
(Ebrahimi-Fakhari et al. 2011). Moreover, in case of dysfunction in one of the two 
systems, the other one is able to compensate (Ding et al. 2007; Shen et al. 2013). 
 
When the protein load is too high, both systems fail, and misfolded proteins 
accumulate inside the cell. The increasing aggregation of aberrant proteins, 
triggers a cascade mechanism known as ER stress, or unfolded protein stress 
response (UPR), whose function is to reduce the load of misfolded proteins by 
inhibiting unnecessary gene expression and protein translation (figure 4.1, point 
5) (Zhang et al. 2000). Since the ER is involved in the production and maturation of 
several proteins including lysosomal enzymes, impairment in the ER secretory 
pathway results in further lysosomal dysfunction, increased stabilisation and 
consequential accumulation of the mutated proteins, that contribute to the cycle 
(Mazzulli et al. 2016). Ultimately, prolonged activation of the ER stress response 
pathway, has been shown to induce cell death via apoptosis (figure 4.1, point 6) 
(Wang et al. 1996).  
Another important PD-related mutation occurs in the gene LRRK2, that encodes a 
cytosolic protein kinase whose targets are involved in autophagosome maturation 
and upregulation of autophagy-associated genes (Reinhardt et al. 2013). Mutated 
LRRK2 abnormally hyper-phosphorylates its targets, often leading to lysosomal 






The loss of DA neurones, and the consequential reduction in dopaminergic 
signalling, induces the surviving neurones to increase dopamine metabolism 
(oxidation) (figure 4.1, point 7), a process that increases oxidative stress, ROS 
production and causes mitochondrial impairment (Burbulla et al. 2017). Moreover, 
increased dopamine oxidation, has been shown to significantly increase the 
misfolding of α-synuclein (Pham et al. 2009), leading to its further accumulation 
inside the Lewy bodies. 
DA neurones death can also occur as a consequence of an exaggerated immune 
response from microglia (figure 4.1, point 8), a population of macrophage-like cells 
involved in brain homeostasis and immune surveillance. Physiological functions of 
brain microglia include clearance of unnecessary synapses (pruning) (Schafer et al. 
2012), myelin remodelling during development (Hughes and Appel 2020), 
activation of defence mechanisms against pathogens (Olson and Miller 2004), and 
scavenging debris from dying neurones to prevent damage to neighbouring cells 
(Damisah et al. 2020). In the brain of PD patients, immune cells are abnormally 
activated from an early stage of the disease (Gerhard et al. 2006). In particular, 
microglia cells express SNCA and LRRK2 genes, that have been shown to directly 
affect microglial function in models of PD (Austin et al. 2006; Kim et al. 2020). 
Extracellular aggregates of α-synuclein promote the activation of neighbouring 
microglia; however if this fails to remove the insoluble proteins from the 
extracellular space, it results in increased tissue inflammation and cell damage 
(Choi et al. 2019). Additionally, damaged and dying neurones release specific 
antigens and molecular signals, like ATP, that induce activated microglia to attempt 
to remove the defective cells (Davalos et al. 2005), creating a vicious cycle of cell 
death and immune cell activation. 
 
Lastly, Parkin/PINK1-mediated mitophagy, previously described in section 1.3.3, 
has been extensively reported to be impaired in PD; indeed, PARK2 mutations are 
the first cause of early onset PD, accounting for 77% of the familial cases and 10-
20% of the sporadic ones, while PINK1 mutations are the second, accounting for 2-
4% of the sporadic cases. Furthermore, malfunctional mitochondria trigger the 
release of cytC from the IMM to the cytoplasm, where it interacts with various heat 
shock proteins and recruits caspase-9 and 3, ultimately leading to cell death (Ott et 





Schematic representation of dying DA neurones and the main molecular pathways 
impaired in PD: (1) protein accumulation, (2) DNA damage, (3) autophagy 
impairment, (4) UPS impairment, (5) ER stress response, (6) apoptosis, (7) 
increase in dopamine oxidation, (8) immune response, (9) mitochondrial 
impairment. Yellow boxes show the localization of the four major PD-associated 
gene products (created with BioRender.com).   
Figure 4.1 PD molecular pathways 
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In addition to PINK1 and PARK2, LRRK2 and α-synuclein are also involved in 
mitochondrial functions. LRRK2 has been recently shown to play a major role in 
regulating mitochondrial biogenesis, even though its localisation is mostly 
cytosolic (Toyofuku et al. 2020), while α-synuclein aggregates are associated with 
the IMM in the brain of PD patients, where they bind to TOM20 and impair the 
import of mitochondrial protein from the cytosol (Devi et al. 2008; Di Maio et al. 
2016). 
Mitochondrial complex I deficits have also been extensively reported in post-
mortem PD brains (Schapira et al. 1990; Hattori et al. 1991; Janetzky et al. 1994; 
Keeney et al. 2006) and are associated with dementia in PDD patients (Gatt et al. 
2016). Post-mortem brains of PD patients exhibit disrupted mitochondria turnover 
(Berenguer-Escuder et al. 2020), conspicuously reduced levels of PGC1α and 
impaired downstream signalling (Zheng et al. 2010), increased markers of 
oxidative damage (Isobe et al. 2010) and extensive mtDNA mutations (Bender et 
al. 2006; Kraytsberg et al. 2006), indicating that deficient mitochondrial quality 
control is a main component in PD pathogenesis. 
 
The first evidence of impaired mitochondrial function in PD was obtained by 
accident. Three medical reports described parkinsonism in six young individuals 
(20 to 40 years of age) with no PD familiarity, as a result of the abuse of a new illicit 
drug, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Ziering et al. 
1947; Davis et al. 1979; William Langston et al. 1983). The first symptoms – 
rigidity, tremor and bradykinesia – appeared just a few weeks after the drug 
injection, and disease progression was slowed by treatment with L-DOPA (William 
Langston et al. 1983). This sparked the interest of the scientific community as 
further studies revealed that the toxin is selectively taken by DA neurones via the 
dopamine transporter, DAT (Javitch et al. 1985). Moreover, MPTP principally 
target mitochondria: the molecule accumulates inside their membrane where it is 
metabolised by mitochondrial enzymes into a more toxic form, MPP+ (Heikkila et 
al. 1984), that specifically impairs complex I of the electron transport chain 
(Ramsay et al. 1986). These studies suggested that the MPTP toxin may 
recapitulate some of the pathogenic mechanisms that occur in the brain of PD 




Indeed, mitochondrial toxins have long been considered the gold standard to 
recapitulate complex I dysfunction and PD pathogenesis in laboratory models. In 
most animal studies, MPTP is largely used as it induces selective degradation of DA 
neurones in rodents (Heikkila et al. 1985; Hamre et al. 1999; D. S. Prediger et al. 
2011) and primates (Burns et al. 1983; Russ et al. 1991; Chassain et al. 2001). 
Similarly, 6-hydroxyl-dopamine (6-OHDA), a synthetic dopamine analogue, is also 
internalised by DAT and causes selective neuronal degeneration and PD-like 
symptoms (Perese et al. 1989; Eslamboli et al. 2003; Iancu et al. 2005). In vitro, one 
of the most common, non-genetic, cellular models of PD is treatment with rotenone, 
a compound extracted from the roots of several plants and extensively used as an 
insecticide and pesticide (Sherer et al. 2002; Ahmadi et al. 2003; Radad et al. 2006). 
Interestingly, the use of rotenone as a pesticide has been associated with higher 
incidence of sporadic PD among rural populations (Priyadarshi et al. 2001; Dhillon 
et al. 2008). Like MPTP, rotenone is a selective inhibitor of mitochondrial complex 
I and has been shown to induce parkinsonism in rats (Betarbet et al. 2000; Alam 
and Schmidt 2002; Fleming et al. 2004). 
 
In summary, the four aforementioned mechanisms – defective degradation 
systems, ER stress response, microglia activation and mitochondrial impairment – 
work together to contribute to PD pathogenesis. However, mitochondrial toxicity 
better and more comprehensively recapitulates PD pathology in most models. 
Hence, mitochondria-specific molecular pathways have been pharmacologically 
targeted in PD models in order to improve the symptoms. For instance, small 
compounds targeting the transcription factor nuclear factor E2 (Nrf2), which is 
involved in mitochondria biogenesis and the antioxidant system, have been shown 
to exert an anti-apoptotic effect and to reduce oxidative stress in a neuronal cell 
line treated with MPTP (Feng et al. 2019a). Generic antioxidant (Roghani and 
Behzadi 2001), and mitochondrial-targeted peptides, such as the Mito-Q10 (Yang 
et al. 2009; Ghosh et al. 2010), have also proven to be effective in reducing 
mitochondrial stress in vitro and improving PD symptoms in vivo, suggesting that 
the mitochondria may indeed be considered a promising therapeutic target in the 




 Ghrelin and PD 
Acyl-ghrelin is an important regulator of mitochondrial health via pAMPK 
signalling (section 1.3.6). Interestingly, acyl-ghrelin has been shown to exert 
neuroprotective function in vivo and in vitro in numerous animal models of PD.  
Using MPTP-treated PD mice, several groups reported that intra-cranial (Jiang et 
al. 2008; Andrews et al. 2009) and peripheral (Moon et al. 2009; Bayliss et al. 
2016a) injections of acyl-ghrelin significantly reduced TH+ cell death in the SN. 
More specifically, acyl-ghrelin improved DA neurones firing rate and enhanced 
dopamine tenor – impoverished by the degenerative process (Andrews et al. 
2009); prevented microglia and astrocyte activation, reducing the release of pro-
inflammatory cytokines (Moon et al. 2009; Bayliss et al. 2016a); increased LC3-II-
mediated protective autophagy (Bayliss et al. 2016a); and attenuated cytC release, 
hence preventing caspase3-mediated apoptosis (Jiang et al. 2008). Similar 
neuroprotective and anti-inflammatory functions have also been shown in MPTP-
treated mouse cell lines (Moon et al. 2009; Bayliss et al. 2016a; Wang et al. 2020). 
Interestingly, acyl-ghrelin neuroprotective effects in the SN of MPTP-treated mice, 
were totally abrogated in UCP2 double KO mice (Andrews et al. 2009), or in AMPK 
KO mice – in which AMPK was selectively deactivated in dopaminergic neurones 
(Bayliss et al. 2016a). Indeed, acyl-ghrelin has been previously shown to 
upregulate UCP2 mRNA levels in the hypothalamus, enhancing mitochondrial 
respiration and protecting neurones from oxidative stress (Andrews et al. 2008), 
suggesting that the AMPK/UCP2 pathway is an essential mediator of acyl-ghrelin 
neuroprotective effects in the brain. 
 
Pharmacological activators of the pAMPK pathway, such as Resveratrol, a diet 
supplement that has been shown to induce SIRT1 and PGC1α pathways (Sun et al. 
2007b; Wu et al. 2011; Wang et al. 2015b; Chiang et al. 2018; Pineda-Ramírez et al. 
2020) and Metformin, currently used in clinics against type II diabetes (Dulovic et 
al. 2014; Patil et al. 2014; Bayliss et al. 2016c; Chiang et al. 2016; Ozbey et al. 2020), 
were found to be protective against DA neurones degeneration in PD models. Since 
both CR and ghrelin are strong activators of pAMPK signalling, these studies 
suggest that every intervention aimed at restoring ghrelinergic levels in the aged 




DA neurones from GHRL KO mice or from GHS-R KO mice, exhibit increased 
susceptibility to death after MPTP treatment (Andrews et al. 2009). Notably, 
plasma ghrelin levels are significantly reduced in aged individuals (section 3.1.1), 
and AMPK activity is also significantly reduced in aged rats – with lower AMPK 
level correlating with reduced mitochondria biogenesis (Reznick et al. 2007). 
Lastly, PD patients show impaired response to food (Unger et al. 2011) and exhibit 
reduced plasma ghrelin levels, compared to age-matched healthy subjects (Song et 
al. 2017; Hornsby et al. 2020; Pietraszko et al. 2020). These data suggest that an 
impairment of the ghrelinergic system may contribute to increased vulnerability of 
DA neurones. Consistently, obesity – a disease associated with lowered plasma 
ghrelin levels (Tschöp et al. 2001) and ghrelin resistance (Andrews 2019) – 
together with diabetes and elevated body mass index, increase the risk of 
developing PD at later age (Palacios et al. 2011; Cereda et al. 2013; Llorens-Arenas 
et al. 2015). Moreover, some of the most common NMS of PD patients such as 
weight loss, cognitive deficit, sleep disorders and depression (Bachmann and 
Trenkwalde 2006; Storch et al. 2008; Fiszer et al. 2010; Unger et al. 2011; Jiao et al. 
2017; Song et al. 2017; Masala et al. 2020), are all associated with physiological 
processes that are mediated by acyl-ghrelin, as seen in section 1.2.2. 
Indeed, acyl-ghrelin has been shown to be highly interconnected with the 
dopaminergic system of the SN; firstly GHS-R1a is known to dimerise with the DA 
receptors D1R and D2R (as seen in section 1.2.9), that are involved in the regulation 
of feeding and food reward (Szczypka et al. 2001; Hnasko et al. 2006; De Melo 
Martimiano et al. 2015); then, acyl-ghrelin is also known to exert an anti-
depressive function (Lutter et al. 2008) by specifically interacting with the DA 
neurones in the midbrain (Abizaid et al. 2006), and PD is also associated with 
depression (Storch et al. 2008). 
In sum, ghrelin seems to be a valuable therapeutic treatment for PD, not only 
because of its protective activity towards DA cells degeneration, but also in its 






In order to develop an effective strategy to modulate the ghrelinergic system in the 
brain of PD patients, we first need to characterise the expression and function of 
ghrelinergic axis in the diseased brain.  
However, PD is a complex disorder with a wide variety of symptoms – from motor 
dysfunctions to cognitive impairment. Since acyl-ghrelin has been associated with 
improved memory function in rodents (see section 1.2.2), and since only PDD 
patients exhibit evident cognitive impairments (see 4.1.1), it is important to 
differentiate between PD and PDD patients when investigating the ghrelinergic 
axis in the diseased brain. More specifically, since cognition and memory functions 
are strongly associated to the hippocampus, this chapter will look at post-mortem 
hippocampus tissue samples from aged controls, PD and PDD individuals. 
Secondly, since post-mortem tissue samples can only give partial information about 
the mechanisms of the disease (section 1.3.5), human stem cell-derived mature 
neurones will also be used to model oxidative stress in PD. 
 
The aims of this chapter are: 
- To quantify the expression of GOAT, APT1 and GHS-R1a in the human 
hippocampus from PD and PDD patients, compared to age-matched healthy 
individuals. 
- To investigate the mitochondrial health of ReN neurones pre-treated with 
acylated or unacylated ghrelin for 5 days (to simulate medium-length CR regimen), 






 The ghrelinergic system is impaired in the hippocampus of PDD 
patients  
GOAT immunoreactivity in the GCL of the human hippocampus, was identified as 
shown in chapter 3. To account for size variations of the hippocampus due to aging 
or disease, GOAT+ cells (figure 4.2 A, black arrowheads) were counted in the GCL 
then normalised for the area of the region. 817.9 ± 70.33 cells per mm2 of GCL were 
counted in controls (n=5) and 748.9 ± 161.7 cells in PD (n=6), with no significant 
difference compared to controls (p=0.5131). While PDD brains had 461.1 ± 66.11 
cells per mm2 of GCL (n=6), a significant reduction compared to controls 
(*p=0.0335), but no difference compared to PD (p=0.1227) (figure 4.2 B). Western 
blot analysis of GOAT, reported as fold change to GAPDH, demonstrated a 
significant reduction between controls (1.226 ± 0.1278) (n=5) and PD (0.7081 ± 
0.1782) (n=6) (*p=0.0415), and PDD (0.6870 ± 0.1221) (n=6) (*p=0.0415), but no 
changes between PD and PDD (p>0.9999) (figure 4.2 D and E), suggesting an 
impairment in GOAT protein expression in both PD and PDD. On the contrary, 
MBOAT4 gene expression from tissue lysates, reported as fold change to β-actin, 
showed no significant differences between control (ΔCt=7.360 ± 0.3432) (n=6) and 
PD (ΔCt=7.048 ± 0.4386) (n=6) (p=0.5164) nor PDD (ΔCt=7.458 ± 0.2327) (n=6) 
(p=0.8711), and no difference between PD and PDD (p=0.4173) (figure 4.2 C). 
Overall, these results suggest that GOAT protein levels, but not mRNA expression, 
are significantly impaired in the hippocampus of diseased patients. 
 
APT1 immunopositive cells in the CA4 (figure 4.3 A, black arrowheads) were 
quantified to be 279.6 ± 59.32 cells per mm2 of CA4 in control brains (n=4), 302.1 
± 111.5 cells per mm2 of CA4 in PD brains (n=6), and 283.2 ± 42.26 cells per mm2 
of CA4 in PDD brains (n=5), with no significant difference reported against the 
control (p>0.9999 for PD; p=0.6171 for PDD) and between the two groups 
(p=0.5796) (figure 4.3 B). Western blot protein quantification, reported as fold 
change to GAPDH, showed that APT1 expression in PDD (0.5802 ± 0.1259) (n=6), 
was about 39% lower than controls (0.9452 ± 0.1179) (n=6), although not 
significantly different (p=0.0836). PD group (0.6969 ± 0.1330) (n=6) was not 
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different from control (p=0.2342), nor from PDD (p=0.5887) (figure 4.3 D and E). 
Lastly, LYPLA1 gene expression from tissue lysates, reported as fold change to β-
actin, showed no difference between controls (ΔCt=6.126 ± 0.2945) (n=6) and PD 
(ΔCt=5.975 ± 0.1993) (n=6) (p=0.6653), or PDD (ΔCt=6.158 ± 0.1344) (n=6) 
(p=0.9139), nor between PD and PDD (p=0.5887) (figure 4.3 C). Overall, these data 
report no significant difference in APT1 protein and mRNA levels between diseased 
and control groups. 
 
GHS-R1a mRNA in the GCL was detected using the BaseScope assay (figure 4.4 A, 
bottom row, black arrowheads), normalised to both the area of the region and the 
positive housekeeper PPIB (figure 4.4 A, top lane), as described in section 2. Data 
are reported as positive dots per mm2 of the GCL. No significant differences were 
found between controls (287,271.00 ± 96,923.00) (n=5) and PD (171,357.00 ± 
48,304.00) (n=7) (p=0.3536), or PDD (552,279.00 ± 243,983.00) (n=5) (p=0.5730), 
nor between PD and PDD (p=0.1244) (figure 4.4 B). Similarly, RT-qPCR analysis of 
GHS-R1a, reported as fold change to β-actin, showed no differences between 
controls (ΔCt=7.455 ± 0.6320) (n=6) and PD (ΔCt=6.716 ± 0.6509) (n=6) 
(p=0.4173), nor PDD (ΔCt=7.484 ± 0.3467) (n=6) (p=0.7456), and no difference 
between the two diseased groups (p=0.2561) (figure 4.4 C), suggesting that GHS-
R1a expression is not affected in PD or PDD. 
 
Interestingly, total ghrelin (tot G) protein level from tissue extract, assessed by 
western blot, was significantly decreased in PDD (0.4389 ± 0.05152) (n=6) 
compared to PD (0.9962 ± 0.2483) (n=5) (*p=0.0383), confirming other reports 
showing that ghrelinergic system is impaired in dementia. However, no difference 
was detected between controls (1.105 ± 0.2901) (n=6) and PDD (p=0.1530), nor 
PD (p=0.4786), probably due to the large spread of the data within the control 








(A) GOAT immunoreactivity by IHC (in brown, black arrowheads) was identified in 
the GCL of controls (left), PD (centre) and PDD (right). (B) Positive cells were 
counted and normalised for the area of the GCL (in mm2). (C) MBOAT4 mRNA 
expression was quantified via RT-qPCR; (D, E) GOAT relative protein expression 
was quantified by WB. ROUT analysis was performed to remove any outliers from 
the groups. Significance was measured by Kruskal-Wallis test with Dunn’s multiple 
comparison. Data are reported as mean ± SEM. (n.s. not significant; *p≤0.05) 
  





(A) APT1 immunoreactivity (in brown, black arrowheads) was identified in the 
CA4 of controls (left), PD (centre) and PDD (right). (B) Positive cells were counted 
and normalised for the CA4 area (in mm2). (C) LYPLA1 mRNA expression was 
quantified via RT-qPCR while (D, E) APT1 relative protein expression was 
quantified by WB. ROUT analysis was performed to remove any outliers from the 
groups. Significance was measured by Kruskal-Wallis test with Dunn’s multiple 
comparison. Data are reported as mean ± SEM. (n.s. not significant) 
  





(A) GHS-R1a mRNA dots (fuchsia dots, bottom lane, black arrowheads) were 
identified in the GCL of controls (bottom left), PD (bottom centre) and PDD (bottom 
right), (B) quantified as number of dots per mm2 of GCL and normalised for the 
positive control, PPIB (A, top lane). (C) GHS-R1a mRNA expression was also 
quantified via RT-qPCR (D, E) while total ghrelin relative protein expression was 
quantified by WB. ROUT analysis was performed to remove any outliers from the 
groups. Significance was measured by Kruskal-Wallis test with Dunn’s multiple 
comparison. Data are reported as mean ± SEM. (n.s. not significant; *p≤0.05)   
Figure 4.4 GHS-R1a expression in PD 
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 Acylated and unacylated ghrelin exert opposite functions on 
rotenone-induced mitochondrial network disruption in vitro 
Rotenone toxicity in ReN neurones was determined by manual cell count (figure 
4.5 B); statistical analysis was performed using two-way ANOVA followed by 
Tukey’s multiple comparison test. In the vehicle treated group (n=2), neither acyl-
ghrelin (115.5 ± 2.24; p=0.9997), nor unacylated ghrelin (113.2 ± 18.08; p>0.9999) 
significantly affected cell number compared to control (107.5 ± 17.47). Similarly, 
in cultures treated with 1µM rotenone (n=2) no significant differences were 
detected between control (130.3 ± 14.28) and acyl-ghrelin (115.7 ± 1.55; 
p=0.9828) or unacylated ghrelin (123.5 ± 12.93; p>0.9999). The same was 
reported for cultures treated with 10µM rotenone (n=3): no significant differences 
were identified between control (91.14 ± 9.64) and acyl-ghrelin (102.4 ± 4.65; 
p=0.9879) or unacylated ghrelin (96.00 ± 2.64; p>0.9999). It is possible that the 
small number of replicates (n=2) may have affected the statistical power of the 
analysis. Therefore, I analysed the overall treatment effects using Tukey’s multiple 
comparison test between vehicle, rotenone 1µM and 10µM, regardless of ghrelin 
treatment, and found that neither 1µM rotenone (p=0.4379) nor 10µM rotenone 
(p=0.1670) affected cell viability compared to vehicle treatment. However, a 
significant difference (*p=0.0150) was detected between 1µM and 10µM rotenone 
treatments, suggesting that, although these conditions are not lethal for the cells, 
10µM rotenone treatment may be detrimental to cell count. 
 
Since mitochondria are responsible for over 90% of the total cellular ATP 
production (Keilin 1925; Chance and Williams 1956), I used the CellTiter Glo kit, to 
assess ATP levels (expressed as fold change) in vehicle-treated (n=3) and 1µM 
rotenone-treated (n=3) ReN neurones (figure 4.5 C). No significant differences 
were detected between the groups (n=3; p>0.8), regardless of ghrelin treatment 
[Vehicle group: control (0.918 ± 0.148), acyl-ghrelin (0.842 ± 0.105), unacylated 
ghrelin (1.06 ± 0.128); rotenone 1µM group: control (0.997 ± 0.225), acyl-ghrelin 
(0.975 ± 0.208), unacylated ghrelin (0.787 ± 0.133)]. This data suggests that the 
ATP levels in our system are not affected by rotenone nor ghrelin treatments, 
although it is also possible that any small difference between the groups may have 
gone undetected due to the sensitivity of the kit, or the small sample size. 
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Cell function is affected by the overall health of the mitochondrial network; 
therefore, the number of active mitochondria may be used as an indirect measure 
of cell health. With this purpose, I performed RT-qPCR on total DNA extract, to 
quantify mtDNA copy number in ReN neurones treated with vehicle (n=3) or 1µM 
rotenone (n=3) (figure 4.5 D). The mitochondria-exclusive housekeeper gene 
LARS2 (leucyl-tRNA synthetase 2) was used, and the delta Ct values were 
normalised to nuclear DNA content using the reference gene β2-microglobulin 
(β2M), as described elsewhere (Zheng et al. 2016). Statistical significance was 
measured based on the Delta Ct values (figure 4.5 F) with two-way ANOVA and 
Tukey’s multiple comparison test. No significant differences were detected in 
mitochondrial DNA content (p>0.3) between any of the groups. [Vehicle group: 
control (ΔCt=7.072 ± 0.143), acyl-ghrelin (ΔCt=6.761 ± 0.156), unacylated ghrelin 
(ΔCt=6.853 ± 0.092); rotenone 1µM group: control (ΔCt=7.179 ± 0.069), acyl-
ghrelin (ΔCt=7.024 ± 0.236), unacylated ghrelin (ΔCt=6.915 ± 0.083)], suggesting 
that mitochondria number is not affected by either rotenone 1µM or ghrelin 
treatment. 
 
Then, I performed RT-qPCR to assess the PGC1α mRNA expression, the key enzyme 
involved in mitochondrial biogenesis (figure 4.5 E). Statistical significance was 
measured with two-way ANOVA and Tukey’s multiple comparison test, based on 
the Delta Ct values (figure 4.5 F), then normalised to β-actin and reported as fold 
change. No significant differences were detected between groups (p>0.5), 
suggesting that PGC1α gene expression is not affected in this experimental setting. 
[Vehicle group: control (ΔCt=9.562 ± 0.359), acyl-ghrelin (ΔCt=9.131 ± 0.153), 
unacylated ghrelin (ΔCt=9.596 ± 0.234); rotenone 1µM group: control (ΔCt=9.218 







(A) ReN neurones (DIV24) were treated as shown in the timeline. (B) Cell number 
was quantified using the Cell Profiler software and reported as percentage ± SEM 
(n=3). (C) Total ATP was measured using the CellTiter Glo kit and reported as fold 
change (n=3). (D) Mitochondrial DNA content was quantified by RT-qPCR and 
normalised per nuclear DNA (n=3) while (E) PGC1α mRNA expression was 
normalised per β-actin (n=3). (F) delta Ct values were used for both RT-qPCRs 
statistical analysis and are reported in the table. Significance was measured by two-
way ANOVA and Tukey's multiple comparison test. Data are reported as mean ± 
SEM. (n.s. not significant; *p≤0,05)  
Figure 4.5 Rotenone effects on cell number and mitochondrial network 
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The data presented so far, failed to report significant mitochondrial changes in this 
cellular model. In order to visualise mitochondria impairment, ReN neurones were 
treated as shown in the timeline (figure 4.6 A). Briefly, ReN DIV24 were pre-treated 
with acyl-ghrelin, unacylated ghrelin or control for 5 days, then at DIV28 were 
treated with vehicle (n=2), rotenone 1µM (n=3) or 10µM (n=3); 24 hours later cells 
were fixed and stained with MitoTracker – a commercial dye that accumulates 
inside the mitochondria proportionally to their MMP (figure 4.6 B) (see section 
1.3.5). Using the open-source software Cell Profiler, various mitochondrial 
parameters were measured, including the single mitochondrial fragments – from 
now on referred to as ‘puncta’ (figure 4.6 C). 
 
First, I analysed the MMP by measuring total (integrated) intensity of the 
mitochondrial dye (figure 4.6 D). Using a two-way ANOVA followed by Tukey’s 
multiple comparison test, no significant differences were reported between groups 
(p>0.1). [Vehicle: control (0.934 ± 0.024), acyl-ghrelin (0.886 ± 0.021), unacylated 
ghrelin (0.775 ± 0.009); rotenone 1µM: control (0.871 ± 0.129), acyl-ghrelin (0.869 
± 0.099), unacylated ghrelin (0.777 ± 0.059); rotenone 10µM: control (1.05 ± 
0.067), acyl-ghrelin (1.17 ± 0.097), unacylated ghrelin (1.03 ± 0.109)]. However, 
when the main treatment effect was analysed as groups, independently of ghrelin, 
the rotenone 10µM treatment group showed significantly higher total MMP 
compared to vehicle (*p=0.037) and rotenone 1µM (**p= 0.009), suggesting that 
10µM rotenone treatment affects mitochondria by increasing the MMP. 
 
Subsequently, I analysed the number of puncta per cell, reported as fold change 
(figure 4.6 E), and no significant changes were detected between the treatments 
(p>0.7). [Vehicle treated: control (1.04 ± 0.062), acyl-ghrelin (1.00 ± 0.064), 
unacylated ghrelin (0.970 ± 0.084); rotenone 1µM treated: control (0.865 ± 0.058), 
acyl-ghrelin (0.923 ± 0.0469), unacylated ghrelin (0.851 ± 0.022); rotenone 10µM 
treated: control (0.990 ± 0.113), acyl-ghrelin (1.07 ± 0.129), unacylated ghrelin 
(0.968 ± 0.147)]. Lastly, no statistically significant treatment effect was reported 
between vehicle treated and rotenone 1µM (p=0.312) or 10µM (p=0.999) groups, 
nor between 1 and 10µM rotenone (p=0.225), suggesting that puncta number is 
not modulated by rotenone, or that our experimental settings are unable to show a 




(A) ReN neurones were treated for five days (DIV24 to DIV28) as shown in the 
timeline. (B) At DIV29, cells were stained with MitoTracker and Hoechst nuclear 
counterstain (blue). (C) Mitochondrial puncta were identified, then (D) Total 
(integrated) intensity and (E) puncta number were measured and reported as 
mean ± SEM (n=3; vehicle n=2). Significance was measured by two-way ANOVA 
and Tukey's multiple comparison test. (n.s. not significant; **p≤0.005; *p≤0.05).  
Figure 4.6 Mitochondrial measurements in rotenone treated ReN neurones 
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To identify any trend that may have gone undetected due to the small number of 
replicates, the integrated intensity and puncta number are presented using a 
SuperPlot graph (Lord et al. 2020), where the average of each replicate is presented 
alongside individual cell values (n≥273). D’Agostino-Pearson’s normality test was 
conducted, and the data were found to be non-parametric. Therefore, statistical 
analysis was performed using Kruskal-Wallis followed by Dunn’s multiple 
comparison test on the expanded dataset, using each cell as a unique replicate. With 
this approach, I detected a significant reduction of the integrated intensity (figure 
4.7 A) between the control of the vehicle group (0.944 ± 0.0224; n=273) and the 
control of the rotenone 1µM group (0.862 ± 0.0170; n=625; **p=0.0032), 
suggesting that the low dose 1µM rotenone reduces the MMP at a single cell level, 
although this effect was not detected in the analysis of the grouped dataset (figure 
4.6 D). Interestingly, the control of the 10µM group (1.05 ± 0.022; n=400) showed 
significantly increased integrated intensity compared to both vehicle group 
(*p=0.0294) and 1µM group (****p<0.0001), confirming the treatment effect 
detected previously (figure 4.6 D). Within the vehicle group, integrated intensity 
was significantly lower after unacylated ghrelin treatment (0.774 ± 0.013; n=347) 
compared to control (****p=<0.0001) and acyl-ghrelin treatment (0.895 ± 0.021; 
n=267; **p=0.0057). In the 1µM rotenone group, unacylated ghrelin treated cells 
(0.770 ± 0.013; n=809) also showed significantly lower intensity compared to 
control (**p=0.0010) and acyl-ghrelin (0.864 ± 0.016; n=699; ***p=0.0003), 
suggesting that 5-day treatment with unacylated ghrelin may have a detrimental 
effect on MMP, when administered on its own or in combination with acute 1µM 
rotenone treatment. Interestingly, within the 10µM rotenone group, unacylated 
ghrelin treatment (1.00 ± 0.027; n=318) was not significantly different from 
control (p>0.999), while acyl-ghrelin treatment (1.17 ± 0.0255; n=345) resulted in 
significantly higher MMP compared to control (*p=0.0308) and unacylated ghrelin 
(****p<0.0001). Overall, these data suggest a specific effect of unacylated ghrelin 
in reducing the MMP and an opposite activity of acyl-ghrelin by either increasing 
MMP or restoring the baseline (vehicle) level.   
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Similarly, I analysed cell puncta number (figure 4.7 B). Interestingly, in the vehicle 
group, neither unacylated ghrelin (0.955 ± 0.018; n=347; p>0.9999), nor acyl-
ghrelin (0.975 ± 0.0201; n=267; p>0.9999) significantly affected puncta number 
compared to control (1.02 ± 0.022; n=273). However, in the rotenone 1µM group, 
all treatments – control (0.861 ± 0.016; n=625), unacylated ghrelin (0.848 ± 0.015; 
n=809) and acyl-ghrelin (0.920 ± 0.016; n=699) – were significantly reduced 
compared to the corresponding treatments in the vehicle group [control 
(****p=<0.0001), unacylated ghrelin (****p<0.0001) and acyl-ghrelin (*p=0.0289)] 
suggesting a treatment effect that could not be detected in the previous analysis 
performed with group means for each replicate (figure 4.6 E). No significant 
differences (p>0.8) were detected between vehicle-treated and 10µM-treated 
group (control: 0.993 ± 0.025, n=397; unacylated ghrelin: 0.938 ± 0.030, n=315; 
acyl-ghrelin: 1.06 ± 0.027, n=342), for any of the treatments, suggesting that the 
1µM rotenone dose specifically reduces the number of puncta; however, this effect 
is lost with treatment at higher doses. 
Moreover, in the 1µM rotenone group, acyl-ghrelin significantly increased puncta 
number compared to unacylated ghrelin (*p=0.0154), but not compared to control 
(p=0.4967), while unacylated ghrelin did not have a significant effect compared to 
control (p>0.9999). Lastly, there was no significant difference in the 10µM 
rotenone group, between control and unacylated ghrelin (p>0.9999), nor acyl-
ghrelin (p=0.4124), while acyl-ghrelin significantly increased puncta number 
compared to unacylated ghrelin (**p=0.006). Similar to what was seen with the 
MMP analysis, these data suggest that unacylated ghrelin and acyl-ghrelin exert 
opposite effects, with acyl-ghrelin significantly increasing mitochondria puncta 





(A) Mitochondria total (integrated) intensity and (B) puncta number are shown 
using a SuperPlot graph, a juxtaposition of the mean ± SEM from figure 4.6 (n=3; 
vehicle n=2) and the corresponding values per single cells (n≥273). Each large dot 
represents a group mean, and each colour-coded small dot represents individual 
cells. Statistical analysis was performed with Kruskal-Wallis and Dunn’s multiple 
comparison on the single cell’s values. (****p<0.0001; ***p≤0.0005; **p≤0.005; 
*p≤0.05)  
Figure 4.7 Single cells mitochondrial measurements in rotenone treated cells 
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My data so far showed that acyl-ghrelin may affect mitochondria health, while 
unacylated ghrelin seems to exert the opposite functions, in a cellular model of PD.  
To better understand mitochondria network remodelling, I analysed the 
distributions of the puncta from the datasets in figure 4.7 B. Cells were 
progressively segregated (‘binned’) into 13 sub-groups (from now on referred to 
as ‘bins’), according to the number of puncta they contain: bin 1 includes all the 
cells with 1 to 10 puncta per cell, cells in bin 2 have 11-20 puncta each, and so on, 
with the final bin having 121-130 puncta per cell. Subsequently, values were 
reported as percentage of the whole group. The heatmap of the puncta distribution 
(figure 4.8 A) show that 10µM rotenone treatment increased the percentage of cells 
with fewer puncta (shift to the left, red arrow) compared to 1µM treatment and 
vehicle. 
 
To determine whether specific bins of cells are more affected than others, I 
performed parametric two-way ANOVA followed by Tukey’s multiple comparison 
test (figure 4.8 B). Data are shown as fragmented bars (that add up to 100%), and 
the numeric values on the top of each bars indicate the highest number of puncta 
that is found in a single cell within that group. In the vehicle group, acyl-ghrelin 
significantly increases the percentage of cells in the 21 to 30 puncta per cell bin 
(21.9 ± 3.99; ~p=0.035) compared to control (8.90 ± 5.24), while there is no 
significant difference among the other treatments or bins. This suggests that acyl-
ghrelin, in the absence of a stressor, increases the number of cells containing less 
puncta. Indeed, the cell with the most puncta number in the AG/vehicle group has 
only 82 fragments, compared to the 125 of the control, reflecting the fact that more 
cells in the AG/vehicle group have less puncta. Interestingly, the cell with most 
puncta in the UAG/vehicle has only 79 fragments, suggesting that unacylated 
ghrelin may also reduce the number of puncta per cell, although no significant 
difference was detected in any of the bins compared to control or acyl-ghrelin. 
 
Both 1µM and 10µM rotenone treatments seem to affect basal puncta content.  
The control of the 1µM rotenone treatment showed a significant increase in the 
percentage of cells containing 21 to 30 puncta per cell (26.4 ± 4.09; ***p=0.0001) 
compared to the control in the vehicle group (8.90 ± 5.24). The control of the 10µM 
rotenone treatment, also showed a significant increase in the 21 to 30 puncta per 
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cell bin (31.1 ± 2.18; ****p<0.0001) compared to the control/vehicle (8.90 ± 5.24), 
and in the 11 to 20 puncta per cell bin (21.6 ± 1.82; ***p=0.0008) compared to the 
control/vehicle (5.84 ± 0.964). Moreover, the control of the 10µM rotenone 
treatment, showed a significant decrease in three groups: the 41 to 50 puncta per 
cell bin (11.2 ± 3.41; *p=0.0331) compared to control/vehicle (23.19± 2.46), the 51 
to 60 puncta per cell bin (2.18 ± 1.38; **p=0.0011) compared to control/vehicle 
(17.7 ± 0.63) and the 61 to 70 puncta per cell bin (0.201 ± 0.201; *p=0.0165), 
compared to control/vehicle (13.0 ± 7.75). Accordingly, the highest number of 
puncta in the control of the 10µM treatment is only 71, compared to the 125 
fragments of the control/vehicle. 
 
Analysis of the UAG/10µM rotenone treatment also reported significant 
differences. The percentage of cells in the 11 to 20 puncta per cell bin was 
significantly increased (17.7 ± 4.92; *p=0.0345) compared to UAG/vehicle (5.81 ± 
3.01); the 41 to 50 puncta per cell bin was significantly decreased (11.4 ± 3.14; 
**p=0.0049) compared to UAG/vehicle (25.5 ± 2.43). These data are very similar 
to those reported for the control of the same treatment, suggesting that the effect 
may be imputable to the rotenone treatment, rather than to the unacylated ghrelin 
per se. However, if the 10µM rotenone treatment is shown to increase the number 
of cells with less puncta (regardless of unacylated ghrelin treatment), this effect is 
abrogated by the treatment with acyl-ghrelin. Indeed, AG/10µM rotenone 
treatment did not significantly affect any bin compared to AG/vehicle, suggesting 
that acyl-ghrelin is opposing to the shift in puncta number per cell mediated by the 
10µM rotenone (and for which unacylated ghrelin is neutral). 
 
Overall, these data suggest that rotenone treatment increases the percentage of 
cells with less fragments, and the effect is especially evident in the 10µM rotenone 
group, where both control and unacylated ghrelin significantly increase the 11-20 
and 21-30 bins. Interestingly, while control/10µM and UAG/10µM both increase 
the number of cells with less fragments, AG/10µM does not, suggesting that acyl-
ghrelin may have an opposite action, counter effecting the increase seemingly 






(A) Heatmap showing the percentage of cells with defined puncta content. (B) The 
same values are represented as stacked bars, in which every colour corresponds to 
the cells being binned by number of puncta. Parametric two-way ANOVA followed 
by Tukey’s multiple comparison was performed between groups with the same 
puncta content. (****p<0,0001; ***p≤0,0005; **p≤0,005; *p≤0,05). 
Legend: (*) = comparison with the vehicle-treated group; (~) = comparison with 
the control treatment of the same group.   




Calorie restriction is neuroprotective in mice (Duan and Mattson 1999) and 
primate (Maswood et al. 2004) models of PD. It attenuates age-related decline in 
dopamine signaling (Roth and Joseph 1994) and prevents cell death in the SN, after 
excitotoxic or oxidative stress (Bruce-Keller et al. 1999). In the hippocampus, CR 
reduces neuronal cell death and induces neurogenesis in wild type but not GHS-R 
KO (Walker et al. 2015), nor in GHRL KO mice (Hornsby et al. 2016), reinforcing 
the hypothesis that acyl-ghrelin is indeed the main mediator of CR beneficial effects 
in the brain (Bayliss et al. 2016b; Morgan et al. 2017; Ratcliff et al. 2019). Indeed, 
acyl-ghrelin has been extensively reported to have a neuroprotective mechanism 
in mouse models of PD, and circulating ghrelin levels are significantly reduced in 
the plasma of diseased patients (section 4.1.3), suggesting that the ghrelinergic axis 
is dysregulated in PD; however, to the best of my knowledge, no study has ever 
investigated the ghrelinergic system by distinguishing between PD and PDD – the 
most advanced stage of PD associated to significant cognitive impairment, hence 
difficult to reproduce in mouse models. 
In my investigations for this chapter, I assessed the ghrelinergic system in the brain 
of PD and PDD patients; furthermore, I investigated the molecular mechanisms 
behind ghrelin effects on the brain, particularly focusing on mitochondrial health 
that represent one of the main cellular hallmarks associated to this disease. 
 
 GOAT 
Ghrelin acylation is essential for binding and activating GHS-R1a (Kojima et al. 
1999) and GOAT is the only enzyme known to mediate this reaction (Gutierrez et 
al. 2008; Kirchner et al. 2009). Interestingly, our group recently showed that the 
ratio between acyl-ghrelin and unacylated ghrelin (AG:UAG) is significantly 
reduced in the plasma of PDD patients under fasting and post-prandial conditions, 
although no significant change was detected in the levels of medium-chain fatty 
acids (MCFAs) C6, C8, and C10 (Hornsby et al. 2020). Moreover, this reduction 
significantly correlates with cognitive impairment as assessed by the Montreal 
Cognitive Assessment (MoCA) – an assay that attributes a numeric score to 
cognitive function. On the contrary, the cognitively intact PD group exhibits normal 
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acyl-ghrelin levels, therefore we suggested that the AG:UAG ratio in the plasma may 
be used as a diagnostic biomarker for dementia in PD (Hornsby et al. 2020).  
A dysregulation in AG:UAG ratio suggests an impairment of the acylation or 
deacylation process. Indeed, I confirmed that GOAT protein expression is 
significantly impaired in the hippocampal lysates of PDD patients (*p=0.014) 
(figure 4.2 D and E) and GOAT+ cells are significantly reduced in the GCL area 
(**p=0.0050) (figure 4.2 A and B) (Hornsby et al. 2020). Since GOAT has been 
shown to re-acylate ghrelin in situ in the brain (Murtuza and Isokawa 2018) and 
peripheral tissues (Hopkins et al. 2017), a diminution of GOAT expression in the 
human hippocampus may be associated with a reduction in the amount of acyl-
ghrelin in the brain. This, in combination with the reduction of peripheral acyl-
ghrelin, may contribute to memory deterioration and dementia. Indeed, our group 
showed that GOAT KO mice exhibit cognitive impairment and memory deficits, that 
could be restored by treatment with acyl-ghrelin (Hornsby et al. 2020). In light of 
these findings, we suggest that increasing circulating AG:UAG ratio may be a 
therapeutic strategy to ameliorate cognitive decline in PDD patients. 
 
My data on MBOAT4 mRNA did not show significant variations in PD or PDD 
patients compared to age-matched healthy controls (figure 4.2 C). This data may 
be explained with an impairment in the protein translation and expression: for 
instance, if MBOAT mRNAs are transcribed at a physiological level but less proteins 
are translated, it could be hypothesised that the mRNAs are degraded before they 
could become accessible to the ribosomal system. 
Another option could be increased GOAT protein degradation, rather than 
impairment in production; indeed, it is well known that the two protein 
degradations pathways in the cell, ALP and UPS, are severely impaired in PD 
(section 4.1.2) and that early inactivation of one of the two pathways, induces the 
over-activation of the other, in a compensatory protective mechanism (Ding et al. 
2007; Ebrahimi-Fakhari et al. 2011; Shen et al. 2013). To my knowledge, the exact 
pathway of GOAT degradation has not been investigated yet. Future experiments 
could study this pathway by using GOAT-expressing cells treated with selective 




Moreover, both degradation pathways require the damaged proteins to be 
bounded to a poly-ubiquitin chain that acts as a recognition “tag”; indeed, further 
insight could be obtained by investigating intracellular GOAT ubiquitination, for 
instance by combining mass spectrometry and co-immunoprecipitation assay (Co-
IP) (Free et al. 2009) using anti-GOAT and anti-ubiquitin antibodies. Lastly, PD is 
associated with DA neurone loss, and PDD patients also exhibit cell death in the 
hippocampus; indeed, in order to better characterise GOAT loss in PD and PDD, 
future studies should also focus on identifying which cell type express the enzyme, 
by determining its co-localisation with markers from different brain cell types. 
 
 APT1 
The main enzyme known to be involved in ghrelin deacylation is APT1 (Shanado et 
al. 2004; De Vriese et al. 2004; Satou et al. 2010). In my data, APT1 mRNA and 
protein levels are not significantly reduced in the hippocampus of brain tissue from 
PD and PDD patients (figure 4.3). Worthy of note, PDD patients exhibit a 39% 
reduction on average of APT1 protein level (figure 4.3 D and E), although this value 
did not reach statistical significance (p=0.0836). This data may raise the question 
of whether APT1 could be somehow affected in PDD, hence paving the way for 
subsequent studies. 
For instance, since APT1 has been detected in numerous peripheral tissues such as 
circulating macrophages (Hopkins et al. 2017), measuring circulating APT1 
extracted from the blood of PD and PDD patients, may give a more comprehensive 
characterisation of how/if the system may be affected in the disease. 
Noteworthy, the quantification performed in this chapter only refers to APT1 
expression in the CA4 of the hippocampus. However, as discussed in section 3.4.2, 
APT1 immunopositivity is also present in other brain areas – such as the rim of 
tissue surrounding the CP, where it may have a major role in determining acyl-
ghrelin access to the brain. Due to technical reasons, the stain in those areas was 
uncountable, hence further studies will be needed; as a matter of fact, acyl-ghrelin 
is significantly reduced in the plasma of aged and diseased subject (as shown in 
sections 3.1.1 and 4.1.3, respectively), hence characterising the expression and 
activity of APT1 in the cells of the BCSFB, may contribute to understanding the 




Regardless of its role in the ghrelinergic system, APT1 is mainly known for its 
activity as de-palmitoylating enzyme, hence it removes palmitic acid from several 
cytoplasmic and membrane-bound substrates – showing little selectivity for very 
diverse targets – most of which are still unknown (Lin and Conibear 2015). Notably 
palmitoylation/de-palmitoylation are key processes for the correct functioning of 
several GPCRs, including the serotonin receptor 5-HT1A (Renner et al. 2007; Kobe 
et al. 2008), although the responsible enzymes have not been identified yet. 
Ultimately, the possible role of APT1 in diverse biological processes in the brain is 
an intriguing open question that needs further studies. 
 
 GHS-R1a and total ghrelin 
My data show no significant difference in GHS-R1a protein expression or mRNA 
levels in hippocampal lysates from PD or PDD patients, compared to the control 
cohort (figure 4.4 A to D), suggesting that the diseased brain may still be receptive 
to acyl-ghrelin. This data is particularly interesting in consideration of a potential 
ghrelin-based therapeutic intervention aiming at increasing AG:UAG ratio. Indeed, 
acyl-ghrelin would require an intact GHS-R1a signalling system in order to exert its 
beneficial therapeutic functions. However, although I was able to confirm GHS-R1a 
expression, my data does not give any information about its activity. Moreover, the 
receptor isoform GHS-R1b, has been shown to interfere with GHS-R1a activity via 
several mechanisms, as will be better described in section 6. 
 
My data also showed a significant reduction of total ghrelin protein expression in 
hippocampal lysates from PDD patients, compared to the control cohort (figure 4.4 
E and F). Interestingly, previous data from our group showed that, while AG:UAG 
ratio is impaired, total ghrelin levels are not different in the plasma of PD or PDD 
patients compared to the control (Hornsby et al. 2020). This discrepancy may be 
explained by the different nature of the samples analysed – brain lysates versus 
plasma. Indeed, since acyl ghrelin is a soluble protein, its concentration in tissue 
lysates may have been underestimated. Moreover, circulating acyl-ghrelin has 
been shown to interact with large plasmatic proteins, that may influence its 
isolation and purification from blood, as seen in section 1.2.2 (Beaumont et al. 
2003; De Vriese et al. 2007; Lufrano et al. 2016).  
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Lastly, it is also possible that, although total ghrelin level is not impaired in the 
plasma of PD and PDD patients, there may be an alteration in the mechanisms that 
regulates its access to the brain, hence determining a reduction of its concentration 
in the brain parenchyma, as detected in our brain tissue lysates. Consistently, 
several studies report dysfunction in the blood-brain permeability of aged healthy 
subjects (Simpson et al. 2010), as well as PD patients (Kortekaas et al. 2005; Wada 
et al. 2006), and poor permeability to drugs represent one of the major obstacle to 
finding a cure for PD (Begley 2004). 
 
 Mitochondrial health 
The second aim of this study, was to determine ghrelin mechanisms of action in 
vitro, using differentiated human neurones treated with acylated or unacylated 
ghrelin, and rotenone 1µM or 10µM to model PD, as shown in figure 4.5 A. 
My experimental conditions did not cause cell death within the timeline of my 
experiments; however, a treatment effect was detected with 10µM rotenone, that 
significantly reduced cell number compared to the 1µM treatment group 
(*p=0.0150) (figure 4.5 B). This data suggests that 10µM may be detrimental for 
the cells; yet none of the treatment groups were significantly different compared 
to the vehicle, suggesting that the differences between the groups may be too small 
to be detected with this assay. To better investigate cell toxicity, future studies 
should incorporate cell viability assays such as MTT or other commercially 
available kits, while also increasing rotenone dosage and exposure time. 
 
The following experiments were designed so that rotenone treatment would 
induce a mild mitochondrial oxidative stress, simulating the early stages of the 
disease and without causing extensive cell death; hence 1µM rotenone 
concentration was deemed appropriate for my experimental aims. However, using 
these settings, neither total ATP production (figure 4.5 C) nor mtDNA copy number 
(figure 4.5 D) showed any significant changes between groups. Similarly, no 
significant difference was detected in PGC1α mRNA levels (figure 4.5 E).  
These results are in contrast with numerous findings showing that acyl-ghrelin 
increases PGC1α via the AMPK pathway, as shown in section 1.4.4. Very recently, a 
study used the human neuroblastoma cell line SH-SY5Y – one of the most used cell 
models – pre-treated with acyl-ghrelin 1µM for 2 hours, then incubated with 
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rotenone 0.5µM for 24 hours. Wang and colleagues showed that the activation of 
the pAMPK/SIRT1/PGC1α pathway in the acyl-ghrelin pre-treated cells was 
associated with increased cell viability, TOM20 expression and autophagy, along 
with reduced ROS, mitophagy, cytC release and α-synuclein accumulation (Wang et 
al. 2021). This discrepancy with my data, may be due to differences in the 
experimental settings such as timing, reagent concentrations, and assays used to 
analyse mitochondrial health. Indeed, countless techniques have been used in 
different models, as described in section 1.3.5; for instance, to model PD in vitro, 
rotenone doses have been ranging from 50nM up to 1mM (Wang et al. 2002; Jiang 
et al. 2004; Hsuan et al. 2006; Pan et al. 2009; Ruan et al. 2010). Furthermore, 
different cell lines show different responses to the same stressors; for instance, 
ReN neurones may have a different response threshold from SH-SY5Y cells, hence 
they may require higher doses or longer incubation times. 
 
For all the reasons above, standardization of mitochondrial analysis, such as MMP 
quantification, is challenging. Currently, one of the gold standard techniques used 
to characterize mitochondrial activity is the Seahorse XF Analyser that measures 
the oxygen consumption rate (OCR) in vitro (section 1.3.5). The assay requires the 
cells to be incubated a few hours in advance in a standardised cell media, supplied 
by the company, with the purpose of maintaining constant pH values during the 
whole length of the experiment (few hours in total). Unfortunately, ReN neurones 
did not respond well to the media composition and died as quickly as thirty 
minutes after the media change (appendix 3). Indeed, the Seahorse media contains 
low amount of nutrients and is therefore supplemented with serum to prevent cell 
death. However, early optimisation studies that I performed at the beginning of my 
Ph.D. (not shown), reported that serum-containing media is detrimental for 
neuronal differentiation of the ReN cells. Indeed, to my knowledge, most published 
studies performed the Seahorse assay on ReN stem cells (Velichkovska et al. 2019), 
or between 7 and 14 days into the differentiation process (Ghosh et al. 2020; Wong 
et al. 2021), due to the frailty of more mature ReN neurones in the seahorse media; 
only recently one study used them at DIV21 (Pamies et al. 2021). Since ReN cells 
do not express GHS-R1a receptor until DIV22-24 of the differentiation process 
(figure 3.8), these technical difficulties have prevented me to use the assay for the 
purposes of this thesis. Future investigations may consider different assays, such 
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as commercial kits to detect intracellular ROS (Ranzato et al. 2012), or may use a 
different cell lines, whose compatibility with the Seahorse media has been 
previously established, such as the SH-SY5Y cells (Alvarez-Fischer et al. 2013) or 
hiPS-derived neurones (Zheng et al. 2016). 
 
Since my data so far failed to show any significant change of mitochondrial health, 
I used the MitoTracker, described in section 1.3.5, in order to visualise and quantify 
MMP and mitochondrial number, or “puncta” (figure 4.6 B and C). Moreover, I 
included the 10µM rotenone treatment in this analysis. Although no effect was 
detected in most of the groups, the 10µM rotenone treatment induced a significant 
reduction of the MMP – regardless of the ghrelin pre-treatment – compared to both 
vehicle and 1µM (figure 4.6 D), although no effect was detected on puncta number 
(figure 4.6 E).  
Due to the low sensitivity of this assay, and the limited number of biological 
replicates (n=3), I also performed the statistical analysis on the expanded datasets 
(figure 4.7; n>200). Using this approach, I was able to pick up differences that could 
not be detected with a smaller dataset; however, this also increased the statistical 
power of the analysis. Hence – although some of these results are significant 
(p<0.05) – we should be cautious to draw definitive conclusions on their biological 
relevance. Indeed, in order to improve the accuracy and replicability of these 
analysis, future experiments should rather increase the number of biological 
replicates to be included in the study. 
Statistical analysis of the expanded dataset showed that rotenone treatments affect 
the MMP (figure 4.7 A). In the vehicle-treated group, unacylated ghrelin reduced 
the MMP compared to the control, while acyl-ghrelin did not, suggesting that 
unacylated ghrelin may have a detrimental effect per se. The 1µM rotenone 
treatment significantly decreased the MMP compared to the vehicle; interestingly, 
unacylated ghrelin decreased the MMP even more, while acyl-ghrelin did not exert 
any effect as it was not significantly different from the control. On the contrary, 
10µM rotenone treatment significantly increased the MMP compared to both 
vehicle and 1µM treatment groups. In this context, unacylated ghrelin did not seem 
to induce any changes compared to the control, while, surprisingly, acyl-ghrelin 
exacerbated the significant increase in MMP. 
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Variations of the MMP are a way for these organelles to regulate their physiological 
functions. For instance, it is well known that a significant drop of the MMP, induces 
the accumulation of PINK1 on the OMM and the activation of the PINK1/Parkin 
mitophagic cascade (section 1.3.3). On the contrary, the MMP increases when the 
mitochondria are particularly active; for instance, in activated lymphocytes during 
cell division (Darzynkiewicz et al. 1982), or epithelial cells during wound healing 
(Johnson et al. 1981). More in general MMP increases when cells undergo a 
complex process that requires a lot of energy, such as replication and motility. 
However, MMP is also known to increase drastically just before mitophagy, when 
the organelles try their last resources to restore respiration by combining and 
increasing their activity. In this sense, the significant MMP increase observed in my 
samples after 10µM rotenone treatment, may represent a feedback effect, driving 
energy production to counteract rotenone-induced complex I inhibition. On the 
contrary, the slight decrease of MMP observed in my samples after 1µM treatment, 
is more difficult to interpret, as it may either represent a reduction in the number 
of mitochondria, or just represent natural MMP fluctuations. A possible way to 
overcome this technical issue, would be to perform live cell imaging in order to 
track mitochondria fate with time (Xu et al. 2021). Another way would be to 
support these data with the analysis of other markers, such as PGC1α to determine 
variations of mitochondrial biogenesis, or indirect markers such as TOM20 and 
mtDNA copy number, to establish the number of functional organelles. 
 
Analysis of the puncta number expanded dataset (figure 4.7 B), showed that 
neither acylated nor unacylated ghrelin exerted any effect in the vehicle-treated 
group. However, 1µM rotenone treatment significantly decreased puncta number 
compared to vehicle, while acyl-ghrelin somehow counteracted this reduction by 
restoring puncta number to the vehicle-treated level. Interestingly, 10µM did not 
affect puncta number compared to vehicle nor 1µM, however acyl-ghrelin seemed 
to increase puncta number compared to unacylated ghrelin. 
Overall, these data show that rotenone treatments affect mitochondrial health in 
our system, although different doses showed different patterns of action, 
suggesting a different level of toxicity. Future studies should include a dose-
response curve, in order to determine rotenone’s window of action on these cells. 
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Interestingly, in most treatment groups unacylated ghrelin seemed to have a 
detrimental effect on mitochondrial health, while acyl-ghrelin showed the opposite 
trend. Wang and colleagues, in their study on acyl-ghrelin neuroprotective activity 
on rotenone-treated SH-SY5Y cells, used MitoTracker and JC-1 – another 
commonly used MMP-sensitive probe – and reported that acyl-ghrelin alleviated 
rotenone-induced MMP loss, restoring the control levels (Wang et al. 2021). 
Although our data were not consistent with this report, the opposite pattern of 
action shown by acylated and unacylated ghrelin is promising. Indeed, our group 
recently showed that unacylated ghrelin exerts a detrimental effect on AHN in 
rodents and that acyl-ghrelin is able to reverse the effect and to rescue memory 
function (Hornsby et al. 2020). 
 
Lastly, when looking in more details at puncta number, my data showed that 
rotenone 1µM and 10µM significantly increased the number of cells with less 
puncta (figure 4.8), suggesting either increased mitochondrial fusion or increased 
mitophagy. In the vehicle group, acylated and unacylated ghrelin both seemed to 
increase the number of cells with less puncta, although only acyl-ghrelin showed a 
significant difference. Interestingly, In the 10µM treatment group, unacylated 
ghrelin significantly reduced the number of cells with less puncta, while acyl-
ghrelin treatment was not significantly different from the control. This effect again 
suggests that acyl-ghrelin acts toward a restoration of the condition in the vehicle 
and this effect is opposite to unacylated ghrelin. 
Although these results further contributed to the investigation of mitochondrial 
health, they also open a number of questions that will need to be addressed in 
future studies. Firstly, a reduction in the number of puncta, or mitochondrial 
fragments, may have two very different causes: on one side, it may be associated to 
a shift in the fission/fusion balance, towards increased fusion; on the other side it 
may be interpreted as an increase in mitophagy – or rather a shift in the balance 
between mitophagy and mitochondrial biogenesis. To add another layer of 
complexity, mitochondrial fusion may also have a dual function: on one side, fusion 
and mitochondrial biogenesis traditionally occur when mitochondria are healthy 
and very active, however fusion is also a protective mechanism that may occur 
when the intracellular levels of oxidative stress significantly increase, hence 
mitochondria join forces to increase the overall respiration rate (Gomes et al. 
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2011). Indeed, a change in the number of fragments does not provide a clear 
picture of the mitochondrial health; however, it may still be useful if combined to 
other elements. For instance, future study could investigate the size and area of the 
puncta, to determine whether a change in their number may correlate to a change 
in the size: indeed, larger puncta may represent a healthier network, while smaller 
fragments may underlie increased fragmentation and degradation. Concerning 
mitochondria size and shape, numerous reports have successfully investigated 
mitochondrial health by analysing their 3D structure by live electron microscopy, 
during cell apoptosis (Sun et al. 2007a; Oztel et al. 2017). Ultimately, these 
evidences highlight the difficulties in quantifying mitochondrial health via 
standardised protocol; therefore, future studies should include a more 




Ultimately, the data from this chapter highlight an impairment in the ghrelinergic 
system in the hippocampus of PD patients, and more evidently in PDD, suggesting 
a correlation with memory and cognitive function. 
ReN neurones were not sufficiently capable of replicating PD oxidative stress in 
vitro, however all data point to a detrimental effect of unacylated ghrelin on 





4.5 Key findings 
 
▪ GOAT protein expression, but not mRNA, is significantly reduced in the 
hippocampus of PD patients, and more evidently in samples from PDD patients, 
suggesting a correlation with cognitive decline (figure 4.2). 
 
▪ APT1 mRNA and protein levels do not vary in the hippocampus of PD, nor PDD 
patients (figure 4.3). 
 
▪ GHS-R1a mRNA level does not vary in the hippocampus of PD not PDD patients 
(figure 4.4). 
 
▪ Total ghrelin protein levels are significantly reduced in hippocampal lysates 
from PDD patients, compared to PD (figure 4.4). 
 
▪ Rotenone affects MMP and puncta number in a dose-dependent way. 
▪ Acylated and unacylated ghrelin exert opposite functions on mitochondrial 







5 Ghrelinergic system in





 Onset, progression, and classification  
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterised by 
progressive memory loss, cognitive decline and reduced lifespan and quality. 
Although AD is a medically distinct pathology, its symptoms are commonly 
associated with normal ageing, probably because 95% of the cases are diagnosed 
between the age of 80 and 90 (Prince et al. 2015). Indeed, it accounts for 60-80% 
of the cases of dementia in the world (Barnes and Yaffe 2011) and affects 1-8% of 
the European population over 65 years of age and 25% over 85 years (Ferri et al. 
2005). In 2016 dementia was reported to be one of the major causes of death, 
accounting for 11.6% of all deaths in England and Wales (Vital Statistics Office of 
National Statistics 2017).  
Despite increasing efforts in the field, there is currently no cure that can stop the 
neurodegeneration and the only existing treatments are limited to improve the 
quality of life for the affected patients. Due to improved health care, AD patients 
can survive up to 10 years after the diagnosis, during which they often develop co-
morbidities, such as heart and lung diseases, that ultimately represent the major 
cause of death (Alzheimer’s disease facts and figures. 2020). Moreover, affected 
patients need to rely on others for assistance, making it one of the most high-cost 





The disease develops over three distinct phases (Dubois et al. 2010). The pre-
clinical, or pre-symptomatic phase occurs when the neuropathological changes 
appear, although the patients maintain normal cognition and show no symptoms 
(Patel et al. 2019). AD has a very long pre-clinical phase, as it has been estimated 
that the biochemical hallmarks of the disease may appear up to 20 years before the 
onset of clinical AD (Bateman et al. 2012; Fagan et al. 2014). 
The second phase is the early symptomatic phase, also referred to as “prodromal 
AD”, characterized by mild cognitive impairment with some evidence of 
neurodegeneration. In these individuals, the cognitive decline is greater than 
expected at their age, although not yet debilitating (Dubois 2000). Interestingly, not 
all pre-symptomatic and prodromal AD will proceed into the last stage of the 
disease. Indeed, there are several evidences of non-demented elderly subjects 
whose brain present extensive lesions, despite intact cognitive functions, 
suggesting that the pathological processes might or might not become 
symptomatic during life (Price and Morris 1999; Aizenstein et al. 2008). It has been 
suggested to use the general term “Alzheimer’s pathology” to refer to the not-
clinically manifested AD (Dubois et al. 2010). 
The third phase is clinical AD, first described in 1907 by Alois Alzheimer 
(Alzheimer 1907), and characterised with dementia and cognitive symptoms 
sufficiently severe to interfere with social functioning and daily activities. This 
phase can be identified in the post-mortem brain, from the presence of specific 
lesions: the senile plaques, also known as amyloid‐β (Aβ) plaques, caused by the 
extracellular deposition of insoluble Aβ protein (Glenner and Wong 1984), and the 
neurofibrillary tangles (NFTs) constituted by hyper-phosphorylated tau protein 
(p-Tau) (Grundke-Iqbal et al. 1986). Traditionally, the loss of acetylcholine (Ach)-
producing cortical neurones was considered the main cause of the memory loss, 
although it is now widely accepted that AD most likely originates from a multi- 
systems failure, and also involves other cells types such as DA neurones, astrocytes 
and microglia (reviewed in Hampel et al. 2019). Other changes that occur in the 
brain include neuronal dystrophy, synaptic loss, astrogliosis and vascular 





AD severity is described using the Braak staging method (figure 5.1 A), that 
attributes a numeric value to the post-mortem brain, based on the extension and 
localisation of the lesions (Braak and Braak 1991). The pre-clinical stage (phases I 
and II) is entirely asymptomatic; the “early AD” (phases III and IV) is characterised 
by an extensive Aβ deposition in the frontal and temporal lobes and a limited NFT 
accumulation in the medial temporal lobes and the hippocampus; lastly, during the 
“late AD” (phases V and VI), Aβ and NFT progressively spreads to other areas of the 
neocortex (Braak et al. 1993) (figure 5.1 A). Ultimately, the most affected areas are 
the frontal and temporal lobes, the limbic system, and the hippocampus, that is also 
one of the earliest areas to be affected (Fox et al. 1996). Indeed, impairments of 
spatial and episodic memory – both mainly dependent on the hippocampus – are 
often the first symptoms experienced by patients (Bature et al. 2017). 
Finding an effective treatment for the disease has become a priority for all 
developed countries, but the lack of knowledge about the pathogenic molecular 
mechanisms is a great obstacle for the development of new treatments. 
 
 Pathogenesis and mitochondrial impairment 
Like PD, most AD cases occur sporadically and the exact etiopathogenesis is 
unknown. However, approximately 1% of the cases are inherited in an autosomal 
dominant fashion and occur between 30 (early onset) and 60 (late onset) years of 
age. Familial AD (fAD) has been associated with more than 200 mutations, mainly 
involving three genes implicated in the production of Aβ peptides: amyloid 
precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) (Games et 
al. 1995; Sherrington et al. 1995; De Strooper et al. 1998; Younkin 1998). 
APP is a large integral membrane glycoprotein of unknown function (figure 5.1, 
point 1) (Kang et al. 1987), that is cleaved to generate a variety of fragments with 
contrasting effects on neural function (Turner et al. 2003). Physiologically, the 
majority of the APP is cleaved in the non-amyloidogenic pathway (Kojro and 
Fahrenholz 2005), mediated by the α-secretase enzyme located on the plasma 
membrane (Epis et al. 2012). First, an 83-aminoacid-long N-terminal intermediate 
is generated, then, this is further processed and secreted as a small soluble peptide 
known as APP-α (Haass and Selkoe 1993). APP-α has been shown to have 
neuroprotective and neurotrophic functions, and to regulate cell excitability and 
synaptic plasticity (Milosch et al. 2014). 
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Less common is the amyloidogenic cleavage pathway, that occurs after APP is 
internalised in endosomes (figure 5.1, point 2) (Selkoe et al. 1996). Inside the 
vesicles, APP is first cleaved by the β-secretase b-site APP-cleaving enzyme 1 
(BACE1), generating a membrane-bound C-terminal fragment, C99, and a 99-
amino acid-long N-terminal fragment, APP-β (Vassar et al. 1999). C99 is further 
cleaved to produce the APP intracellular domain (AICD) peptide, a transcription 
factor involved in regulating expression of numerous genes, including APP and 
BACE 1 (figure 5.1, point 3) (von Rotz et al. 2004). The APP-β peptide is 13 amino-
acids longer than its α isomer, and it contains a short hydrophobic region known 
as Aβ region. Inside the endosome, APP-β is further processed by the γ-secretase 
complex, that cleaves the hydrophobic domain at different sites, generating Aβ 
peptides of variable length, between 36 and 43 amino acidic residues (Mundy 
1994). Therefore, the exact site of cleavage is critical for the development of AD: 
the most common variant produced, Aβ40, is released outside the cell where it 
maintains its monomeric form, while the two longer isoforms, Aβ42 and Aβ43, less 
frequent in physiological conditions, display high self-aggregating activity (Burdick 
et al. 1992). In the brain of AD patients, Aβ42 monomers rapidly aggregate to form 
Aβ oligomers (AβOs), that induce other monomers to aggregate, acting as “seeds” 
(figure 5.1, point 4), ultimately leading to the formation of long Aβ fibrils and senile 
plaques (Sowade and Jahn 2017). The extracellular Aβ plaques are toxic to 
neurones as they are responsible for the disruption of cellular communication and 
the induction of microglia-mediated inflammatory response (figure 5.1, point 5) 
(Eng et al. 2004). Pathogenic mutations in PSEN1 and PSEN2, two components of 
the γ-secretase complex, favour the production of the longer peptides (Le Guennec 
et al. 2017; Szaruga et al. 2017), causing an increase in the Aβ42/Aβ40 ratio, that 
has been recently suggested as an early biomarker of AD (Vergallo et al. 2019). 
 
The other main hallmark of AD are the intracellular inclusions of NFTs, composed 
of the microtubule-associated protein Tau (figure 5.1, point 6). Tau’s role is to 
assemble tubulin dimers into microtubules and to regulate their dynamics and 
activity during axonal transport (Cleveland et al. 1977). The protein has 79 serine 
and threonine residues that could be differentially phosphorylated, allowing a fine 
space-time regulation of microtubule function and stability (Kishi et al. 2005; 
Zempel et al. 2010). However, in AD Tau is three-four times more phosphorylated 
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than normal, causing aberrant polymerisation into toxic fibrillary structures 
(Rossor et al. 1996). p-Tau, trapped inside the NFTs, cannot efficiently bind the 
microtubule networks, that collapses (Mandelkow et al. 1995; Liu et al. 2005). This 
results in impaired axonal transport of organelles, such as peroxisomes and 
mitochondria, making the cell more vulnerable to oxidative stress, ultimately 
leading to cellular dysfunction (Stamer et al. 2002; Mandelkow et al. 2003). 
Moreover, the accumulation of NFTs in the cytoplasm triggers the ER response 
(figure 5.1, point 7), and vice-versa, causing an increase in oxidative stress and 
inducing cell death via apoptosis (figure 5.1, point 8) (Ho et al. 2012).  
AD has not been linked to any mutation in the Tau gene (MAPT), however p-Tau 
accumulation positively correlate with cognitive decline in AD patients (Ghoshal et 
al. 2002) and their localisation in the brain serve as diagnostic criteria for staging 
disease progression (Braak and Braak 1991). 
 
In the past decade, growing interest has been dedicated to mitochondrial 
dysfunction, that is also considered to be one of the main hallmarks of AD (recently 
reviewed in Butterfield and Halliwell 2019). AD patients often display impaired 
mitochondrial morphology (Johnson and Blum 1970) and number (Hirai et al. 
2001), defective oxidative phosphorylation and ROS hyper-production (Pamplona 
et al. 2005), increased mtDNA oxidation and mutations (Wang et al. 2006). 
Several Tau isoforms bind the mitochondrial membranes or enter the lumen 
(Amadoro et al. 2011; Cieri et al. 2018); mitochondrial p-Tau has been shown to 
impair ATP production (Atlante et al. 2008), calcium flux and communication with 
the ER (Cieri et al. 2018). Aβ has also been shown to enter the cell and directly 
induce mitochondrial impairment (figure 5.1, point 9). Indeed AβOs are formed in 
the extracellular compartment from secreted monomers, however they can re-
enter the cell via numerous uptake mechanisms (Bates et al. 2009). The main entry 
pathway is mediated by lipid rafts (figure 5.1, point 10), highly specialised areas in 
the cellular membrane, rich in cholesterol and proteins, whose function is to favour 
cellular communication and signal transduction (Vetrivel and Thinakaran 2010). 
This is consistent with reports showing that cholesterol interacts with both soluble 
and fibrillar Aβ (Wood et al. 2002). Moreover, high cholesterol-diets increase the 
risk to develop AD (Kivipelto et al. 2001) while cholesterol depletion in the culture 




A Aβ and p-Tau deposition during AD, according to the Braak staging method 
(reprinted with permission from Jouanne et al. 2017, Elsevier licence number 
5007761374603). B AD molecular pathways: 1 APP protein; 2 amyloidogenic 
pathway; 3 increased gene transcription; 4 Aβ seeding effect; 5 activation of the 
immune response; 6 p-Tau NFTs; 8 induction of apoptosis; 9 mitochondrial 
impairment; 10 lipid rafts (created with BioRender.com).   
Figure 5.1 AD staging and molecular pathways 
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Another possible access pathway is endocytosis mediated by receptors such as the 
N-methyl-D-aspartate (NMDA) glutamate receptor (Snyder et al. 2005) or the α7 
nicotinic acetylcholine receptor (α7nChR) (Nagele et al. 2002), although the 
precise mechanisms are still unclear. Either way, a study performed on cultured 
neurones showed that only the small oligomers can enter the cells, while fibrils and 
filaments remain in the media for 24 hours after incubation (Chafekar et al. 2008). 
This may be explained by the different 3D conformation of the aggregates: AβOs 
are spherical structures with an average diameter (z-height) of 5-10 nm (Chromy 
et al. 2003), while fibrils are rod-shaped aggregates with a diameter of 7-15 nm and 
over 1μm in length (Hill et al. 2011), and thus their structural features is not 
compatible with internalization.  
Once internalised by the cell, AβOs accumulate in a time-dependent manner inside 
the mitochondrial membrane (Caspersen et al. 2005) and their presence has been 
confirmed in the mitochondria of affected brain cells in both AD patients and 
transgenic mice (Brunetti et al. 2020). The two main mitochondrial 
transmembrane channels, TOM and TIM, form complexes with AβOs, allowing 
them to go through the highly selective mitochondrial membranes and to 
accumulate in the lumen (Hansson Petersen et al. 2008; Pagani and Eckert 2011). 
Ultimately, both extracellular and intracellular AβOs-mediated toxicity promote 
mitochondrial fragmentation through the mitochondrial pro-fission protein DRP1 
(Barsoum et al. 2006; Manczak et al. 2011). 
 
Interestingly, AβOs made from the Aβ42 peptide are more toxic than fibrils both in 
vivo (He et al. 2012) and in vitro (Nimmrich et al. 2008). However, Aβ42 peptide 
has very high self-aggregating activity as it quickly polymerises when exposed to 
aqueous solutions – such as cell media – producing insoluble aggregates and long 
fibrils. These irregular structures are difficult to quantify, since the aggregation 
process occurs randomly, hence the exact conditions of each experiment are not 
reproducible. To avoid compromising the accuracy of my data, I used a protocol 
created by Dr. Klein’s lab (Lambert et al. 2001), described in chapter 2, that consists 
of resuspending the lyophilised peptide through a series of decreasingly 
hydrophobic solvents, before being diluted in cell culture media, in order to 




This protocol has been extensively used in literature because of its simplicity – 
although it requires two days of preparation – and because of the numerous 
advantages of using oligomers over fibrils. Notably, oligomers enter the cells, as 
previously shown, therefore are more efficient in quickly inducing oxidative stress, 
making them the gold standard in reproducing AD molecular stress in vitro. 
 
 Ghrelin and AD 
In humans, ghrelin plasma levels decrease with age (Rigamonti et al. 2002) and this 
reduction mediates the appetite loss, slower gastric emptying and reduced 
gastrointestinal hormone secretion typically found in aged subjects, as shown in 
chapter 3. AD patients also commonly exhibit significant weight and appetite loss 
(Gillette-Guyonnet et al. 2000), although a study reported that ghrelin plasma level 
in AD patients was not significantly different from age-matched healthy subjects 
(Proto et al. 2006). Notably, other components of the ghrelinergic system have 
been found to be affected in AD. In the temporal lobe of AD patients, GOAT and GHS-
R1a mRNA were shown to be decreased compared to controls, while GHS-R1b 
mRNA was increased (Gahete et al. 2010a), suggesting that the ghrelinergic axis 
may be altered in the brain of AD patients, possibly contributing to the severe 
cognitive deficit observed in this pathology. 
To the best of my knowledge, the work mentioned above from Gahete and 
colleagues, is the only one linking the ghrelinergic system to AD using human brain 
samples. Indeed, ghrelin has never been administered to AD patients, despite the 
numerous reports about its beneficial effects on memory and cognition in animal 
models of AD. For instance, intra-hippocampal injections of ghrelin protect against 
neurones loss, prevent synaptic degeneration, and rescue memory deficits in mice 
injected with Aβ42 and in the APPSwDI transgenic model of AD (Moon et al. 2011; 
Kunath et al. 2015; Eslami et al. 2018). Administrations of ghrelin or other GHS-
R1a agonists, reduce Aβ accumulation and plaque deposition in the hippocampus 
(Dhurandhar et al. 2013; Kang et al. 2015), decrease tau hyperphosphorylation 
(Chen et al. 2010; Kang et al. 2015), and delay the onset of early AD events such as 
microgliosis and inflammation (Santos et al. 2017; Jeong et al. 2018). Notably, 
ghrelin treatment in hippocampal primary cells has been shown to reduce AβOs-
induced mitochondrial dysfunction and oxidative stress, in a GHS-R1a-dependent 
manner (Martins et al. 2013; Gomes et al. 2014). 
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As previously mentioned in chapter 4, ghrelin-mediated neuroprotective effect in 
PD occurs through the rapid activation of AMPK/UCP2 pathway, that enhances 
mitochondrial respiration and proliferation; hence, several studies have been 
investigating chemicals aimed at increasing AMPK tenor in the brain.  
Interestingly, two of these compounds, Resveratrol and Metformin, have also been 
investigated in the context of AD (Guo et al. 2013; Rotermund et al. 2018). Genetic 
mouse models of AD, display reduced expression levels of AMPK in the 
hippocampus, as well some of its downstream signals such as reduced PGC1α and 
NRF (Pedro et al. 2014).  
Considering all evidence, the AMPK pathway and any compound that activates it, 
such as acyl-ghrelin, may represent an effective strategy against both PD and AD.  
Alas, the number of studies investigating the ghrelinergic system in the brain of AD 
patients is inadequate and pose a large limitation to the possibility of a 





5.2 Aims  
My work for this chapter will attempt to address the lack of knowledge about the 
ghrelinergic system in the brain of AD patients; hence, I will investigate the 
ghrelinergic axis in human tissue and cellular models of AD.  
 
The aims of this chapter are: 
- To quantify the expression levels of key enzymes involved in ghrelinergic 
signalling axis, such as GOAT, APT1 and GHS-R1a, in the human hippocampus of AD 
patients at different stages of the disease.  
- To analyse the effect of ghrelin in an in vitro model of human neurones, pre-
treated with acylated or unacylated ghrelin for 5 days, then treated with AβOs at 
different concentrations. Several parameters of mitochondrial health will be taken 







 The ghrelinergic axis is deregulated in the hippocampus of AD 
patients 
GOAT immunopositivity in the GCL was identified as before (figure 5.2 A, black 
arrowheads). Immunopositive cells were counted to be 433.3 ± 160.8 cells per mm2 
of GCL in controls (n=4), 444.7 ± 71.52 cells per mm2 of GCL in early AD (n=6), and 
664.9 ± 91.38 cells per mm2 of GCL in late AD (n=6), with no significant differences 
reported relative to the control (p=0.9136 for early AD; p=0.2328 for late AD), nor 
between disease groups (p=0.2253) (figure 5.2 B). Western blot analysis, reported 
as fold change to GAPDH, showed no significant changes between controls (0.9616 
± 0.09621) (n=5) and early AD (0.6775 ± 0.1646) (n=5) (p=0.1306), or late AD 
(0.8753 ± 0.1617) (n=4) (p=0.7350) (figure 5.2 D and E), nor between early and 
late AD (p=0.2771). On the contrary, MBOAT4 gene expression from tissue lysates, 
reported as fold change to β-actin, was significantly increased (lower ΔCt) in late 
AD (ΔCt=6.023 ± 0.2255) (n=5), compared to controls (ΔCt=7.025 ± 0.2016) (n=5) 
(**p=0.0058). No significant difference was detected between controls and early 
AD (ΔCt=6.553 ± 0.1848) (n=5) (p=0.2031), nor between early and late AD 
(p=0.1376) (figure 5.2 C). These data suggest a dysregulation in MBOAT4 gene 
transcription, although they are not supported by an alteration at the protein level. 
 
APT1 immunopositive cells in the CA4 (figure 5.3 A, black arrowheads) were 
quantified to be 134.3 ± 56.62 cells per mm2 of CA4 in control brains (n=4), 107.3 
± 15.38 cells per mm2 of CA4 in early AD brains (n=6), and 157.3 ± 25.00 cells per 
mm2 of CA4 in late AD brains (n=5), with no significant differences reported 
between the groups (control vs early AD p=0.8625; control vs late AD p=0.1936; 
early vs late AD p=0.2093) (figure 5.3 B). Similarly, western blot protein 
quantification, reported as fold change to GAPDH, showed no significant changes 
of APT1 expression between control (1.019 ± 0.2594) (n=5) and early AD (1.172 ± 
0.1516) (n=5) (p=0.6714), or late AD (1.038 ± 0.2441) (n=5) (p=0.8320), nor 
between disease groups (p=0.5245) (figure 5.3 D and E). Interestingly, LYPLA1 
gene expression from tissue lysates, reported as fold change to β-actin, showed a 
trend, close to significance, between controls (ΔCt=5.780 ± 0.1409) (n=5) and late 
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AD (ΔCt=5.279 ± 0.1457) (n=5) (+p=0.0660), but no significance with early AD 
(ΔCt=5.295 ± 0.2920) (n=5) (p=0.0771), nor between early and late AD (p=0.9436) 
(figure 5.3 C), suggesting that APT1 expression may also be impaired in late AD, 
although not quite to a significant level. 
 
Because of technical difficulties in performing the BaseScope assay in FFPE tissues, 
GHS-R1a mRNA expression was analysed via RT-qPCR. Gene expression in tissue 
lysates, reported as fold change to β-actin, showed no differences between controls 
(ΔCt=6.447 ± 0.6679) (n=5) and early AD (ΔCt=6.980 ± 0.7244) (n=5) (p=0.4963), 
or late AD (ΔCt=6.368 ± 0.1607) (n=4) (p=0.8586), as well as between early and 
late AD (p=0.4124) (figure 5.4 A).  
 
Lastly, western blot quantification of total ghrelin in tissue lysates, reported as fold 
change to GAPDH, also showed no changes between controls (0.5543 ± 0.03914) 
(n=2) and early AD (0.6833 ± 0.08998) (n=4) (p=0.5423), or late AD (0.6924 ± 
0.1978) (n=5) (p=0.9139), and no difference between early and late AD (p=0.3568) 
(figure 5.4 B and C), although the small number of replicates in the control group 







(A) GOAT immunoreactivity (in brown, black arrowheads) was identified in the 
GCL of controls (left), early AD (centre) and late AD (right), (B) quantified and 
normalised per the area of the GCL (in mm2). (C) MBOAT4 mRNA expression was 
quantified via RT-qPCR while (D, E), GOAT relative protein expression was 
quantified by WB. ROUT analysis was performed to remove any outliers from the 
groups. Significance was measured by Kruskal-Wallis test with Dunn’s multiple 
comparison. Data are reported as mean ± SEM. (n.s. not significant; **p≤0,005) 
  





(A) APT1 immunoreactivity (in brown, black arrowheads) was identified in the 
CA4 of controls (left), early AD (centre) and late AD (right) and (B) quantified as 
positive cells per mm2 of CA4. (C) LYPLA1 mRNA expression was quantified via RT-
qPCR while (D, E) APT1 relative protein expression was quantified by WB. ROUT 
analysis was performed to remove any outliers from the groups. Significance was 
measured by Kruskal-Wallis test with Dunn’s multiple comparison. Data are 
reported as mean ± SEM. (n.s. not significant; +p=0,0660) 
 
  






 (A) GHS-R1a mRNA expression was quantified via RT-qPCR. (B, C) Total ghrelin 
protein expression was quantified by WB. ROUT analysis was performed to remove 
any outliers from the groups. Significance was measured by Kruskal-Wallis test 
with Dunn’s multiple comparison. Data are reported as mean ± SEM. (n.s. not 
significant) 
  
Figure 5.4 GHSR1a and tot ghrelin expression in AD 
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 Amyloid affects cell viability and mitochondria homeostasis 
For each batch of Aβ peptide that was resuspended, structure and size validation 
was performed by AFM with the help of our collaborator, Dr. Andrea Gazze 
(Swansea University, Medical school) (Gazze et al. 2021).  
As a result of using Klein’s lab protocol, ordered oligomeric structures were 
generated, appearing at the AFM as spheroids of uniform size, with diameter of 
approximately 10nm (figure 5.5 A). As a negative control for fibril formation, the 
Aβ peptide-HFIP stock solution was diluted straight in distilled water for 24 hours 
at 4ᴼC, generating heterogeneous (“disordered”) particles (figure 5.5 B). Lastly, 
when the peptide was left in water for one week at 4ᴼC, oligomers polymerised in 
a disorderly fashion generating small and medium-length fibrils – such as the one 
shown in figure 5.5 C, consisting in the aggregation of 4 oligomers (numbered 1 to 
4). For the purpose of this thesis, only ordered AβOs such as those shown in figure 
5.5 A, were used for cell treatments.  
 
ReN neurones at day in vitro 28 (DIV28), were treated for 24 hours with AβOs, then 
assessed for immunoreactivity to anti-Aβ42 antibody (6E10). Mostly of the cells 
appear immunopositive (figure 5.5 D), indicating they internalised the AβOs 
preparation. Interestingly, some cells presented granularity in the cytoplasm 
(figure 5.5 D, white arrowheads), suggesting a compartmentalised distribution of 
the peptide inside the cell. Furthermore, some large aggregates of variable size 
(approximately 20-80µm) were identified in the areas between the cells (figure 5.5 






(A) The homogeneity of AβOs obtained with the protocol from Klein group, was 
verified by AFM and compared to preparations obtained using different protocols, 
such as (B) disordered oligomers or (C) fibrils. (D) ReN neurones (DIV28) treated 
with AβOs for 24 hours, were assessed for immunopositivity to anti-6E10 antibody.  
(E, F) Possible extra-cellular large AβOs aggregations. Scale bar 50um. 
 
  
Figure 5.5 AFM validation of the amyloid-β oligomers preparation 
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ReN neurones treated with vehicle, AβOs 1µM and 10µM, were stained with 
Hoechst and analysed (figure 5.6 B), as shown previously. In the vehicle treated 
group (n=5), neither acyl-ghrelin (114 ± 2.44; p>0.9999), nor unacylated ghrelin 
(103 ± 7.87; p>0.9999) significantly affected cell number compared to control (110 
± 6.01). Similarly, in cells treated with 1µM AβOs (n=2) no significant differences 
were detected between control (84.8 ± 5.22) and acyl-ghrelin (108 ± 25.5; 
p=0.9103) or unacylated ghrelin (126 ± 34.5; p=0.3291). Cultures treated with 
10µM AβOs (n=3) were not significantly different [control (90.1 ± 0.986); acyl-
ghrelin (111 ± 4.49; p=0.8316); unacylated ghrelin (88.8 ± 6.06; p>0.9999)]. When 
analysing the overall treatment effects, no significant differences were detected 
between vehicle, AβOs 1µM and 10µM, regardless of AG/UAG treatment (p>0.2), 
suggesting that these treatment conditions are not detrimental to the cells. 
I then investigated total cellular ATP production using CellTiter Glo kit (figure 5.6 
C), as shown in chapter 4. No significant differences were detected between any of 
the groups (n=3; p>0.5), regardless of AG/UAG treatment, suggesting that ATP 
levels are unaffected by AβOs treatment. [Vehicle group: control (1.00 ± 0.115), 
acyl-ghrelin (0.745 ± 0.0457), unacylated ghrelin (1.03 ± 0.231); AβOs 1µM group: 
control (1.23 ± 0.283), acyl-ghrelin (0.976 ± 0.196), unacylated ghrelin (0.936 ± 
0.212)]. 
To further investigate mitochondrial health, I quantified mtDNA copy number in 
ReN neurones treated with vehicle (n=3) or AβOs 1µM (n=3), and normalised to 
DNA content (figure 5.6 D and F). No significant differences were detected (p>0.8) 
between any of the groups, suggesting that AβOs treatment does not affect 
mitochondria number. [Vehicle group: control (ΔCt=7.60 ± 0.123), acyl-ghrelin 
(ΔCt=7.31 ± 0.111), unacylated ghrelin (ΔCt=7.35 ± 0.111); AβOs 1µM group: 
control (ΔCt=7.61 ± 0.193), acyl-ghrelin (ΔCt=7.44 ± 0.187), unacylated ghrelin 
(ΔCt=7.67 ± 0.382)]. 
Lastly, I assessed the expression of PGC1α mRNA (figure 5.6 E and F) from 
neurones treated with vehicle (n=3), AβOs 1µM (n=3), or 10µM (n=3). No 
significant differences were detected between groups (p>0.5), suggesting that 
PGC1α gene expression is not affected in these experimental settings. [Vehicle 
group: control (ΔCt=10.6 ± 0.131), acyl-ghrelin (ΔCt=10.7 ± 0.172), unacylated 
ghrelin (ΔCt=10.4 ± 0.0963); AβOs 1µM group: control (ΔCt=10.4 ± 0.200), acyl-




ReN neurones (DIV24), were treated as shown in the timeline. (B) Cell number was 
quantified using the Cell Profiler software and reported as percentage ± SEM (n=3). 
(C) Total ATP was measured using the CellTiter Glo kit and reported as fold change 
(n=3). (D) Mitochondrial DNA content was quantified by RT-qPCR and normalised 
per nuclear DNA (n=3) while (E) PGC1α mRNA expression was normalised per β-
actin (n=3). (F) delta Ct values were used for both RT-qPCRs statistical analysis and 
are reported in the table. Significance was measured by two-way ANOVA and 
Tukey's multiple comparison test. Data are reported as mean ± SEM. (n.s. not 
significant).   
Figure 5.6 AβOs affect ReN neurones cell number and mitochondrial network 
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Similar to rotenone treatment, the experimental settings used in the first part of 
the experiment failed to report a significant difference between treatments for all 
the mitochondrial parameters analysed. In order to visualise any significance that 
may have been undetected, I used MitoTracker to stain ReN neurones treated with 
either vehicle (n=6), AβOs 1µM (n=3) or 10µM (n=3), as shown in the timeline 
(figure 5.7 A and B). 
 
First, I measured the total (integrated) intensity of the MMP stain (figure 5.7 C). 
Using a two-way ANOVA followed by Tukey’s multiple comparison test, no 
significant differences were reported between groups (p>0.3). [Vehicle: control 
(0.966 ± 0.0893), acyl-ghrelin (1.00 ± 0.0830), unacylated ghrelin (0.993 ± 0.132); 
AβOs 1µM: control (0.696 ± 0.0576), acyl-ghrelin (0.782 ± 0.0561), unacylated 
ghrelin (0.654 ± 0.0919); AβOs 10µM: control (0.985 ± 0.0416), acyl-ghrelin (0.987 
± 0.0563), unacylated ghrelin (0.917 ± 0.0708)]. Interestingly, a strong treatment 
effect was detected. The group of cells treated with AβOs 1µM (regardless of 
AG/UAG) exhibit significantly reduced MMP (integrated intensity) compared to 
either the control group (**p=0.0068) or the 10 µM group (*p=0.0361), while no 
difference was detected between the 10µM and control group (p=0.9521). These 
data show that AβOs treatments may affect mitochondria health differently, 
according on the peptide concentration, therefore suggesting the existence of 
multiple regulatory mechanisms. 
Subsequently, I analysed the number of puncta per cell reported as fold change 
(figure 5.7 D) and did not detect any significant changes between the groups 
(p>0.4). [Vehicle treated: control (1.01 ± 0.0439), acyl-ghrelin (1.03 ± 0.0445), 
unacylated ghrelin (1.03 ± 0.0542); AβOs 1µM treated: control (0.866 ± 0.105), 
acyl-ghrelin (0.953 ± 0.0271), unacylated ghrelin (0.836 ± 0.0899); AβOs 10µM 
treated: control (0.982 ± 0.0420), acyl-ghrelin (0.979 ± 0.0507), unacylated ghrelin 
(0.899 ± 0.101)]. Interestingly, a significant treatment effect was detected, with 
puncta number being reduced in the AβOs 1µM group compared to control 
(*p=0.0299), but not to the 10µM (p=0.3823), nor between 1 and 10µM AβOs 
(p=0.4739). This data confirms the previous evidence that AβOs 1µM treatment 
affects mitochondrial network, and that this effect is somehow abrogated at 10µM, 





(A) ReN neurones (DIV24) were treated as shown in the timeline. (B) Cells were 
stained with MitoTracker and Hoechst nuclear counterstain (blue). Mitochondrial 
“puncta” were identified using Cell Profiler software. (C) Total (integrated) 
intensity and (D) puncta number were measured and reported as mean ± SEM 
(n=3; vehicle n=6). Significance was measured by two-way ANOVA and Tukey's 
multiple comparison test. (n.s. not significant; **p≤0.005; *p≤0.05).  
Figure 5.7 Mitochondrial measurements in AβOs treated cells 
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The SuperPlot graph was used to present the single cell data (n≥222), as shown in 
chapter 4. Data distribution was found to be non-parametric after D’Agostino-
Pearson’s normality test; hence, analysis was performed using Kruskal-Wallis and 
Dunn’s multiple comparison test on the expanded dataset. Using these settings, I 
detected a significant reduction of the MMP (figure 5.8 A) between each treatment 
of the vehicle group (control:0.926 ± 0.0148, n=1071; unacylated ghrelin:0.925 ± 
0.0142, n=1247; acyl-ghrelin:0.998 ± 0.0153, n=1065) and the corresponding 
treatments of the AβOs 1µM group (control:0.720 ± 0.0152, n=498, ****p<0.0001; 
unacylated ghrelin:0.685 ± 0.0151, n=492, ****p<0.0001; acyl-ghrelin:0.778 ± 
0.0146, n=550, ****p <0.0001) (dashed lines). Similarly, the AβOs 1µM group was 
significantly reduced compared to the corresponding 10µM treatment 
(control:0.967 ± 0.0289, n=248, ****p<0.0001; unacylated ghrelin:0.885 ± 0.0330, 
n=222, ****p<0.0001; acyl-ghrelin:0.950 ± 0.0260, n=260, ****p<0.0001) (dotted 
lines), consistently with the treatment effect detected earlier (figure 5.7 C). On the 
contrary, no difference was detected between vehicle and AβOs 10µM (p>0.5), 
reinforcing the hypothesis that 1µM and 10µM doses exert different effects on 
mitochondria. Acyl-ghrelin significantly increased the MMP in the vehicle group, 
compared to control (**p=0.0024) and unacylated ghrelin (****p<0.0001), and in 
the 1µM groups compared to unacylated ghrelin (***p=0.0004). No other 
significant differences were detected within the 1µM nor the 10µM treatment. 
Subsequently, I analysed puncta number per cell (figure 5.8 B). In the vehicle group, 
neither unacylated ghrelin (1.03 ± 0.014; n=1247; p>0.9999), nor acyl-ghrelin 
(1.07 ± 0.0161; n=1065; p=0.1668) significantly affected puncta number compared 
to control (0.997 ± 0.0147; n=1071). However, all three treatments were 
significantly higher compared to the corresponding treatments in the AβOs 1µM 
group [control (0.909 ± 0.0201; n=498; **p=0.0025), unacylated ghrelin (0.872 ± 
0.0193; n=492; ****p<0.0001) and acyl-ghrelin (0.951 ± 0.0174; n=550; 
**p=0.0011)], supporting the treatment effect reported previously (figure 5.7 B). 
Interestingly, within the 1µM treatment group, acyl-ghrelin significantly increases 
puncta number compared to unacylated ghrelin (*p=0.0355. Lastly, no significant 
difference (p>0.2) was detected between any of the treatments in the 10µM group 
[control (0.975 ± 0.0274; n=317), unacylated ghrelin (0.866 ± 0.0309; n=291) and 
acyl-ghrelin (0.970 ± 0.0257; n=328)], reinforcing the hypothesis of a dose-




(A) Mitochondria integrated intensity and (B) puncta number are shown using a 
SuperPlot graph, combining the mean ± SEM from figure 5.7 (n=3; vehicle n=6) and 
the corresponding values per single cells (n≥222). Each large dot represents a 
group mean, and each colour-coded small dot represent individual cells. Statistical 
analysis was performed with Kruskal-Wallis and Dunn’s multiple comparison on 
the single cell’s values. (****p<0.0001; ***p≤0.0005; **p≤0.005; *p≤0.05).  




Memory loss and cognitive decline are the most typical symptoms of AD. CR has 
been shown to improve memory performance in elderly humans and to rescue 
memory loss in transgenic AD models, as shown in section 1.1.2. Notably, acyl-
ghrelin and ghrelin agonists have been shown to improve AD-related symptoms 
and pathogenesis in several mice model, reducing tau hyperphosphorylation (Chen 
et al. 2010), rescuing cell loss by inducing AHN (Moon et al. 2014), reducing Aβ 
plaques and preventing synaptic loss and tissue inflammation (Santos et al. 2017; 
Jeong et al. 2018). Most importantly, acyl-ghrelin has been shown to significantly 
rescue cognitive function and memory impairment (Kang et al. 2015; Kunath et al. 
2015; Santos et al. 2017; Eslami et al. 2018). Despite the growing number of 
evidence linking acyl-ghrelin axis to neuroprotection in vitro and in vivo, its role in 
the human brain has been poorly considered; hence, to the best of my knowledge 
this is the first study investigating the ghrelinergic system enzymes in the AD brain. 
 
 GOAT, APT1, GHS-R1a and total ghrelin 
My experiments show no significant difference of GOAT protein expression in the 
hippocampus, whilst MBOAT4 mRNA level was significantly increased in late AD 
patients compared to age-matched healthy controls (figure 5.3, **p=0.0058). 
Consistently, GOAT+ cells in the DG of late AD patients were approximately 44% 
higher than control, although this value did not reach statistical significance (figure 
5.3 B, p=0.2328); moreover, no changes in GOAT protein level were detectable in 
whole-hippocampus tissue lysates (figure 5.3 D and E).  
A poor correlation between mRNA and protein expression may have the most 
diverse causes, such as post-translational modification, ribosome occupancy, 
protein degradation, and more. However, there are several factors that are known 
to specifically upregulate MBOAT4 mRNA, such as CR (Hatef et al. 2015) or acyl-
ghrelin administration (Gahete et al. 2010b). Interestingly, a recent study showed 
that MBOAT4 gene may also be transactivated by mTOR, via the gene enhancer 
ERM transcription factor variant 5 (ETV5), in murine GOAT-producing cells (Mao 
et al. 2019). mTOR is traditionally considered an endogenous antagonist of the 
pAMPK pathway; indeed, pAMPK inhibits mTOR signalling by phosphorylating its 
deactivator Raptor (section 1.2.9), while mTOR pathway is responsible for the 
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leptin-induced post-prandial inhibition in AMPK phosphorylation (Dagon et al. 
2012). In animal models of AD, upregulation of mTOR signaling has been shown to 
drive the pathological progression of the disease, while several mTOR inhibitors, 
including rapamycin, rescue the cognitive deficits (Spilman et al. 2010; Wang et al. 
2014a). In light of this, the upregulation of MBOAT4 in late AD patients reported in 
this thesis, may be associated to increased mTOR signalling and may serve as 
compensatory mechanism against oxidative stress and metabolic impairment. 
Indeed, since GOAT can re-acylate ghrelin in situ (section 1.4.4), its overexpression 
could potentially increase acyl-ghrelin tenor in the hippocampus of these patients. 
Nevertheless, more studies are needed to characterise the role of GOAT in memory 
and cognition; for instance, animal models of AD could be treated with either GOAT 
inhibitors or agonists, to study how it may affect memory. Another approach could 
be to use GOAT KO mice (Hornsby et al. 2020) treated with Aβ or other toxins to 
simulate AD, to determine the role of the enzyme in the pathogenesis of the disease. 
Subsequently, animals could be treated with acylated or unacylated ghrelin, to 
investigate whether the treatment may potentially rescue the effect. 
 
In my data, APT1 expression was not significantly different in early or late AD, 
compared to age-matched healthy subjects. Although, LYPLA1 in late AD showed a 
slight increase close to significance (+p=0.0660), this trend did not match a change 
in protein levels and suggests that APT1 is not impaired in the brain of AD subjects. 
Consistently, neither GHS-R1a mRNA, nor total ghrelin protein expressions were 
found altered in the brain of AD patients.  
 
Overall, these data are consistent with previous reports showing that ghrelin levels 
are not impaired in the plasma of AD patients (Proto et al. 2006), however, they 
seem to stand against the hypothesis previously postulated (chapter 4), that GOAT 
level correlates with dementia in the brain of patients affected with PD and PDD. 
This apparent contradiction is easily explained when looking at the main 
characteristics of PD and AD. Indeed, despite the numerous shared molecular and 
pathological pathways, the two diseases affect different areas of the brain. More 
specifically, even if both diseases are associated with memory loss and cognitive 
impairment, the specific symptoms are different enough to suggest the activation 
of diverse molecular mechanisms, as will be better described in section 6. 
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 Mitochondrial health 
The second aim of this study was to induce Aβ toxicity and to characterise the role 
of ghrelin in maintaining cell homeostasis in vitro. AβOs were produced as 
described in section 2, and their internalisation in ReN neurones was successfully 
verified 24 hours after treatment (figure 5.5). Then, ReN neurones were treated as 
shown in figure 5.6, and analysed to assess mitochondrial health. 
 
Analogously to what seen in chapter 4, in vitro results from this section are 
contradictory. 1µM AβOs treatment negatively affected both MMP and puncta 
number, while the 10µM treatment did not induce any change in any of the 
mitochondrial aspects analysed in this chapter. The reason for that may be found 
in the technical conditions of the experiments. As previously mentioned, AβOs are 
quite challenging to prepare, because of the high self-aggregation tendency when 
in contact with aqueous solutions. Indeed, the last step of the AβOs preparation, 
requires for the compounds to rest at 4ᴼC for 24 hours, in a very small volume of 
cell media. As the 10µM preparation is highly concentrated, it is plausible that, in 
this last step, some of the amyloid peptide may have formed small proto-fibrils or 
fibrils in solution; in this scenario, some of the peptide could have been 
‘sequestered’ inside the fibrils, hence the final concentration of the oligomers could 
have been significantly lower than expected.  
Moreover, as previously mentioned, fibrils have been shown to be less toxic than 
AβOs both in vivo (He et al. 2012) and in vitro (Nimmrich et al. 2008), therefore it 
is possible that 24 hours treatment with the oligomer/fibril mix, may have not been 
sufficient to exert any detectable effect.  
Furthermore, since the cells have been growing as a monolayer, any proto-fibril or 
fibril that could have formed, would have then been washed away during the 
fixation steps at the end of the treatment, hence remaining undetected. To test this 
hypothesis, future studies should use live confocal microscopy to investigate AβOs 
internalisation in ReN neurones, and more specifically whether the peptides would 
be able to directly interact with mitochondria.  
Lastly, the protocol elaborated from Dr. Klein’s group was originally designed for 
low concentration-treatments (100‐500nM); although I carefully calculated each 
quantity and volume in a way that would have maintained the concentration of 
each solution consistent with the original protocol, it is possible that the presence 
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of a more concentrated amount of peptide may have negatively affected the 
oligomerisation process. Hence, future studies should better characterise AβOs at 
different concentrations, and design experiments that would utilise less 
concentrated peptide for longer incubation periods. 
 
Notably, the analysis of the extended mitochondria dataset (figure 5.8) reported 
that unacylated ghrelin exerts a detrimental effect on both MMP and puncta 
number, while acyl-ghrelin produces a statistically significant counteracting effect. 
Interestingly neither unacylated nor acylated ghrelin exerted any effect in the 
group treated with 10µM AβOs, and the overall observed effects were in general 
less evident than the one produced in chapter 4 (figure 4,7). For this reason, I did 
not perform any further analysis on the puncta distribution.  
 
Overall, these data suggest a scarce reproducibility of the experimental conditions 
used in this study. To overcome these technical issues and obtain more consistent 
results in the future, a different cell type may be adopted such as the SH-SY5Y, for 
which decades of previous researches have contributed establishing a vast number 
of standardised protocols. 
 
 Conclusions 
In summary, this chapter shows that some components of the ghrelinergic system 
may be affected in the hippocampus of late AD patients, although the data are 
circumstantial and will need further studies. ReN neurones did not recapitulated 
AD mitochondrial stress in vitro, however the data confirmed that unacylated 
ghrelin exerts a detrimental activity on mitochondrial health, to which acyl-ghrelin 




5.5 Key findings 
 
▪ GOAT mRNA expression is significantly increased in the hippocampus of late AD 
patients, whilst protein level is not affected (figure 5.2). 
 
▪ APT1 mRNA and protein, GHS-R1a mRNA and total ghrelin protein expression 
levels do not vary in the hippocampus of early AD, nor late AD patients (figure 
5.3 and 5.4). 
 
▪ Orderly-structured AβOs can be successfully produced using Dr. Klein’s protocol 
and are internalised by ReN neurones in vitro (figure 5.5). 
▪ 1µM, but not 10µM AβOs, affects MMP and puncta number independently of 
ghrelin treatment (figure 5.7 and 5.8). 
▪ Acylated and unacylated ghrelin exert opposite functions on mitochondrial 












 Neurodegenerative diseases and the ghrelinergic system 
In the past fifty years, age-related neurodegenerative diseases have become one of 
largest health care problems in the developed countries. The available therapeutic 
treatments significantly improve survival rate and life quality, so patients can have 
a near-normal life expectancy; however, since the physical and mental 
deteriorations cannot be stopped, with time patients become gradually more 
dependent on others, increasing the economic burden on the healthcare system 
and patient families, calling for a quick identification of a new, definitive cure. 
PD and AD are the two most common neurodegenerative disorders and, together, 
represent most of the cases of dementia in the world. PD affects DA neurones of the 
SN and the striatum, hence is mostly associated to motor impairment, tremors, and 
postural instability (chapter 4). AD mostly affects the cholinergic system in the 
hippocampus and entorhinal cortex, and is responsible for gradual memory loss, 
also affecting the capability of forming of new ones (chapter 5). The two diseases 
are likely to have different causes – or possibly different combinations of similar 
factors – and this is especially evident from the diverse brain areas involved. 
However, these two pathologies share some common ground; they are both 
characterised by age-related, irreversible, accumulation of intracellular damage, 
such as misfolded proteins and oxidative stress (reviewed in Umeno et al. 2017). 
At the molecular level, both diseases exhibit ER stress (Ho et al. 2012; Mazzulli et 
al. 2016), ALP and UPS failure (Bates et al. 2009; Ebrahimi-Fakhari et al. 2011), 
inflammation and microglia activation (Bartels et al. 2020), and mitochondrial 
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impairment (Schapira et al. 1990; Bates et al. 2009) (figures 4.1 and 5.1); indeed, 
in both pathologies oxidative stress and impaired energy metabolism affect 
neuronal plasticity and cognition, ultimately resulting in failure of the quality 
control systems and accumulation of damage in the brain.  
There are also numerous biochemical players that are known to intervene in both 
diseases: Aβ plaques accumulate in the brain of PD patients and trigger 
inflammation (Masliah et al. 2001); p-tau co-localises with α-synuclein in Lewy 
bodies (Arima et al. 1999) and α-synuclein accumulates in the brain of AD patients 
(Larson et al. 2012). Moreover, although PD was originally thought to be a motor 
disease, it is now more evident that non-motor deficits are prominent features. 
Post-mortem brain tissue of patients affected by PD, exhibit extensive cell loss in 
the hippocampus and the entorhinal cortex (Hu et al. 2001) and memory 
impairment affects 67% of patients with PD at a later stage (Portin and Rinne 1987; 
Aarsland et al. 2003; Noe et al. 2004; Hely et al. 2005) – thereby renamed PD with 
dementia, PDD (Dubois et al. 2007; Emre et al. 2007). Memory loss in PDD is less 
severe than in AD (Paolo et al. 1995; Aarsland et al. 2003) and it is generally agreed 
that memory deficit in PDD affects memory retrieval, rather than encoding and 
storage as typically seen in AD. Nonetheless, PDD patients exhibit impairment in 
object recognition, non-verbal memory and visual recognition memory, 
comparable to what observed in subjects with AD (Noe et al. 2004); verbal fluency 
and concept formation are also compromised (Paolo et al. 1995; Starkstem et al. 
1996; Aarsland et al. 2003; Noe et al. 2004). Lastly, spatial memory is impaired 
(Starkstem et al. 1996), but in PD this is also associated to a worse perception of 
the environment, therefore suggesting a distinct mechanism to AD (Mosimann et 
al. 2004). 
 
Several therapeutic approaches that have been clinically assessed in rodents for 
one disease, have also proven effective against other disease models; this is the 
case of the AMPK activators Resveratrol (Guo et al. 2013), Metformin (Rotermund 
et al. 2018), and CR (Srivastava and C. Haigis 2011). Indeed, CR has been 
extensively reported to extend longevity in rodents and non-human primates, and 
to prevent age-associated cellular stress, by activating AMPK pathway and 
reducing mitochondrial impairment (section 1.1.2).  
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Acyl-ghrelin is the main mediator of the beneficial effects of CR in the brain, acting 
as a feedback signal of negative energy balance and contributing to maintaining 
physiological and neurological function during low energy state (section 1.2.2).  
This thesis was designed to compensate for the lack of studies about the 
ghrelinergic system in the human brain, especially in the context of 
neurodegenerative diseases. Therefore, I investigated the expression of key 
regulatory proteins in post-mortem brain tissue from PD and AD subjects, and the 
effects of ghrelin on mitochondria in human neurones. 
 
 GOAT and APT1 are affected in the diseased brain 
The experiments performed in this thesis showed that the three main proteins of 
the ghrelinergic system – GOAT, APT1 and GHS-R1a – are expressed in the human 
brain and their levels are unchanged at both protein and mRNA level in the 
hippocampus of aged healthy subjects (chapter 3). 
However, GOAT protein expression is significantly reduced in the hippocampus of 
PDD patients (chapter 4), suggesting a reduced ability to produce acyl-ghrelin in 
the brain. Indeed, our group recently reported that circulating AG:UAG is reduced 
in the plasma of PDD patients, and correlates significantly with the cognitive ability 
of the patients, measured by the MoCA score (Hornsby et al. 2020). These data, in 
combination with my findings, point to the possibility that the impairment of the 
ghrelinergic system may have a role in exacerbating cognitive dysfunction in these 
patients.  
Late AD patients also show prominent cognitive impairment, however in our 
investigations MBOAT mRNA levels were significantly increased in these patients, 
compared to early AD and controls (chapter 5). The discrepancy between late AD 
and PDD patients – suggesting that the ghrelinergic system is differently regulated 
in those two diseases – does not come entirely as a surprise since AD and PD have 
very distinct pathogenesis, despite them sharing some characteristics. 
Interestingly, the increase observed at mRNA level did not match with an increase 
in protein levels, probably due a general impairment of the protein translation 
machinery, as described in chapter 5.  
To my knowledge, the ratio between acylated and unacylated ghrelin has never 
been measured in the plasma of AD patients – despite total ghrelin levels having 
been reported to be unaffected (Proto et al. 2006). If AG:UAG ratio is found to be 
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impaired in late AD – the same way we found it impaired in PDD (Hornsby et al. 
2020) – this could explain the increase in MBOAT mRNA levels, aiming at 
compensating the lack of acylated-ghrelin. Future studies should investigate the 
ghrelinergic system in AD patients at different stages of the disease, in order to 
confirm or refute this hypothesis and shed further light on the role of acyl-ghrelin 
in dementia and cognitive impairment. 
 
Another key element that is missing from our knowledge of the ghrelinergic system 
in the human brain, is which cell type express the ghrelin-related enzymes and 
whether this may change with age or during disease progression. For instance, as 
mentioned in chapter 3, the newly found localisation of APT1 in the cells of the 
BCSFB could point to a local regulation of acyl-ghrelin access to the brain. Similarly, 
since GOAT has been found to re-acylate ghrelin in situ (Hopkins et al. 2017; 
Murtuza and Isokawa 2018), it is of high priority to investigate its activity and role 
in determining acyl-ghrelin availability in the brain.  
Interestingly, full length monomeric and dimeric GOAT was detected in the 
circulation of fasted rodents (Stengel et al. 2010), and in human plasma (Goebel-
Stengel et al. 2013), suggesting that the enzyme may be able to re-acylate ghrelin 
in the circulation. Future studies should investigate the transport mechanism of 
GOAT enzyme in plasma, since transmembrane proteins would evidently need a 
specific delivery system, such as albumin or small vesicles. Moreover, several 
ELISA kits are commercially available, that could allow precise measurement of 
GOAT protein level in the plasma of patients affected with PD and AD. Lastly, in 
order to determine whether circulating GOAT extracted from patient’s plasma is 
fully functional, its enzymatic activity should be investigated for instance using the 
enzyme-linked click-chemistry (cat-ELCCA), a fluorescent assay that was 
previously used to assess GOAT activity in vitro (Garner and Janda 2010). 
 
Opposite to GOAT, both LYPLA1 mRNA and APT1 protein levels were found to be 
unaffected in our investigations. Since ghrelin is the only substrate of GOAT 
(Darling et al. 2015) and GOAT is the only acylating enzyme of ghrelin (Gutierrez 
et al. 2008; Kirchner et al. 2009), an impairment in GOAT expression may be 
directly connected to defects in the ghrelinergic axis. On the contrary, APT1 shows 
very little specificity for its ligands, therefore a variation in its expression and/or 
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activity, may involve a much greater number of systems. For instance, APT1 is 
responsible for the de-palmitoylation of PSD-95, an important synaptic protein 
implicated in neurodegenerative disease (Virlogeux et al. 2021). Hence, our 
findings that APT1 were not affected in the diseases brain, do not undermine the 
original hypothesis of a ghrelinergic system impairment. 
Notably, numerous enzymes have been shown to deacylate ghrelin, such as APT2 
(Satou et al. 2010), α2-macroglobulin (Eubanks et al. 2011), butyl-cholinesterase 
(BChE) (Schopfer et al. 2015), and notum (Zhao et al. 2021), while the involvement 
of others, like the platelet activating factor (PAF), has been hypothesised (Shanado 
et al. 2004). Satou et al. showed that both APT1 and APT2 can catalyse acyl-ghrelin 
deacylation in a ghrelin-expressing cell line (Satou et al. 2010). This study also 
reported that APT1 was profusely present in the cell supernatant, while APT2 was 
not detectable, suggesting that APT1 may be released into the circulation. Based on 
these evidences, the authors suggested that APT1 deacylating ability in vivo is more 
relevant than that of APT2 – since APT1 would have access to the circulating 
hormone, that is indeed the largest percentage of the hormone in the body. A few 
years later, others advocated a role for both enzymes in ghrelin deacylation (Won 
et al. 2018), although this hypothesis was never experimentally confirmed. 
Notably, the original authors later claimed that APT2 is not able to deacylate 
ghrelin at all (Satou et al. 2011), although, to the best of my knowledge, no data is 
available to either support or refute this hypothesis. 
The only other research published on the matter, from De Vriese and colleagues, 
suggested that ghrelin deacylation is mediated by distinct enzymes in rodents 
compared to humans (De Vriese et al. 2004). In particular, they showed that ghrelin 
deacylation was significantly reduced by a pan-serine protease inhibitor, in a 
ghrelin-producing human cell line; interestingly, both APT1 and BChE belong to the 
same group of enzymes that would have been inhibited in this experiment. 
However, the study did not mention APT1; the authors hypothesised that – among 
the many enzymes inhibited in the assay – BChE may be the main one involved in 
ghrelin deacylation. In order to confirm this theory, they treated the same cell line 
with purified human BChE and observed a significant increase of ghrelin 
deacylation, proportional to the dose of the enzyme used. These results were later 
replicated in other studies (De Vriese et al. 2007; Dantas et al. 2011); yet, none of 
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these researches ever reported the total inhibition of ghrelin deacylation process, 
suggesting that it may occur via a combination of enzymes. 
Nevertheless, BChE is an interesting enzyme, since it increases during AD and BChE 
inhibitors have been tested for several decades on numerous animal models of the 
disease (Darvesh 2016; Macdonald et al. 2017). Indeed, as mentioned in chapter 5, 
one of the main biochemical changes that occur in the brain of AD patients, is the 
loss of cholinergic innervation in the cortex, and BChE is mostly known for its 
activity in degrading excess Ach (Li et al. 2000). Two BChE inhibitors, rivastigmine 
and galantamine, originally developed against mild cognitive impairment in early 
AD, are now routinely administered in PDD patients and in subjects with other 
forms of memory impairment (Tricco et al. 2013). 
Ultimately, more studies are needed to characterise the enzymes mentioned above, 
the extent of their involvement in ghrelin de-acylation process, and their 
expression in the healthy and diseases human brain. 
 
Ghrelin acylation is essential for its activity and binding with GHS-R1a, as described 
in section 1.2.8. Indeed, stabilization of the acyl-group – hence preventing the 
conversion of acyl-ghrelin to unacylated ghrelin – in order to increase its central 
bioavailability, could represent a potential therapeutic approach to improve 
memory and cognition. A pharmaceutical strategy to achieve this, could be to use 
compounds preventing its deacylation. For instance, since APT1 has been shown to 
be involved in some cancer types (Wang et al. 2015b), small inhibitory compounds 
have been extensively used in cancer research. Moreover, with the availability of 
the APT1 and APT2 crystal structures (Devedjiev et al. 2000; Won et al. 2017), 
different studies have been focusing on synthetising more effective and well-
tolerated small molecules that could effectively reduce APT1 de-acylation activity 
in the brain. One of this compounds, Palmostatin B, that inhibits both APT1 and 2, 
has been tested for neuroprotective effects in rodent models of neurodegenerative 
disease (Dekker et al. 2010), confirming the potential therapeutic relevance of 




 The human hippocampus is receptive to acyl-ghrelin signalling 
in ageing and diseases 
GHS-R1a expression is intact in the brain of aged healthy subjects, as well as in both 
PD (chapter 4) and AD patients (chapter 5), regardless of the progression of the 
disease. These data are very promising, since the presence of a ghrelin-receptive 
system would favour any therapeutical strategy aimed at increasing the 
ghrelinergic tenor in the brain. 
However, GHS-R gene originates two variants of the receptor (section 1.2.8, figure 
1.3). The less known isoform, GHS-R1b, lacks the intracellular sequence: although 
it can still bind acyl-ghrelin, it is not able to induce any intracellular signalling 
pathways. Yet, GHS-R1b has been shown to interfere with GHS-R1a activity via 
several mechanisms, such as acting as a dominant negative and sequestrating acyl-
ghrelin from the extracellular space (Leung et al. 2007), increasing GHS-R1a 
internalization (Chow et al. 2012), or dimerising with GHS-R1a and directly 
modulating its signal transduction (Mary et al. 2013; Navarro et al. 2016). Notably, 
GHS-R1b mRNA is overexpressed in diseased human tissue, for instance in certain 
tumours (Arnaldi et al. 2003; Barzon et al. 2005), suggesting a disease-specific 
regulation of the ghrelinergic system.  
 
Although my data show GHS-R1a mRNA expression to be unchanged with ageing 
and in diseases, it cannot be excluded that variation of GHS-R1b expression (either 
increase or reduction) may still influence acyl-ghrelin signalling in the aged brain.  
It is of high priority to identify a strategy aimed at accurately quantify GHS-R1b in 
the human brain.  
GHS-R1b originates from alternative splicing, in which the splice site between 
exon1 and intron1 is skipped and a short intronic sequence is included in the final 
transcript – before an early stop codon terminates transcription. Because of this, 
targeting the mRNA sequence of the 1a isoform is easy, as long as the 
oligonucleotide probe is designed to recognise the sequence spanning the exon1-
exon2 region (see section 1.2.8, figure 1.3, yellow boxes). However, to detect the 
mRNA of the 1b isoform, the probe should be designed to recognise the exon1-
intron sequence, but this region is not exclusively present in GHS-R1b transcript. 
Indeed, the GHS-R mRNA precursors will also include the exon1-intron segment in 
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their sequence. Consequently, any probe that would be able to recognise GHS-R1b 
mRNA, would also target any other transcript originating from the GHSR gene, 
except for the GHS-R1a. For this reason, it is not possible to specifically identify 
GHS-R1b mRNA presence and activity in the human brain tissue. On the contrary, 
to investigate GHS-R1b protein, there are few commercially available antibodies 
that specifically detect the short intronic sequence typical of the 1b splice variant. 
However, the close similarity between the 1a and 1b isoform – that share 267 
amino acids, and only differ for a short 24-amino acid-long sequence – significantly 
increase the chance of cross-reaction with the other variant, therefore reducing the 
specificity of the antibody. 
 
 Antibody limitations in the staining of human tissues 
The use of antibody-based protein-staining in human tissue can be quite 
challenging. The first problem is that all proteins have both a 2D and a 3D structure. 
The term “2D structure” refers to the sequence of consecutive amino acids, 
corresponding to the codon sequences in the original mRNAs. This structure is very 
rarely detectable inside the cell; indeed, during protein translation, the newly 
formed proteins, emerging from the ribosomes, are immediately bound to specific 
chaperon enzymes, and quickly folded into what will ultimately represent their 
functional “3D” structure. Some commercially available antibodies are able to 
detect both the native (2D) and the final (3D) protein structures; however, some of 
them can only detect one of the two forms. This is the case of the two anti-GOAT 
antibodies used in this thesis (reported in section 2, table 8): one is specifically able 
to detect the 3D protein structure – by binding amino acids that are present on 
different part of the native proteins, but are adjacent after protein folding – and 
therefore can be only used to detect in situ immunoreactivity (i.e., 
immunohistochemistry), while the other antibody only recognises the 2D 
sequence, therefore can only be used with those techniques that require protein 
denaturation (unfolding) (i.e., Western blot).  
The second problem is antibody specificity against its target. Indeed, proteins that 
have multiple isoforms (mostly splicing variants), such as GHS-R and ghrelin, are 
more likely to be erroneously detected. Our group has previously shown that one 
anti-GHS-R1a antibody commercially available is not specific for the 1a isoform, as 
claimed, since its immunoreactivity is unaffected in GHS-R-ablated mice (Ratcliff et 
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al. 2019). Interestingly, a new antibody has been recently produced and 
commercialised, that seem to show increased specificity against the 1a isoform, 
although more studies will be needed to confirm its efficiency. Similarly, it has been 
extensively reported that the most used anti-ghrelin antibodies cannot distinguish 
between the numerous splice variants produced from the GHRL gene (Wortley et 
al. 2004; Furness et al. 2011). Accordingly, in this thesis neither anti-GHSR1a nor 
anti-ghrelin antibodies have been used in immunohistochemistry; however, both 
antibodies have been used in Western blot, because this technique provide an 
additional checkpoint, the protein molecular weight, that should reduce the chance 
of quantifying non-specific proteins. 
 
 Acyl-ghrelin and unacylated ghrelin have opposite effects on 
rotenone-induced mitochondrial health in vitro 
The second aim of this study, was to characterise the mechanisms in vitro of acyl-
ghrelin neuroprotection, using human stem cell-derived mature neurones. More 
specifically, I pre-treated ReN neurones with acylated or unacylated ghrelin for 5 
days, then treated them for 24h with either rotenone or AβOs. Finally, I quantified 
cell number, total ATP levels, mitochondrial DNA content and other mitochondrial 
health markers such as PGC1α mRNA expression, MMP and mitochondria “puncta” 
number. My data showed a very low sensitivity of ReN neurones to the stressor 
used, since a treatment effect between 1 and 10µM doses was barely detectable. 
When analysing the extended dataset (n>220) some effects started to appear more 
clearly. First of all, in both rotenone and AβOs treatment, 1µM and 10µM exert very 
different effects in mitochondria health. Moreover, the extended group showed a 
large spread of the data, suggesting there is a lot of variability in the same 
experiment.  
In order to better characterise the precise molecular mechanisms – and to exclude 
the possibility that these data only show random fluctuations – future study should 
combine live microscopy with mitochondrial tracking. Moreover, diverse 
mitochondrial markers, such as TOM20 or DPR1, or assays, such as Seahorse, 
should be combined to obtain more relatable data. Another possible strategy would 
consist in increasing acylated and unacylated ghrelin concentration, extend the 
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timeline of the experiments, or even inhibit serine hydrolases to prevent acyl 
ghrelin from being prematurely degraded in the media. 
 
An interesting element from the experiments in this thesis, is that acyl- and 
unacylated ghrelin treatment seems to consistently exert an opposite effect on 
mitochondrial health. Future studies should investigate whether the double 
treatment AG+UAG may rescue unacylated ghrelin detrimental effect on 
mitochondria health. However, since ReN neurones express both protein and 
mRNA of APT1, as well as GOAT mRNA (figure 3.7), these data need to be 
considered cautiously. Indeed, GOAT and APT1 – if functioning – may interfere with 
acylated and unacylated ghrelin concentration and influence the outcome of the 
experiment. Furthermore, although GHS-R1a mRNA was present on ReN neurones 
at DIV 22-24 (figure 3.8), I could not investigate its protein level nor its activity. 
  
Notably, a number of technical noises may also have contributed to such variability. 
For instance, DMSO and other chemicals commonly used to prepare and dissolve 
reagents may have an effect by themselves, altering cellular response and affecting 
the final data (Sanmartín-Suárez et al. 2011). Moreover, Phenol red, one of the main 
components of the cell media, has been shown to interact with Aβ at high 
concentration (Wu et al. 2006), hence it could reduce the efficacy of the treatment. 
Indeed, both DMSO and Phenol red were also present in the vehicle treatment, 
therefore it was not possible to determine whether they may have influenced the 
culture. Although we can exclude that neither DMSO nor Phenol red may be 
responsible for the variations detected between the well – since both components 
were present in all the wells – it still cannot be ruled out that they may have 
influenced the ability of the cells to respond to the stressors. Further studies should 
determine in advance the best media condition in order to exclude any interference 
with the treatments.  
 
For what concern the disease model, several groups reported that longer 
treatments at lower doses better recapitulate the complexity of these diseases. For 
instance, chronic low-dosage of rotenone treatments in cells, are able to induce the 
formation of α-synuclein intracellular occlusions and neuritic changes, such as 
synapse loss, hence better recapitulating the molecular features of PD (Borland et 
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al. 2008). Since my aim was to induce mild oxidative stress to simulate the early 
stage of the diseases, I did not consider longer treatments in my experimental 
settings. However, future studies should determine whether incorporating longer 
treatments may be more appropriate for investigating the ghrelinergic axis in this 
context. 
 
Lastly, human stem-cell neurones, although being the closest systems currently 
available to model neurodegenerative diseases, have flaws in their capability of 
recapitulating the complexity of the adult human brain, whose maturation occurs 
through several decades. One of the main issues is generating authentically “aged” 
neuronal cells in vitro, since primary cells would have accumulated unique features 
over several decades, such as epigenetic modifications, that would be difficult to 
accurately reproduce in cell culture (Studer et al. 2015). For instance, the type and 
position of epigenetic modifications in the DNA of “mature” stem cell-derived 
neurones, correspond to those found in immature (embryonal) neuronal 






PD and AD are two different – yet similar – neurodegenerative disorders, affecting 
millions of people worldwide and for which no cure has been identified yet. Due to 
the numerous common elements between the two diseases, an increasingly 
number of studies are now focusing on identifying a “common cure”, aimed at 
increasing mitochondria homeostasis, reducing oxidative stress, and restoring 
impaired metabolism. Acyl-ghrelin is a promising therapeutic tool due to its ability 
to reach the brain and to exert numerous beneficial effects via the activation of its 
receptor GHS-R1a.  
 
My thesis reports for the first time that the expression levels of key enzymes of the 
ghrelinergic axis are impaired in the brain of patients with PDD, and may also be 
affected in late AD, paving the way for future studies investigating a potential 
correlation between the ghrelinergic axis and cognitive functions in human. 
Moreover, my data also show that unacylated ghrelin exerts a detrimental effect on 
mitochondrial health in vitro, opposite to its acylated counterpart. In combination 
with previous studies, these data suggest the therapeutic potential of a new 
pharmacological approach, in which AG:UAG ratio is maintained or increased in the 
brain of aged and diseased patients, in order to counteract the oxidative stress and 
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A.1. ReN cells karyotipisation 







A.2. RT-qPCR primer sequences and optimisation 
The following table shows the oligonucleotide sequences of all human primers 
used in this thesis. All primers were determined to be optimal at 60 ᴼC. Melt curves 















































































































































































































































































































































































































































































































A.3. ReN neurones seahorse protocol 
The following figure summarises diverse Seahorse protocols performed on ReN 
neurones (DIV24) (n=1) in separate days. Stem cells (DIV0) were seeded in 
seahorse 96well plates at various cell densities, then allowed to differentiate as 
described in section 2.2. At DIV24, cells were treated with either vehicle, AβOs 1µM 
or 2µM for 24 hours, then media was changed, and cells were processed following 
the specific protocol from the supplier. More specifically, pH-controlled media was 
added to the cells for 1 hour, then plates were inserted in the Agilent Seahorse 
XFe96 Analyzer that performed three consecutive injections indicated by the black 
arrows: 1µM of Oligomycin A was injected after approximately 20 seconds, 1µM of 
FCCP was injected after approximately 50 seconds, and a combination of 1µM of 
rotenone + 1µM of antimycin A were injected after approximately 70 seconds. 
During the whole procedure, ROS released in the media were measured; error bars 








A.4. GHS-R1a signalling, full figure 
The following figure summarises the most known GHS-R1a-mediated intracellular 
pathways, as described in section 1.2.9 (figure 1.4) and section 1.3.6 (figure 1.6). 
 
 
 
